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Hinney, Roaa Naaresh, Manuel Föcker, Johannes Hebebrand, Inke R. König and Triinu
Peters
Vitamin D and the Risk of Depression: A Causal Relationship? Findings from a Mendelian
Randomization Study
Reprinted from: Nutrients 2019, 11, 1085, doi:10.3390/nu11051085 . . . . . . . . . . . . . . . . . . 73
v
Mariska C Vlot, Laura Boekel, Jolijn Kragt, Joep Killestein, Barbara M. van Amerongen,
Robert de Jonge, Martin den Heijer and Annemieke C. Heijboer
Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)2D, but No
Difference in Ratio of 25(OH)D/24,25(OH)2D and FGF23 Concentrations
Reprinted from: Nutrients 2019, 11, 2774, doi:10.3390/nu11112774 . . . . . . . . . . . . . . . . . . 85
Vito Francic, Stan R. Ursem, Niek F. Dirks, Martin H. Keppel, Verena Theiler-Schwetz,
Christian Trummer, Marlene Pandis, Valentin Borzan, Martin R. Grübler, Nicolas D.
Verheyen, Winfried März, Andreas Tomaschitz, Stefan Pilz, Annemieke C. Heijboer and
Barbara Obermayer-Pietsch
The Effect of Vitamin D Supplementation on its Metabolism and the Vitamin D Metabolite Ratio
Reprinted from: Nutrients 2019, 11, 2539, doi:10.3390/nu11102539 . . . . . . . . . . . . . . . . . . 101
Jen-Yin Chen, Yao-Tsung Lin, Li-Kai Wang, Kuo-Chuan Hung, Kuo-Mao Lan, Chung-Han
Ho and Chia-Yu Chang
Hypovitaminosis D in Postherpetic Neuralgia—High Prevalence and Inverse Association with
Pain: A Retrospective Study
Reprinted from: Nutrients 2019, 11, 2787, doi:10.3390/nu11112787 . . . . . . . . . . . . . . . . . . 111
Rebeca Reyes-Garcia, Antonia Garcia-Martin, Santiago Palacios, Nancy Salas, Nicolas
Mendoza, Miguel Quesada-Charneco, Juristo Fonolla, Federico Lara-Villoslada and Manuel
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Calcium is the main mineral in the body. It is involved in a variety of structural and functional
roles, but the maintenance of calcium homeostasis is perhaps the most studied function of vitamin D.
This Special Issue of Nutrients, “Calcium, Vitamin D, and Health” contains 12 original publications and
two reviews investigating the contribution of (mainly) vitamin D and calcium on relevant health outcomes
in a variety of populations, which reflect the evolving and broad interests of research on this topic.
Three studies were published examining the association between vitamin D and body composition.
Rabufetti et al. [1] observed that an increase in body fat percentage was a risk factor for 25-hydroxyvitamin
D [25(OH)D] insufficiency in a healthy population of 1045 late adolescent males living in southern
Switzerland. Abboud et al. [2], in their study on men and women with overweight/obese and undergoing
a weight loss program, found greater weight loss, as well as a larger reduction in body mass index
(BMI), and waist circumference in those with higher baseline 25(OH)D levels. Moreover, a similar effect
was also observed in those with insufficient baseline 25(OH)D levels but supplemented with vitamin
D3 for three months. In a study with middle-aged sedentary adults, De-la-O et al. [3] found negative
associations between 1,25-dihydroxyvitamin D (1,25(OH)2D, also known as calcitriol, and BMI, lean
mass index, and bone mineral density (BMD). The latter finding backs up the notion that 1,25(OH)2D
increases bone resorption via stimulating intestinal calcium absorption after calcium intake.
Two other studies investigated the links between 25(OH)D and bone outcomes in young
populations. Gil-Cosano et al. [4] revealed a mediating effect of muscular fitness on the relationship
between 25(OH)D levels and BMD in children who were overweight/obese, while Rapun-Lopez et al. [5]
showed similar bone remodeling in adolescent male cyclists than age-matched active controls over one
year, but lower 25(OH)D. In adult and older women from the Chilean National Health Survey 2016–2017
(total N = 1931), Solis-Urra et al. [6] found a joint association of high sedentary time/passive commuting
to be associated with 25(OH)D deficiency, even after controlling for sun exposure. This finding connects
with the studies mentioned above [1–3] due to the proposed link between sedentary time and increased
adiposity, as well as between adiposity and reduced 25(OH)D levels.
Libuda et al. [7] studied six single nucleotide polymorphisms (SNPs), which were genome-wide
significantly associated with 25(OH)D concentrations in more than 79,000 subjects from the SUNLIGHT
genome-wide association study (GWAS). However, they did not identify the potential role (from a
genetics perspective) of 25(OH)D in the onset of depressive symptoms or broad depression. Multiple
sclerosis (MS) has been negatively associated with BMD through various factors, and previous
research has suggested that vitamin D could play a role in the pathogenesis of MS by possibly
modulating T-lymphocyte subset differentiation. In this regard, Vlot et al. [8] studied the vitamin
D-fibroblast-growth-factor-23 (FGF23) and measured multiple vitamin D metabolites and bone turnover
markers in a cohort of MS patients and healthy controls. They found lower serum concentrations
of total 25(OH)D, free 25(OH)D, free 1.25(OH)2D, and 24,25 dihydroxyvitamin D [24,25(OH)2D]
in female MS patients compared with their healthy peers, while serum concentrations of vitamin
D binding protein (VDBP) were higher in male MS patients, compared with male controls. This
study strengthens the idea that a single measurement of total 25(OH)D may not be enough to
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fully reflect all changes in vitamin D metabolism in MS patients. In a randomized clinical trial
conducted in hypertensive adults, Francic et al. [9] did not support the routine measurement of
24,25 dihydroxycholecalciferol (24,25(OH)2D3) in order to individually optimize the dosage of
vitamin D supplementation. Interestingly, the activity of 24-hydroxylase increased after vitamin D
supplementation. In patients with postherpetic neuralgia (PHN), Chen et al. [10] showed a higher
prevalence of hypovitaminosis D (as reflected by 25(OH)D levels) than in the controls, and those with
hypovitaminosis D also had a lower vitamin D supplementation rate and greater pain intensity.
In healthy post-menopausal women, Reyes-Garcia et al. [11] investigated the response of serum
25(OH)D and its predictive factors after a 24-month dietary intervention with milk fortified with
vitamin D and calcium. It was found that the improvement in 25(OH)D after the intervention was
mainly dependent on the baseline levels of serum 25(OH)D and the percentage of body fat. The study
by Jurimae et al. [12] is one of the few studies investigating the association between calcium and
adiposity in young populations, and found inverse associations between dietary calcium intake and
total body and abdominal adiposity in healthy male adolescents.
Finally, two timely reviews were included in this Special Issue. Brandao-Lima et al. [13] conducted
a systematic review of randomized controlled trials aiming to discuss food fortification as a strategy for
maintenance or recovery of nutritional status related to vitamin D in children. Marino and Misra [14],
in their review, discussed the biological effects of vitamin D beyond the skeleton, using evidence from
randomized controlled trials and meta-analyses.
The present Special Issue provides a short summary of the progress on the topic of calcium,
vitamin D, and human health in different populations, which will be of interest from a clinical and
public health perspective. It also underlines the current limitations and the necessity of more powerful
study designs to further advance in the knowledge.
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Abstract: Background: Poor vitamin D status is a worldwide health problem. Yet, knowledge
about vitamin D status among adolescents in Southern Europe is limited. This study investigated
concentrations and modulating factors of vitamin D in a healthy population of male late adolescents
living in Southern Switzerland. Methods: All apparently healthy subjects attending for the medical
evaluation before the compulsory military service in Southern Switzerland during 2014-2016 were
eligible. Dark-skin subjects, subjects on vitamin D supplementation or managed with diseases or
drugs involved in vitamin D metabolism were excluded. Anthropometric measurements (body
height, weight, fat percentage, mid-upper arm and waist circumference) and blood sampling for
total 25-hydroxy-vitamin D, total cholesterol and ferritin concentrations testing, were collected.
Participants filled in a structured questionnaire addressing their lifestyle. Characteristics of the
subjects with adequate (≥50 nmol/L–≤250 nmol/L) and insufficient (<50 nmol/L) vitamin D values
were compared by Kruskal-Wallis test or χ2 test. Odds ratios for 25-hydroxy-vitamin D insufficiency
were calculated by univariate and AIC-selected multiple logistic regression models. Results: A total
of 1045 subjects volunteered to participate in the study. Insufficient concentrations of vitamin D were
detected in 184 (17%). The season of measurement was the most significant factor associated with
vitamin D levels and approximately 40% of subjects presented insufficient vitamin D concentrations
in winter. After model selection, body fat percentage, frequency and site of recreational physical
activity, and the seasonality were significantly associated with the risk of vitamin D insufficiency.
Conclusions: Among healthy male late adolescents in Southern Switzerland, about one every fourth
subject presents a poor vitamin D status in non-summer seasons. Body fat percentage, frequent and
outdoor recreational physical activity are modulating factors of vitamin D status in this population.
Keywords: macronutrients; sunlight; physical activity; season; body composition
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1. Introduction
There are two natural sources of vitamin D: food and especially ultraviolet B radiation on the
skin [1]. A limited number of foods naturally contain vitamin D. Fish (mostly fatty fish), egg yolk
and liver are good sources of vitamin D3. On the other hand, vitamin D2 is contained in various
wild mushrooms [1,2]. Among European adolescents, the natural vitamin D intake is low except for
countries such as Poland and Norway, which is attributed to high consumption of fish [3].
The amount of cutaneous vitamin D3 synthesis depends on a number of factors, including time
spent outdoors, latitude, season, ethnicity and use of sunscreen [1]. Vitamin D synthesis occurs
for about half the year in northern regions above approximately 35◦ latitude [3,4]. Unsurprisingly,
therefore, lower-than desired concentrations of total 25-hydroxy vitamin D have often been detected,
especially during the fall and winter months, in countries such Canada, Ireland, the United Kingdom
and the northern United States [3,4]. It would be assumed that, in the sunniest areas of the world, this
problem would be uncommon. However, in Australia, Brazil, India, Iran, Lebanon and Saudi Arabia
many adolescents were found to have lower-than-desired concentrations of vitamin D [3,4].
Limited information is available on vitamin D status in adolescents living in Southern Europe.
The objective of the present analysis was to obtain reliable and comparable data on vitamin D status
from a large population of late adolescents living in Southern Switzerland, the sunniest region of
this country (latitude 46◦). The secondary aim was to investigate the role of a broad number of
possibly relevant anthropometric, lifestyle and biochemical characteristics on vitamin D status in
this population.
2. Methods
This investigation is part of the “CENERI study”, a cross sectional study in healthy male adolescents
living in Southern Switzerland to investigate risk factors for chronic diseases later in life. In Switzerland,
ostensibly male citizens between 18 and 19 years of age have to undertake a medical evaluation before
the compulsory military service in the Army [5]. All apparently healthy subjects attending for the
medical evaluation before the compulsory military service in Southern Switzerland from January 2014
to December 2016 were eligible for the “CENERI study”. Dark-skin subjects (Fitzpatrick skin phototype
V or VI), subjects on supplementation with any form of vitamin D and subjects on treatment with
anticonvulsant, glucocorticoid, antifungal, and anti-retroviral drugs or with any chronic endocrinologic
or metabolic disease potentially affecting vitamin D metabolism, were excluded for the present analysis.
Among the 4663 subjects who underwent the medical examination before the compulsory military
service, 1045 (22%) Caucasians volunteered to participate in the study.
All measurements and data were collected in the same morning for each subject after an overnight
fast. Beyond the routinely collected data on anthropometric measurements (body height and weight),
participants were asked to answer a self-administered structured questionnaire addressing their main
activity and lifestyle (especially recreational physical activity, smoking behavior and alcohol consumption).
Body fat percentage, mid-upper arm and waist circumference were also measured. In addition, blood
for total 25-hydroxy-vitamin D, total cholesterol and ferritin concentrations testing, was also collected.
Questions on lifestyle were structured as follows: (i) Frequency of recreational physical activity
(never, 1 per week, 2–4 per week, 5–6 per week, every day), (ii) Duration of recreational physical
activity session (≤1 h, >1–≤2 h, >2–≤3 h, >3 h), (iii) Site of recreational physical activity (indoor only,
outdoor only, both indoor and outdoor), (iv) Frequency of alcohol consumption (never, 1 per week,
2 per week, 3–4 per week, 5–6 per week, every day), (v) Smoking (never, 1–10 cigarettes per day,
11–20 cigarettes per day, >20 cigarettes per day).
Subjects were weighed (wearing light clothes only) on a calibrated platform scale, with weight
being rounded off to the nearest 0.1 kg. Standing height was measured barefooted to the nearest 0.1 cm.
These measurements were used to calculate the body mass index. Mid-upper arm circumference
was measured to the nearest 0.1 cm midway the acromion and the olecranon in the non-dominant
arm. Waist circumference was measured to the nearest 0.5 cm with a non-stretching tape placed
6
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around the abdomen at the iliac crest. Body fat percentage was assessed by a validated bioimpedance
analysis device (Omron®BF306, Omron Healthcare Europe BV, Hoofddorp, The Netherlands) [6].
After entering demographic and anthropometric data, the subjects were asked to remain in standing
position while holding the hand-to-hand bioimpedance device by both hands and straightening both
arms forward [7]. All demographics, anthropometric and lifestyle information were prospectively
collected by a trained nurse.
An Abbott chemiluminescent microparticle immunoassay, which measures both 25-hydroxy
vitamin D2 and 25-hydroxy vitamin D3, was applied for the determination of total 25-hydroxy vitamin
D concentration in serum [8]. At an average total concentration of 49 nmol/L, 99 nmol/L and 187 nmol/L,
the intra-assay coefficient of variation was 3.9%, 4.0%, and 4.0%, respectively. The corresponding
inter-assay coefficient was 1.0%, 1.2%, and 2.6% [8]. Accuracy and reliability of the assay are assessed
both in the Vitamin D Standardization Program [9] and in the Vitamin D External Quality Assessment
Scheme [10]. The circulating levels of total cholesterol (enzyme assay) and ferritin (immunoassay)
were measured in serum. All laboratory assessments were performed in the same accredited central
laboratory (Viollier, Basel, Switzerland) using an Architect CI8200 (Abbott, Chicago, IL, USA) analyzer.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Ethics Committee of Southern Switzerland (RIF CE 2775). Informed written consent
was obtained from all subjects to participate in the study.
Data Analysis
Frequency distribution of continuous data were presented as median and interquartile range.
Dichotomous data were presented as absolute and relative frequency. Concentrations of total
25-hydroxy-vitamin D were considered adequate if≥50 nmol/L–≤250 nmol/L, insufficient if <50 nmol/L,
deficient if <30 nmol/L or potentially toxic if >250 nmol/L [11]. Anthropometric, lifestyle and
further laboratory characteristics of the subjects with adequate (50–250 nmol/L) and insufficient
(<50 nmol/L) 25-hydroxy-vitamin D values were compared by Kruskal-Wallis test. χ2 test was used
for comparing frequencies of categorical variables. The Bonferroni test adjustment for multiple
comparisons was applied.
Odds ratios (ORs) of 25-hydroxy-vitamin D insufficiency and corresponding 95% confidence
intervals (CI) from univariate logistic regression models were calculated for the following variables:
age, body height, body weight, body mass index, body fat percentage, frequency/length and site
of recreational physical activity, frequency of alcohol consumption, smoking, season (winter from
21 December; spring from 21 March, summer from 21 June and autumn from 21 September), cholesterol
and ferritin concentrations. ORs of 25-hydroxy-vitamin D insufficiency and corresponding 95% CI
were also derived from the best AIC-selected multiple logistic regression model including the following
variables: age, body mass index, body fat percentage, waist circumference frequency/length and site
of recreational physical activity, frequency of alcohol consumption, smoking, season, cholesterol and
ferritin concentrations. In all analyses, significance was assumed if p < 0.05. Statistics was performed
using the open source statistical language R, Vienna, version 3.5.3 (11 March, 2019).
3. Results
Body height (178.0 (173.5–182.0) vs. 177.5 (173.0–182.5) cm) and weight (72.2 (65.7–80.0) vs.
72.0 (65.0–80.5) kg) were similar in subjects who volunteered to participate in the study as compared
with the remining 3618 subjects. Anthropometric, lifestyle and laboratory findings of the 1045 recruited
subjects are given in Table 1. One hundred seventy-nine (17%) subjects presented with concentrations
of total 25-hydroxy-vitamin D < 50 nmol/L. Among subjects with a concentration of vitamin D below
50 nmol/L, 24 (13%) had deficient levels of total 25-hydroxy-vitamin D. No subject presented with
potentially toxic concentrations of the 25-hydroxy-vitamin D. The concentration of 25-hydroxy-vitamin
D2 was always≤5 nmol/L. The characteristics of the subjects with adequate or insufficient concentrations
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of 25-hydroxy-vitamin D are shown in Table 2. A total of 76 (7.2%) out of 1045 had a body mass
index ≥ 30 kg/m2 and 34 (3.3%) ≤ 18.5 kg/m2.
The season of measurement was the most significant factor associated with insufficient
concentrations of 25-hydroxy-vitamin D. The concentrations vitamin D in the four seasons are depicted
in Figure 1 (upper panel). Of note, 64 (38%) out of 170 subjects tested for 25-hydroxy-vitamin D level in
winter presented insufficient concentrations of this vitamin, 70 (18%) out of 383 in spring, 18 (5.4%)
out 331 in summer and 28 (17%) out of 161 in autumn. A total of 13 (7.6%) subjects in winter, 6 (1.6%)
in spring and 5 (3.1%) in autumn, presented with deficient concentrations of 25-hydroxy-vitamin D.
No subject had a deficient level of 25-hydroxy-vitamin D in summer (Figure 1, lower panel).
Table 1. Baseline characteristics of the enrolled subjects. Data are given as absolute frequency






Body height, cm 178.0 (173.5–182.0)
Body weight, kg 72.2 (65.7–80.0)
Body mass index, kg/m2 23.0 (21.0–25.1)
Body fat percentage, % 17.8 (13.7–23.1)
Mid-upper arm circumference, cm 27.0 (25.0–30.0)
Waist circumference, cm 80 (75–87)
Frequency of recreational physical activity
Never 219 (21)
1 per week 174 (17)
2–4 per week 472 (45)
5–6 per week 88 (8.4)
Every day 92 (8.8)
Length of recreational physical activity session
≤1 h 66 (8.0)
>1–≤2 h 602 (73)
>2–≤3 h 143 (17)
>3 h 15 (1.8)
Site of recreational physical activity
Indoor (only) 148 (18)
Outdoor (only) 340 (41)
Both indoor and outdoor 338 (41)
Frequency of alcohol consumption
Never 201 (19)
1 per week 393 (38)
2 per week 285 (27)
3–4 per week 112 (11)
5–6 per week 42 (4.0)
Every day 12 (1.2)
Smoking
Never 602 (58)
1–10 cigarettes per day 299 (29)
11–20 cigarettes per day 130 (12)
>20 cigarettes per day 14 (1.3)
Biochemical indices
Total 25-hydroxy-vitamin D, nmol/L 68 (55–82)
Cholesterol, mmol/L 3.9 (3.5–4.3)
Ferritin, μmol/L 76.0 (52–109)
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Table 2. Characteristics of subjects with adequate and insufficient circulating 25-hydroxy-vitamin D.
All variables were non-normally distributed. Data are given as absolute frequency (and percentage)
or median (and interquartile range). The Kruskal-Wallis test was used for continuous variables.
Chi-squared test was used for categorical variables. The Bonferroni test adjustment was applied to








N 866 (83) 179 (17)
Main activity
Student 356 (41) 77 (43) 0.7
Worker 510 (59) 102 (67)
Anthropometric characteristics
Body height, cm 178.0 (173.0–182.0) 176.0 (171.5–180.0) 0.003 **
Body weight, kg 72.5 (65.9–80.0) 71.3 (64.9–82.0) 0.9
Body mass index, kg/m2 22.9 (21.0–25.0) 23.0 (20.7–26.3) 0.3
Body fat percentage, % 17.4 (13.4–22.7) 20.1 (14.6–25.2) <0.0001 ***
Mid-upper arm circumference, cm 27.0 (25.0–29.5) 27.0 (24.0–30.1) 0.4
Waist circumference, cm 80 (75–86) 80 (75–91) 0.1
Frequency of recreational physical activity
Never 177 (20) 42 (24) 0.03 *
1 per week 134 (16) 40 (22)
2–4 per week 396 (46) 76 (43)
5–6 per week 81 (9.4) 7 (3.9)
Every day 78 (9.0) 14 (7.8)
Duration of recreational physical activity
session
≤1 h 50 (7.3) 16 (12) 0.3
>1–≤2 h 509 (74) 93 (68)
>2–≤3 h 118 (17) 25 (18)
>3 h 12 (1.7) 3 (2.2)
Site of recreational physical activity
Indoor (only) 117 (17) 31 (23) 0.1
Outdoor (only) 281 (41) 59 (43)
Both indoor and outdoor 289 (42) 47 (34)
Frequency of alcohol consumption
Never 161 (19) 40 (22) 0.1
1 per week 338 (39) 55 (31)
2 per week 224 (26) 61 (34)
3–4 per week 97 (11) 15 (8.4)
5–6 per week 35 (4.0) 7 (3.9)
Every day 11 (1.3) 1 (0.6)
Smoking
Never 483 (56) 119 (67) 0.018 *
1–10 cigarettes per day 253 (29) 46 (26)
11–20 cigarettes per day 118 (14) 12 (6.7)
>20 cigarettes per day 12 (1.4) 2 (1.1)
Season of measurement
Winter 106 (12) 64 (36) <0.0001 ***
Spring 313 (36) 70 (39)
Summer 313 (36) 18 (10)
Autumn 134 (16) 27 (15)
Biochemical indices
Cholesterol, mmol/L 3.9 (3.5–4.3) 4.0 (3.6–4.4) 0.049 *
Ferritin, μmol/L 76.0 (52.0–109.0) 76.5 (51.0–103.5) 0.9
* p < 0.05, ** p < 0.01, *** p < 0.0001.
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Figure 1. Upper panel. Box-plot of the circulating concentrations of 25-hydroxy-vitamin D across the
four seasons. The boxes include values between the 1st and the 3rd quartile (i.e., the interquartile
range). The whiskers include values between: 1st quartile − 1.5 times interquartile range and
3rd quartile + 1.5 times interquartile range. Lower panel. Frequency of adequate, insufficient or
deficient concentrations of 25-hydroxy-vitamin D according to seasonality.
In the univariate logistic regression models (Table 3), body height (ORs 0.96, 95% CI 0.94–0.98),
body mass index (OR 1.05, 95% CI 1.00–1.07, body fat percentage (OR 1.04, 95% CI 1.02–1.07), waist
circumference (OR 1.02, 95% CI 1.00–1.03), the frequency of recreational physical activity 5–6 per week
(OR 0.36, 95% CI 0.16–0.85), cigarettes consumption of 11–20 cigarettes per day (OR 0.41, 95% CI
0.22–0.77), the season (spring, OR 0.37, 95% CI 0.25–0.56, summer, OR 0.09, 95% CI 0.05–0.17, and
autumn, OR 0.33, 95% CI 0.20–0.56) and cholesterol (OR 1.29, 95% CI 1.02–1.62) were positively (OR >1)
or inversely (OR < 1) associated with the risk of 25-hydroxy-vitamin D insufficiency.
Table 4 shows results from the multiple regression analysis. After model selection based on clinical
plausibility and Akaike information criterion, the increase of body fat percentage was a significant
risk factor (ORs >1) for 25-hydroxy-vitamin D insufficiency. A frequent (5–6 times per week) and
outdoor physical activity and non-winter seasons were significant protective factors (ORs < 1) against
25-hydroxy-vitamin D insufficiency.
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Table 3. Odds ratios (ORs) of 25-hydroxy-vitamin D insufficiency and corresponding 95% confidence







Body height, cm 0.96 0.94 0.98 0.004 **
Body weight, kg 1.01 0.99 1.20 0.4
Body mass index, kg/m2 1.05 1.00 1.07 0.03 *
Body fat percentage, % 1.04 1.02 1.07 <0.0001 ***
Mid-upper arm circumference, cm 0.99 0.95 1.04 0.09
Waist circumference, cm 1.02 1.00 1.03 0.03 *
Frequency of recreational physical activity
Never reference
1 per week 1.26 0.77 2.05 0.4
2–4 per week 0.81 0.53 1.23 0.3
5–6 per week 0.36 0.16 0.85 0.02 *
Every day 0.76 0.39 1.46 0.5
Duration of recreational physical activity session
≤1 h reference
>1–≤2 h 0.57 0.31 1.05 0.06
>2–≤3 h 0.66 0.33 1.35 0.3
>3 h 0.78 0.19 3.12 0.7
Site of recreational physical activity
Indoor reference
Both indoor and outdoor 0.79 0.49 1.29 0.4
Outdoor (only) 0.61 0.37 1.01 0.05
Frequency of alcohol consumption
Never reference
1 per week 0.66 0.42 1.03 0.06
2 per week 1.10 0.70 1.71 0.7
3–4 per week 0.62 0.33 1.19 0.1
5–6 per week 0.80 0.33 1.95 0.6
Every day 0.37 0.05 2.92 0.3
Smoking
Never reference
1–10 cigarettes per day 0.74 0.51 1.07 0.1
11–20 cigarettes per day 0.41 0.22 0.77 0.006 **
>20 cigarettes per day 0.68 0.15 3.06 0.6
Season of measurement
Winter reference
Spring 0.37 0.25 0.56 <0.0001 ***
Summer 0.09 0.05 0.17 <0.0001 ***
Autumn 0.33 0.20 0.56 <0.0001 ***
Biochemical indices
Cholesterol, mmol/L 1.29 1.02 1.62 0.03 *
Ferritin, μmol/L 1.0 0.99 1.01 0.9
* p < 0.05, ** p < 0.01, *** p < 0.0001.
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Table 4. Odds ratios (ORs) of 25-hydroxy-vitamin D insufficiency and corresponding 95% confidence
intervals (CIs) as derived from the best Akaike information criterion-selected multiple logistic regression
model. The original model included the following variables: body mass index, body fat percentage,
mid-upper arm circumference, waist circumference, frequency of recreational physical activity, duration
of recreational physical activity session, site of recreational physical activity, season, frequency of
alcohol consumption, smoking, cholesterol and ferritin.
Subject Characteristic OR Lower 95%CI Upper 95%CI p-Value
Body fat percentage, % 1.04 1.01 1.07 0.01 *
Frequency of recreational physical activity
2–4 per week 0.64 0.40 1.02 0.6
5–6 per week 0.32 0.13 0.78 0.01 *
Every day 0.64 0.31 1.35 0.2
Site of recreational physical activity
Both indoor and outdoor 0.80 0.47 1.37 0.4
Outdoor (only) 0.56 0.33 0.96 0.04 *
Season of measurement
Spring 0.31 0.19 0.49 <0.0001 ***
Summer 0.08 0.04 0.17 <0.0001 ***
Autumn 0.24 0.13 0.45 <0.0001 ***
Biochemical indices
Cholesterol, mmol/L 1.25 0.95 1.66 0.1
* p < 0.05, *** p < 0.0001.
4. Discussion
This study points out that a large minority (17%) of healthy male late adolescents in Southern
Switzerland, a region with a low natural vitamin D intake, has a poor vitamin D status. In this group of
subjects, an increase in body fat percentage is a risk factor for vitamin D insufficiency. On the contrary,
frequent and outdoor recreational physical activity and, especially, non-winter seasons are protective
factors against vitamin D insufficiency. Yet, about one every fifth subject has insufficient concentrations
of vitamin D also in spring and autumn.
The prevalence of hypovitaminosis D among adolescents from high-income countries largely varies
among studies [12,13]. In the southeastern United States, vitamin D concentrations < 50 nmol/L were
observed in about 4% of white male adolescents [14]. In the HELENA study, among 1006 subjects living
in ten European countries, about 40% presented vitamin D concentration < 50 nmol/L [15]. Our data
point out that insufficient concentrations of vitamin D are frequent among male late adolescents in
Southern Switzerland and emphasize that vitamin D concentrations are strongly season dependent.
Of note, the frequency of vitamin D insufficiency was very high in winter and still rather important
(>15%) in autumn. A previous study suggests that in Ireland (latitude 51–55◦) ultraviolet B radiation
is effective for some vitamin D synthesis also in October [16]. On the other hand, very low doses
were found in November and December. This study did not specifically investigate the ultraviolet B
radiation in Southern Switzerland. However, the concentration of 25-hydroxy-vitamin D2 was always
≤5 nmol/L, confirming that also vitamin D of non-animal origin played a marginal role in vitamin D
status in our population.
The peak bone mass is usually reached between 25 and 35 years of age and, in male subjects, is
predicted by vitamin D status [17]. Hence, the years preceding the peak bone mass are considered as a
critical period to maximize bone strength and maturation [18]. The European Academy of Pediatrics,
the American Academy of Pediatrics and Endocrine guidelines currently do not routinely recommend
supplying vitamin D in non-dark skinned, non-obese healthy adolescents or young adults [19–21].
The results of this study suggest that longitudinal studies should address the advantages of vitamin D
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supplementation in Caucasian late adolescents during winter. This finding is even more crucial for
the bone metabolism, considering that only vitamins D concentrations >75 nmol/L have a clear-cut
antifracture effect [22]. On the other hand, an increasing body of evidence highlights that vitamin D
deficiency is associated with chronic and potentially life-threating conditions such as cardiovascular
disease later in old adults and elderly [23]. In this study, about one every thirteen subjects had deficient
concentrations of vitamin D in winter.
We found an association between vitamin D concentrations, frequent and outdoor physical
recreational activity after adjusting for confounders. Although sun-light exposure does not occur
exclusively during recreational physical activity, this finding confirms the beneficial role of outdoor
activities. Yet, seasonal fluctuations of ultraviolet-B radiations might decrease the effects of sun-light
exposure during non-summer seasons and especially in winter [22,23]. Differently from previous
observations [24,25], this study did not identify any association between vitamin D and a marker of
inflammation such as ferritin. This might be due to the fact that the population of this study exclusively
included healthy late adolescents without any chronic disease. Also, we did not find any association
with cholesterol or alcohol consumption. A possible explanation is that most prior studies have included
subjects with a much broader range of age and the mentioned factors could become determinant when
persisting for long-term periods [26]. Previous studies found body mass index to be inversely associated
with vitamin D concentrations. However, residual confounding such as physical activity or body
composition assessment have not always been considered [27]. Furthermore, body mass index cannot
distinguish lean from fat mass, especially in youth [28]. One of the advantages of this study is that many
anthropometric characteristics were explored disclosing an association between body fat percentage and
vitamin D concentrations levels after adjusting for confounders. A tendency to accumulate vitamin D
(a liposoluble compound) in fat depots or an impaired vitamin D intestinal absorption or hydroxylation
in adipose tissue are likely to underly this association [29]. Of note, some studies have also hypothesized
that vitamin D insufficiency itself could reduce weight loss or favoring weight gain [29].
This study has many strengths and limitations. The main strengths are the large number of
apparently healthy subjects enrolled with a narrow range of age and the concomitant determination of
many potential modulators of vitamin D including the body fat percentage. Furthermore, Southern
Switzerland is considered the sunniest region of Switzerland: therefore, it is possible that the number
of late adolescents with vitamin D insufficiency might be even higher in the other parts of Switzerland.
The main limitation of this study is the exclusion of females. Second, results are partly based on
self-reports, which might not always correspond to the actual behavior of the responders. Third, its
cross-sectional nature prevents to longitudinally evaluate vitamin D concentrations throughout the
seasons. Fourth, we did not analyze some common inflammatory indices, such as C-reactive protein.
Finally, the use of sunscreen, which is usually not very common among male adolescents and young
adults in Switzerland [30], was not investigated.
5. Conclusions
This study showed that about one every fourth healthy male late adolescent in Southern
Switzerland presents insufficient concentrations of vitamin D during non-summer seasons. Low body
fat and both frequent and outdoor recreational physical activity are associated with adequate vitamin
D level this population.
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Abstract: Context: Obesity and low vitamin D status are linked. It is not clear that weight loss
through lifestyle intervention is influenced by vitamin D status. Objective: The aim of this study
was to investigate the effect of baseline vitamin D status and vitamin D supplementation on weight
loss and associated parameters for participants on a weight loss program in a primary care setting.
Design: A retrospective analysis of clinical records of patients who underwent an individually
tailored weight loss program at a single dietetic clinic in Sydney, Australia. Setting: Primary care
centers. Patients: 205 overweight and obese men and women aged from 18 to 50 years. Interventions:
Patients were referred to a dietetic clinic for a weight loss program. Patients with low serum
25-hydroxyvitamin D (25(OH)D) concentrations at baseline were advised to increase sun exposure
and take multivitamins supplemented with 2000 IU or 4000 IU per day of vitamin D3, according
to the preference of their primary care physician. Main outcome measures: Clinical parameters of
weight, height, waist circumference, and serum 25(OH)D, as well as blood pressure and fasting lipid
profile were collected from both baseline and three-month follow-up consultations. Results: Subjects
with sufficient baseline 25(OH)D levels (≥50 nmol/L) experienced significantly greater weight loss
(−7.7 ± 5.9 kg vs. −4.2 ± 3.3 kg) and reductions in BMI (−2.6 ± 1.8 kg/m2 vs. −1.5 ± 1.1 kg/m2) and
waist circumference (−5.2 ± 3.5 cm vs. −3.1 ± 3.1 cm) as compared with those who were vitamin D
insufficient at baseline (p < 0.001 for all). Vitamin D insufficient patients who were supplemented
with daily 2000 IU or 4000 IU vitamin D experienced significantly greater decreases in weight (−5.3
± 3.6 kg vs. −2.3 ± 1.6 kg), BMI (−1.9 ± 1.2 kg/m2 vs. −0.8 ± 0.6 kg/m2) and waist circumference
(−4.2 ± 3.4 cm vs. −1.2 ± 1.3 cm) as compared with those not supplemented (p < 0.001 for all). We
also observed a greater decrease in low-density lipoprotein (LDL) cholesterol (−0.4 ± 0.5 mmol/L
vs. −0.2 ± 0.5 mmol/L) in subjects insufficient at baseline and supplemented as compared with
those insufficient at baseline and not supplemented (p < 0.01). Conclusion: In a weight loss setting
in a dietetic clinic, adequate vitamin D status at baseline, or achieved at three months through
supplementation, was associated with significantly greater improvement of anthropometric measures.
The study has implications for the management of vitamin D status in obese or overweight patients
undergoing weight loss programs.
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1. Introduction
Vitamin D has multiple pleiotropic functions beyond its traditional role in calcium homeostasis,
as well as bone and muscle function [1]. Actions of the vitamin D hormone, calcitriol, have been
demonstrated in many tissues, including adipocytes [2] and the cardiovascular system [3]. The first
evidence of a relationship between vitamin D and body fat was described in 1972 by Mawer et al. [4].
Inadequate vitamin D status, obesity, and chronic noncommunicable disease often cluster [1,3,5–7].
They are important public health issues that contribute significantly to modern healthcare costs,
morbidity, and mortality [8,9]. Many studies support the proposal that obesity could be driving
low serum 25(OH)D concentrations mainly due to decreased bioavailability of vitamin D through
sequestration in body fat compartments [4,10–13]. There is limited human research which indicates
that vitamin D could potentiate weight loss and improvements in metabolic markers [14,15]. A recent
randomized controlled trial in postmenopausal women reported that while supplementation with
vitamin D did not alter weight loss or associated parameters overall as compared with a placebo group,
women in the supplemented group who reached 25(OH)D concentrations of ≥32 ng/mL (≥80 nmol/L),
had greater improvement in several measured weight loss parameters as compared with those women
whose final 25(OH)D concentrations were below 80 nmol/L [16].
In this study, we hypothesized that overweight and obese patients presenting adequate 25(OH)D
levels will have a greater reduction in body weight, body mass index (BMI), and waist circumference as
compared with those with inadequate vitamin D levels while undergoing a three-month clinic-specific
individually tailored weight loss management program. Furthermore, we expect that vitamin D
repletion of those who were insufficient at baseline, through short-term daily vitamin D supplementation
would enhance weight loss, decrease waist circumference, and improve biochemical markers. This
was investigated using clinic records of a population of overweight and obese men and premenopausal
women who participated in an individually tailored three month weight loss program.
2. Study Design and Population
This study is a retrospective analysis of a clinical databank that was recorded in a health
giver-receiver setting. The Human Ethics Committee at the University of Sydney approved the research
protocol (Protocol 2013/206). Between September 2011 and March 2013, a total of 935 patients who
attended three medical centers in Sydney, Australia, were referred to a dietetic clinic (established by
author MA) to assist with a program for weight loss, under the Chronic Disease Management Plan of
Medicare Australia [17]. This care plan entitled each patient to five consultations with a dietician or
another allied health professional. Under an agreed protocol, patients had blood taken for 25(OH)D
and blood lipid measurements at the initial visit with the primary care physician. These patients were
seen by the dietician fortnightly for the first month and then monthly after that. Thus, the initial visit
was the first visit, then, after two weeks (second visit), then, another two weeks (third visit), then,
after one month (fourth visit), then, after one month (fifth visit). This fifth visit coincided with the
three-month follow-up, when the follow-up blood for testing was taken. The referring doctors differed
in their approach to management of patients who had 25(OH)D concentrations less than 50 nmol/L at
baseline. Some referring doctors advised their patients to take supplements of vitamin D3 at 2000 IU
per day, and some at 4000 IU per day. The remaining patients with low baseline 25OHD were advised
to increase their sun exposure and take multivitamins (with only small amounts, 40 IU of vitamin
D). The dietician performed anthropometric measures at each visit. Weight was measured using the
same scales, which were calibrated monthly. Height and waist circumference were measured at the
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initial and final visits. Waist circumference was measured with the patient standing, at a level midway
between the iliac tubercle and lower lateral rib margin, and hip circumference was measured at the
level of the iliac tubercle.
For the individually tailored weight loss protocol, at the initial consultation with the dietician,
each patient’s daily estimated energy requirement (EER) was calculated using the Harris-Benedict
equation [18] and physical activity factors (see more detailed information in the supplementary Tables
S1–S3). Overweight and obese individual caloric goals were calculated to be 300 and 500 Kcal/day,
respectively, less than their EER. Once the EER was calculated, a meal plan was designed by the
dietitian and given to the participant at the initial consultation, and adherence was checked via a 24-h
recall method during each of the follow-up visits. The reported intake was relatively compliant with
the prescribed energy intake. The participants were not seen by any exercise physiologist and did not
undertake any major changes in physical activity that could have altered their energy needs.
As part of continuing care, a report was sent to the referring primary care physician requesting a
follow-up on 25(OH)D and other biochemical markers at three months from the initial consultation,
which coincided with the final dietary consultation. This blood test was performed on the same day as
the final dietary consultation.
All 935 records of patients who were referred to this program between September 2011 and March
2013 were examined. Of these, 676 records were excluded based on the following predetermined
exclusion criteria: a history of diabetes mellitus, polycystic ovary syndrome, parathyroid disorder,
kidney or liver disease, osteopenia or osteoporosis, or current pregnancy, or taking any medication
known to affect body weight (such as steroids) or supplements such as calcium or vitamin D (>400 IU
of vitamin D2 or vitamin D3, not prescribed as part of this intervention). A further 47 patients were
excluded as they did not complete the follow-up blood test at three months. There were seven subjects
in the group which had sufficient 25(OH)D concentrations (≥50 nmol/L) at baseline, who received
vitamin D supplements. These were also excluded from the analysis.
Records of 205 healthy men and premenopausal women between the ages of 18 and 50 were coded
for analysis. Clinical parameters including blood pressure; fasting lipid profile, i.e., total cholesterol
(TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and
triglycerides (TG), and serum 25 hydroxyvitamin D (25(OH)D; as well as anthropometric measurements
(weight, height, and waist circumference) were collected from both baseline and three-month follow-up
consultations. Patients reported sun exposure frequency at baseline and exercise levels.
Overweight and obesity were classified according to BMI (overweight 25 to 29.9 kg/m2 and obesity
≥30 kg/m2) and waist circumference (overweight men 94.0 to 101.9 cm, women 80.0 to 87.9 cm, obesity
men ≥102.0 cm, and women ≥88.0 cm).
Biochemistry
Plasma levels of cholesterols and triglycerides were determined by standard laboratory methods
and were all performed by Laverty Laboratory, North Ryde, Sydney, Australia. They were measured
using an enzyme-based Siemens platform, where LDL was calculated in accordance with the Friedewald
equation (18). Normal ranges for lipid profile were provided by the commercial laboratory: TC (3.5–5.4
mmol/L), LDL (2.1–4 mmo/L), HDL (>=1 mmol/L), TG (0.1–2 mmol/L). Plasma 25(OH)D concentrations
were all determined at the Laverty Laboratory using the Diasorin Siemens chemiluminescent assay
and vitamin D insufficiency was defined as 25(OH)D level <50 nmol/L [19]. The assay characteristics
are described in [20].
3. Statistical Analysis
All analyses were performed using SPSS for Windows (version 17.0 SPSS, Inc., Chicago, IL, USA).
Analyzed data were collected from a clinical setting with intention-to-treat approach. Differences
in anthropometric and blood parameters between patients who had sufficient baseline 25(OH)D,
and insufficient baseline 25(OH)D with or without prescription of vitamin D supplementation, were
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assessed by one-way ANOVA followed by Tukey’s post-test. Comparisons for the within-group changes
in Table 1 were made using paired Student t-tests. Correlations were assessed by calculating Pearson
correlation coefficients. LOESS plots [21] were calculated by the SPSS program. Multivariate analysis
of changes in weight, BMI, and waist circumference were regressed against 25(OH)D concentrations
at follow-up using stepwise linear regression models using the following independent variables:
25(OH)D values at follow-up, adjusting for age, sex, season of baseline appointment, sun exposure,
and exercise and were split by prescription of vitamin D supplements. In the initial analyses, the
subjects who were vitamin D insufficient at baseline (25(OH)D <50 nmol/L) and supplemented with
2000 IU vitamin D3 per day, were analyzed separately from those who were supplemented with 4000
IU/day. There were no differences between these groups in terms of baseline parameters, except for
baseline 25(OH)D which was significantly lower at 31 ± 13 nmol/L in the subjects who were prescribed
4000 IU per day, as compared with 39 ± 16 nmol/L in those prescribed 2000 IU per day (p < 0.02). For
ease of data presentation and statistical power, these supplemented groups have been combined.





Parameters Mean ± SD Mean ± SD p value
Weight, kg 88.5 ± 18.3 82.9 ± 17.6 <0.001
BMI, kg/m2 31 ± 5.3 29.1 ± 5.2 <0.001
Waist circumference, cm 97.7 ± 14.1 93.7 ± 13.8 <0.001
25(OH)D, mmol/L 45.2 ± 18.7 54.0 ± 16.8 <0.001
BP systolic, mm Hg 126.1 ± 14.3 122.9 ± 11.4 <0.001
BP diastolic, mm Hg 77.8 ± 10.4 78.0 ± 8.5 NS
Total cholesterol, mmol/L 5.7 ± 3.7 5.1 ± 0.9 0.02
LDL, mmol/L 3.2 ± 0.9 2.9 ± 0.8 <0.001
HDL, mmol/L 1.5 ± 0.4 1.4 ± 0.3 NS
Triglycerides, mmol/L 1.6 ± 1.1 1.4 ± 0.8 <0.001
25(OH)D indicates serum 25-hydroxyvitamin D; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and
BP, blood pressure. Data are shown as mean values ± SD data from 205 subjects, except for total cholesterol and
triglycerides (204), LDL (194), and HDL (197). p values show differences between baseline and follow-up values, NS,
non-significant p > 0.05.
4. Results
4.1. Subject Characteristics
As shown in Table 1, there was a significant overall reduction in weight, BMI, waist circumference,
systolic blood pressure, LDL, and triglycerides after the three-month weight loss program.
There were 70 men and 135 women whose records were included in the study. Although the
men were significantly older (mean 39 years vs. 37 years, p = 0.007) and had significantly higher
weight, waist circumference, blood pressure, LDL, and triglyceride values, and lower HDL, at baseline,
they were not significantly different from the women in terms of baseline BMI, 25(OH)D, or the
proportion who were vitamin D sufficient (see Supplementary Table S1). At three months, there were
again no significant differences between males and females in terms of BMI, 25(OH)D concentrations,
or the proportion who were vitamin D sufficient, but differences in the other parameters persisted
(Supplementary Table S2). Sex had no significant effect on changes in weight, BMI, waist circumference,
25(OH)D concentration, or total cholesterol over the three-month period of analysis (p values of >0.05
for all). For this reason, in Table 1 and subsequent tables, data for male and female subjects have
been combined.
Consistent with the high prevalence of vitamin D insufficiency with obesity, the mean baseline
serum 25(OH)D concentration was insufficient (45 ± 19 nmol/L) and the mean baseline BMI classified
subjects as obese overall. At baseline, 3% of the baseline subjects were in the normal weight range,
50% were overweight, and 47% were obese. After three months on a weight loss program and
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supplementation with vitamin D for some individuals, the mean serum 25(OH)D level was significantly
higher than that of the baseline at 54± 17 nmol/L (p< 0.001) with a three month median and interquartile
range of 55 and 23 nmol/L, respectively, while the mean BMI and waist circumference were significantly
lower than that of the baseline (Table 1). After three months on the program, 22% of subjects were
normal weight, 45% were overweight, and 33% were obese.
4.2. Effect of Vitamin D Status and Supplementation on Anthropomorphic Measures and Other Parameters
Baseline serum 25(OH)D was significantly higher in the sufficient group as compared with the
deficient group (64 ± 11 vs. 33 ± 10 nmol/L, p < 0.001, Table 2). After three months on the program,
25(OH)D concentrations were similar to baseline values in both vitamin D sufficient and vitamin D
insufficient individuals not given supplemental vitamin D, despite advice to increase sun exposure
and take multivitamins (Table 2).
Table 2. Baseline values for anthropomorphic measures, lipids, and blood pressure, and baseline and
follow-up values for 25(OH)D with or without the three month supplementation with vitamin D.
Values are presented as means ± SDs.








N 82 123 48 75
Age (years) 37 ± 8.2 38 ± 7.5 37 ± 7.4 38 ± 7.6 0.485
% Female 60% 70% 67% 73%
Weight, kg 89 ± 17 88 ± 19 88 ± 17 87 ± 21 0.764
BMI, kg/m2 31 ± 5 31 ± 5 31 ± 4 31 ± 6 0.534
Waist, cm 97 ± 14 98 ± 14 98 ± 13 98 ± 15 0.922
Baseline 25(OH)D nmol/L 64 ± 11 a,b 33 ± 10 34 ± 10 32 ± 10 <0.001
Follow-up
25(OH)Dnmol/L 62 ± 11 a,b 49 ± 18 35 ± 11 57 ± 16
c <0.001
BP-systolic, mmHg 126 ± 14 126 ± 15 127 ± 13 125 ± 16 0.793
BP-diastolic mmHg 77 ± 10 78 ± 11 78 ± 10 78 ± 11 0.908
Total cholesterol mmol/L 5.9 ± 5.8 5.5 ± 1.1 5.5 ± 1.2 5.5 ± 1.0 0.704
LDL mmol/L 3.2 ± 0.8 3.2 ± 1.0 3.1 ± 1.1 3.3 ± 0.9 0.647
HDL mmol/L 1.5 ± 0.4 1.5 ± 0.4 1.5 ± 0.5 1.5 ± 0.4 0.950
triglyceride mmol/L 1.4 ± 0.9 1.7 ± 1.2 1.8 ± 1.4 1.6 ± 1.1 0.203
# For differences between sufficient at baseline, Insuf-NonSup and Insuf-Sup. The total column is presented for
information. a p < 0.05 Suf vs. Insuf-NonSup (Tukey’s post hoc test); b p < 0.05 Suf vs. Insuf-Sup (Tukey’s post hoc
test); c p < 0.05 Insuf-NonSup vs. Insuf-Sup (Tukey’s post hoc test). Significant p values are shown in bold.
At three months, the subjects who were vitamin D sufficient at baseline experienced significantly
greater body weight loss, BMI decrease, and waist circumference reduction than those with baseline
vitamin D deficiency (p < 0.001 for all, Table 3). The season of baseline appointment did not affect the
weight changes at three months.
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Table 3. Changes in 25(OH)D, weight, BMI, waist circumference, lipids, and blood pressure with or
without the three month supplementation with vitamin D. Values are presented as means ± SDs.
Sufficient at Baseline Insufficient at Baseline
ANOVA
p-Value #





N 82 123 48 75
Δ25(OH)D, mmol/L −1.7 ± 7 b 16 ± 17 1.0 ± 4.8 25 ± 16 c <0.001
Δweight, kg −7.7 ± 5.9 a,b −4.2 ± 3.3 −2.3 ± 1.6 −5.3 ± 3.6 c <0.001
ΔBMI, kg/m2 −2.6 ± 1.8 a,b −1.5 ± 1.1 −0.8 ± 0.6 −1.9 ± 1.2 c <0.001
Δwaist circum-ference, cm −5.2 ± 3.5 a −3.1 ± 3.1 −1.3 ± 1.3 −4.2 ± 3.4 c <0.001
Δsystolic BP, mmHg −4.8 ± 9.2 −2.2 ± 11 −3.1 ± 8.4 −1.6 ± 12 0.165
Δdiastolic BP, mmHg −0.2 ± 8.6 0.4 ± 9.1 1.4 ± 8.2 −0.2 ± 9.6 0.553
ΔTotal Cholesterol mmol/L −1.0 ± 5.6 −0.3 ± 0.5 −0.2 ± 0.4 −0.4 ± 0.5 0.378
ΔLDL mmol/L −0.4 ± 0.4 a −0.26 ± 0.5 −0.1 ± 0.4 −0.4 ± 0.5 c 0.002
ΔHDL mmol/L −0.1 ± 0.2 −0.1 ± 0.2 −0.1 ± 0.2 −0.1 ± 0.2 0.380
Δtriglycerides mmol/L −0.2 ± 0.4 −0.2 ± 0.7 −0.2 ± 0.9 −0.2 ± 0.5 0.920
# For differences between sufficient at baseline, Insuf-NonSup and Insuf-Sup. The total column is presented for
information. a p < 0.05 Suf vs. Insuf-NonSup (Tukey’s post hoc test); b p < 0.05 Suf vs. Insuf-Sup (Tukey’s post hoc
test); c p < 0.05 Insuf-NonSup vs. Insuf-Sup (Tukey’s post hoc test). Significant p values are shown in bold.
Of the subjects with baseline vitamin D insufficiency, 60% received vitamin D supplements, which
raised 25(OH)D concentrations significantly (p< 0.001, Tables 2 and 3). The initially low vitamin D status
subjects who received supplemental vitamin D also experienced significantly greater body weight loss,
as well as a greater reduction in BMI and waist circumference than those who were not supplemented
(p < 0.001 for all parameters, Table 3). Vitamin D supplementation resulted in a significant decrease in
LDL-cholesterol levels in this group as compared with the non-supplemented subjects (p < 0.01, Table 3).
However, there were no significant differences in the changes in total cholesterol, HDL-cholesterol,
TG, diastolic, or systolic BP between the subjects who received supplements and those who did not.
Even with supplementation, the reductions in weight, BMI, and waist circumference in the initially
vitamin D deficient group were significantly lower than those of the initially vitamin D sufficient group
(p < 0.001).
The increase in 25(OH)D concentrations in those subjects who were initially vitamin D deficient
and prescribed 2000 IU/day (n = 40) was 15 ± 7 nmol/L, significantly lower than the 37 ± 15 nmol/L
increase in 25(OH)D concentrations in those subjects prescribed 4000 IU/day of vitamin D (n = 30) (p <
0.02 as compared with the lower dose group). Those subjects who were vitamin D deficient at baseline
and who were prescribed 4000 IU of vitamin D3 daily, lost significantly more weight (−6.9 vs. −4.4 kg;
p < 0.001), significantly reduced their BMI to a greater extent (−2.5 vs. −1.5 kg/m2; p = 0.001), and
reduced their waist circumference more effectively (−5.3 vs. −3.3 cm; p < 0.001) than those who were
told to take 2000 IU daily. The dose of supplemental vitamin D did not significantly affect changes in
LDL, HDL, and total cholesterol.
The relationship between changes in weight, BMI, and waist circumference, and concentrations of
25(OH)D at three months, for all patients are shown in Figure 1a–c. In general, the largest decreases in
each of these measurements were in patients whose follow-up 25(OH)D was above 50 nmol/L. After
adjusting for age, sex, season, sun exposure, and exercise, a stepwise multivariate regression model for
changes in weight, BMI, and waist circumference showed that body weight loss, and decreases in BMI
and waist circumference reduction were all significantly associated with 25(OH)D concentrations as
the independent variable at three months (Table 4).
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Table 4. Multivariate regression model # for the association between changes in weight, BMI, and waist
circumference with concentrations of 25(OH)D at 3 months.
Insufficient at Baseline N = 123 All SubjectsN = 205







N 48 75 130 75
Δweight, kg −0.45 *** −0.61 *** −0.47 *** −0.60 ***
ΔBMI, kg/m2 −0.45 *** −0.63 *** −0.46 *** −0.63 ***
Δwaist circumference, cm −0.75 *** −0.29 *** −0.55 *** −0.29 ***
Data expressed as adjusted beta coefficients # Adjusted for age, sex, season, sun exposure, and exercise. Difference =
(follow-up – baseline) values, *** p < 0.001.
5. Discussion
The results presented here, derived from clinical dietetic practice, showed that higher baseline
vitamin D status was associated with significantly greater weight loss and larger reductions in BMI
and in waist circumference during a weight loss program. The analysis also showed that, on this
individually tailored weight loss program, vitamin D supplementation for those participants who
were vitamin D insufficient at baseline, enhanced weight loss, BMI reductions, and reductions in
waist circumference.
Although there have been a number of studies on the effects of vitamin D status and vitamin
D supplementation on weight loss and related parameters over time (reviewed in [22–24]), most of
these studies did not include subjecting participants to an individually tailored weight loss regimen.
Overall, the results of meta-analyses of studies which did not include a specific weight loss regimen,
showed that while better vitamin D status before or during a randomized controlled trial of vitamin D
supplementation predicted greater weight or fat loss over time in a few studies, overall there was no
effect of vitamin D supplementation on body mass index or fat mass, even in larger studies of longer
duration, such as that of Sneve et al. [25]. A recent publication reported a significant reduction in
waist circumference in subjects in a randomized controlled trial of 16 weeks of high dose vitamin D
supplements vs. placebo [26]. The subjects were of Asian ethnicity living in Melbourne, Australia and
this was a secondary analysis of the trial, which did not include instructions on weight loss. Vitamin D
status has been reported to affect weight loss and related parameters in some trials involving weight
loss regimens [27,28], but not in the majority of such studies, although body weight or composition
were secondary outcomes in most of these studies [22,23]. A recent review by Bassatne et al. (2019)
found no clear evidence for a beneficial effect of vitamin D supplementation on cardiometabolic
parameters in obese individuals and the authors concluded that Vitamin D supplementation had no
effect on weight loss [24], although data on biochemical parameters and weight loss are very scarce.
In a study of children with variants in the fat mass and obesity-associated gene (FTO), which affect
adiposity in an age-dependent manner, it was reported that FTO genotype re9939609 was associated
with a significant weight gain in children who were vitamin D insufficient, defined as <75 nmol/L, but
no significant genetic effects were observed in vitamin D sufficient children [29].
There have been very few randomized controlled trials which were designed to examine the
effect of vitamin D supplementation on weight loss and body composition during a weight loss
program. Zittermann et al. [14] randomized 200 healthy overweight men and women, with mean
25(OH)D of 30 nmol/L, who were on an individually tailored weight loss program, to either vitamin D3
supplementation (83 ug = 3332 IU/day) or a placebo. At the end of 12 months, 25(OH)D concentrations
were 55 nmol/L higher in the supplemented group, but there was no significant difference in weight
loss over this time between the two groups. Mason et al. [16] enrolled 218 overweight or obese women
over 50 years, with baseline 25(OH)D between 25 and 80 nmol/L (mean 53 nmol/L) and randomized
them to a weight loss program with 2000 IU/d of vitamin D3 or to weight loss with a placebo. Although
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changes in weight, BMI, and waist circumference were similar between the groups overall at 12 months,
those women whose 25(OH)D rose to above 80 nmol/L (≥32 ng/mL) lost significantly more weight and
reduced their waist circumference and percent body fat to a significantly greater extent than women
who achieved a 25(OH)D of <80 nmol/L [16].
In our study there was no effect of vitamin D status at baseline or of vitamin D supplementation
on changes in systolic or diastolic blood pressure, or changes in total cholesterol, HDL, or triglycerides.
The decrease in LDL, however, was significantly greater in the baseline sufficient subjects as compared
with the deficient group as a whole, and in the latter group, was significantly greater in those
supplemented with vitamin D (Table 3). Mason et al. [16] did not report lipid data but did show a
significant decrease in C-reactive protein in the vitamin D supplemented group amongst those with
complete pill counts (97%) as compared with a placebo. Although Zitterman et al. [14] showed no
effect of vitamin D supplementation on weight loss in their 12-month randomized controlled trial,
vitamin D supplementation resulted in significant decreases in triglyceride and TNF-α concentrations,
but a significant increase in LDL cholesterol. There have been inconsistent results reported in
several studies, overall showing no effect on cardiovascular or inflammatory markers with vitamin D
supplementation, although these were not carried out in conjunction with an individually tailored
weight loss program [30].
The current analysis examined data was neither randomized nor blinded, and therefore the
potential effects of conscious or unconscious bias cannot be discounted. Another limitation is the use of
24 h recall to assess adherence to the dietary plan, which is known to be biased by misreporting [31,32],
specifically underreporting. Due to this limitation, which is difficult to overcome, it is not possible to
properly assess the role that different energy intakes affected weight loss. The initial data included all
records of those who attended the clinic for the standardized chronic disease management plan in
the period September 2011 to March 2013. The criteria for exclusion were decided in advance of the
data collection and, as expected, excluded a very large number of subjects. Nevertheless, the cohort of
patients whose data were analyzed were all part of a standardized chronic disease management plan
established through a clinical partnership between three medical centers and a dietetics clinic. The main
variable was the referring primary care physician’s preference for improvement of vitamin D status in
the patients (either advice to increase sun exposure +multivitamins (in Australia, multivitamins have
negligible vitamin D), or supplementation with either 2000 IU/d or 4000 IU/d of vitamin D3). Based
on the data in Table 2, the groups were well matched. As patients were not randomized, there is a
possibility that the effects of vitamin D supplementation were chance findings. The patient numbers in
each of these groups were limited, so it is difficult to make definitive interpretations, although the
apparently greater weight loss in the group supplemented with 4000 IU/day, who achieved higher
25(OH)D concentrations than those supplemented with 2000 IU/day, is intriguing and may at least
provide preliminary data for future studies. Critical for vitamin D studies that are interpretable [33],
the mean baseline 25(OH)D concentrations in the deficient group in this study were both well below
50 nmol/L, nearly 60% of subjects were deficient at baseline, and, although tablet counts were not
performed, those who were supplemented increased their 25(OH)D concentrations by an average of 25
nmol/L (baseline deficient group).
A strength of this analysis is that the female and male subjects in the clinical cohort were relatively
young, with a mean age <40 y. BMI and 25(OH)D concentrations did not differ between men and
women at baseline or at three months (Supplementary Tables S1 and S2). Sex had no significant
effect on changes in BMI, waist circumference, or 25(OH)D, and therefore males and females were
combined for further analysis to increase statistical power. Nevertheless, there were effects of sex on
other parameters tested. A further limitation of the analysis is that the data in Tables 2 and 3 were not
adjusted for sex or other factors, unlike Table 4, which may have influenced the outcomes reported.
As indicated by the multivariate analysis (Table 4), the effect of the achieved 25(OH)D concentration
on changes in weight, BMI, and waist circumference was present even after adjustment for age, sex,
season, and physical activity, indicating that these factors did not explain the effect of vitamin D
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supplementation. The mechanisms which might explain an effect of vitamin D status on weight loss
are poorly understood. It is generally agreed that high body fat is likely to cause low vitamin D status,
due to sequestration of vitamin D in adipose tissue [11]. A Mendelian randomization approach has
also reported that a higher BMI leads to low vitamin D status and not the other way around [13].
Possible explanations about how vitamin D status could influence adiposity are still speculative.
Since low vitamin D results in increased parathyroid hormone, this increased parathyroid hormone
could increase calcium influx into adipocytes, which in turn, could inhibit lipolysis and stimulate
lipogenesis [34]. Adipocytes express 1α-hydroxylase [35] and actively accumulate 25(OH)D [36]. As
reviewed by Ding et al. [2] the vitamin D receptor (VDR) is expressed in adipocytes and preadipocytes
and its expression has been shown to be dynamically upregulated during adipogenesis. Paradoxically,
VDR knockdown in adipocytes inhibited adipogenesis and VDR knockout mice showed less body
fat and were resistant to diet-induced obesity [37]. Effects of vitamin D status on central control of
appetite are also plausible, considering the wide expression of the VDR in the central nervous system,
including the hypothalamus [38].
Decreases in anthropomorphic parameters in our study were generally greater in those subjects
who were initially vitamin D sufficient, regardless of later supplementation. In those who were
vitamin D deficient at baseline, supplementation with vitamin D improved the weight loss parameters
measured. After initiation of a supplementation regimen, it takes approximately three months for
25(OH)D to reach a plateau [39,40], and therefore the initially deficient patients would have remained
relatively deficient for part of the study period.
On the basis of these findings, we cannot discard the hypothesis that sufficient serum 25(OH)D
concentrations could be a determinant of the success of a weight loss program. Since vitamin D is
synthesized endogenously, it would not be possible to show an effect of supplementation in subjects
who are already “sufficient” by whatever criteria this is determined. Indeed, in this study, a large
proportion (60%) of the clinic population were vitamin D deficient at baseline. The results of the study
support the proposal that correction of low levels of 25(OH)D could benefit weight loss and the lipid
profile of some overweight or obese patients, leading to the conclusion that, in clinical practice, it is
important to individualize vitamin D therapy and educate the patient on the need for supplementation
only when necessary.
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Abstract: Vitamin D deficiency is a worldwide health problem that, in addition to its well-known
negative effects on musculoskeletal health, has been related to a wide range of acute and chronic
age-related diseases. However, little is known about the association of body composition with the
active, hormonal form of vitamin D, 1,25-dihydroxyvitamin D plasma levels (1,25(OH)2D). Therefore,
the aim of this study was to investigate the association of 1,25(OH)2D with body composition including
lean and fat body mass as well as bone mineral density (BMD) in middle-aged sedentary adults. A total
of 73 (39 women) middle-aged sedentary adults (53.7 ± 5.1 years old) participated in the current study.
We measured weight and height, and we used dual energy X-ray absorptiometry to measure lean body
mass, fat body mass and BMD. Body mass index (BMI), lean mass index (LMI), and fat mass index (FMI)
were calculated. 1,25(OH)2D was measured using a DiaSorin Liaison®immunochemiluminometric
analyzer. The results showed a negative association of 1,25(OH)2D with BMI, LMI and BMD
(β = −0.274, R2 = 0.075, p = 0.019; β = −0.268, R2 = 0.072, p = 0.022; and β = −0.325, R2 = 0.105,
p = 0.005, respectively), which persisted after controlling for age and sex. No significant differences in
1,25(OH)2D across body weight status were observed after controlling for the same covariates. In
summary, our results suggest that 1,25(OH)2D could be negatively associated with BMI, LMI and
BMD whereas no association was found with FMI in middle-aged sedentary adults.
Keywords: vitamin D; calcitriol; body mass index; lean mass; fat mass; bone mineral density
1. Introduction
As the world´s population ages, the prevalence of chronic diseases increases, particularly over
the last decades, becoming one of the great challenges that society faces [1,2]. Abnormalities in body
composition such as a decrease of lean body mass and/or bone mineral density (BMD) or an increment
in fat body mass are powerful predictors of morbidity and mortality risk as well as overall quality
of life [3]. Epidemiologic studies indicate that these body composition changes are closely related to
obesity, sarcopenia and/or osteoporosis in the elderly population [3,4]. However, these chronic diseases
are progressive and initiate at a younger age [5,6]. Their high prevalence and concomitant health
risk make them a particularly relevant worldwide public health problem and a social and economic
burden [7–9].
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Vitamin D is a fat-soluble vitamin essential for normal homeostasis of calcium and phosphorus, as
well as for bone health [10] and preventing falls [11] and fractures [12]. Globally, vitamin D deficiency
has been considered as a major public health problem affecting not only musculoskeletal health
but also a wide range of several age-related chronic diseases [13]. 25-hydroxyvitamin D (25(OH)D)
is the most commonly used biomarker when evaluating the relationship of vitamin D status with
health-related outcomes [14–17]. However, 25(OH)D is thought to be largely inactive since it requires
to be metabolized in the kidney by the enzyme 25-hydroxyvitamin D-1α-hydroxylase to be active.
Therefore, 1,25-dihydroxyvitamin D (1,25(OH)2D), also known as calcitriol, is responsible for most, if
not all, of its biological effects [18,19]. The association between 1,25(OH)2D and body composition
parameters has been hard to establish for several reasons: (i) previously there was not a reliable and
sensitive assay for calcitriol [20,21] and (ii) 25(OH)D has a higher concentration and longer half-life
than 1,25(OH)2D, thus requiring less sample volume for reliable measurements [22].
Consequently, epidemiological data are scarce, and a review of the scientific literature found
no large studies examining the relationship between 1,25(OH)2D and body composition outcomes.
There is some evidence of the existence of an inverse association of 1,25(OH)2D with body mass index
(BMI) and fat body mass [23,24], however these data are conflicting with other studies [25–28]. In
contrast, data are scarce on the potential relationship between 1,25(OH)2D and lean body mass. Two
recent studies found a significant association between low 1,25(OH)2D and low lean body mass [29,30],
which is highly dependent on the individual’s age [29]. Similarly, controversial findings have been
discovered regarding the role of 1,25(OH)2D in bone health. Previous cross-sectional studies have
reported an inverse association between 1,25(OH)2D and BMD [31–33], whereas other studies found
that 1,25(OH)2D was unrelated to bone mineral content [34], bone loss [33,35] or hip fracture risk [36,37].
There are limited data on the study of body composition parameters in relation to 1,25(OH)2D
status in middle-aged adults. Thus, understanding whether 1,25(OH)2D is associated with body
composition parameters in this population is of clinical interest since, as previously established, the
interventions to delay or reverse body composition related diseases are preferable when individuals
are still relatively young and healthy [38,39].
Therefore, the aim of this study was to investigate the association of 1,25(OH)2D with body
composition including lean and fat body mass as well as BMD in middle-aged sedentary adults.
2. Materials and Methods
2.1. Study Design and Participants
The present cross-sectional study was conducted under the framework of the FIT-AGEING study
(clinicaltrial.gov: ID: NCT03334357) [40]. The Ethics Committee on Human Research of the Regional
Government of Andalucía approved the rationale, design, and methodology of the study [0838-N-2017]
and all participants signed written informed consent in accordance with the Declaration of Helsinki
(last revision guidelines, 2013).
Seventy-three middle-aged sedentary adults were recruited via electronic media, social networks
and leaflets. The inclusion criteria were as follows: (i) to be sedentary (i.e., less than 20 min of
physical activity on less than 3 days/week), (ii) not to have had greater body weight changes than
3 kg in the past 3 months, (iii) to be aged between 45 and 65 years old, (iv) not to be a smoker, (v) to
be taking no long-term medication, (vi) not to be pregnant and (vii) not to suffer from any chronic
cardiometabolic disease.
All tests were performed during September–October 2016/17 at the Sport and Health University
Research Institute (iMUDS, Granada, Spain) and at the “Campus de la Salud” Hospital (Granada, Spain).
2.2. Anthropometric Parameters and Body Composition Assessment
A pre-validated Seca model 799 scale and stadiometer (Seca, Hamburg, Germany) was used
to measure body weight and height with light clothing and without shoes. BMI was subsequently
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calculated as weight (kg)/height (m2). Body composition outcomes were determined by a dual-energy
X-ray absorptiometry scanner (Discovery Wi, Hologic, Inc., Bedford, MA, USA) obtaining lean body
mass in kg, fat body mass in kg, and BMD in g/cm2. A spine phantom quality check scan was conducted
on each study day. A whole-body scan was performed considering all manufacturer´s guidelines
(i.e., the positioning of participants, the analysis of results and the quality controls among others).
The APEX 4.0.2. software was used to draw an automatic delineation of anatomic regions. The lean
mass index (LMI) was calculated as lean body mass (kg)/body height (m2). Similarly, we calculated
the fat mass index (FMI) as fat body mass (kg)/body height (m2). Fat mass was also expressed as a
percentage of the total body mass. The participants were categorized into three groups on the basis of
BMI levels: (i) normal weight (BMI ≥ 18.5 and <25 kg/m2), (ii) overweight (BMI ≥ 25 and <30 kg/m2),
and (iii) obese (BMI ≥ 30 kg/m2).
2.3. Dietary Intake Assessment
We performed a total of three 24-hour dietary recalls collected on non-consecutive days (one
weekend day included). This validated method is able to determine the energy intake to within 8–10%
of the current energy intake [41]. The interviews were meal sequence-based, in which a detailed
description of the food consumed by the participants was recorded. The 24-hour dietary recalls were
collected by an experimented and qualified research dietitian (L.J.-F.), using a photograph guide to
improve the quality of the information provided on portion sizes of food and assisting participants in
the estimation of the consumed food quantity [42]. The software EvalFINUT® updated with data from
USDA (U.S. Department of Agriculture) and BEDCA (“Base de Datos Española de Composición de
Alimentos”) was used to calculate energy and micronutrient (i.e., vitamin D, calcium and phosphorus)
intake derived from the 24-hour recalls.
2.4. Physical Activity Assessment
Physical activity levels were objectively assessed with a wrist-worn accelerometer (ActiGraph
GT3X+, Pensacola, FL, United States) for 7 consecutive days (24 hours/day) [40]. The sampling
frequency was previously set at 100 Hz to store raw accelerations [43]. The ActiLife v.6.13.3 software
(ActiGraph, Pensacola, FL, United States) and the GGIR package (v.1.5-122) in R (v.3.1.23) were used
to process these files [44,45]. The participants came to the laboratory and specific information about
how to wear the accelerometer was given. They were also reminded to remove it only during
water-based activities such as swimming or bathing. Only the participants who wore the accelerometer
for ≥16 hours/day for 4 days (including 1 weekend day) were included in the analysis.
2.5. Blood Samples Assessment
A 10 mL peripheral blood sample was taken from the antecubital vein after overnight fasting. It
was collected using the Vacutainer SST system (Becton Dickinson, Plymouth, UK) in ethylenediamine
tetra-acetic acid-containing tubes. Blood samples were centrifuged at four thousand revolution per
minute for seven minutes at 4 ◦C and stored at −80 ◦C. Plasma levels of 1,25(OH)2D were measured
using a DiaSorin Liaison®immunochemiluminometric analyzer (DiaSorin Ltd, Wokingham, Berkshire,
UK) and expressed in pg/mL.
2.6. Statistical Analysis
Data were checked for normality with the use of distribution plots (i.e., visual check of histograms,
and Q-Q plots) and the Shapiro-Wilk test. The descriptive parameters were reported as mean and
standard deviation.
Differences between sexes were examined using an independent samples T test. Given that
no interaction for sex was observed (p > 0.05), data are presented for men and women together.
Simple linear regression models were built to test the association of 1,25(OH)2D and body composition
outcomes (i.e., BMI, LMI, FMI, and BMD). We also performed multiple linear regression models to
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analyze these associations controlling for age (Model 1), sex (Model 2), and age and sex (Model 3).
Additionally, we also adjusted these models for total energy, vitamin D, calcium, phosphorus intake
and/or physical activity levels (i.e., light, moderate-vigorous and total physical activity). To test
whether 1,25(OH)2D was different across body weight status (i.e., normal-weight, overweight and
obese individuals), an analysis of variance (ANOVA) was conducted. Moreover, we performed an
analysis of covariance to test the differences of 1,25(OH)2D across weight status adjusting for age
and sex.
Data were analyzed with the use of the Statistical Package for Social Sciences (SPSS, v. 22.0, IBM
SPSS Statistics, IBM Corporation, Armonk, NY, USA). Graphical plots were built using the GraphPad
Prism 5 (GraphPad Software, San Diego, CA, USA). The level of significance was fixed at <0.05.
3. Results
Table 1 shows the descriptive parameters of our study participants by sex. No significant
differences in 1,25(OH)2D were observed between men and women (p = 0.576).
Table 1. Descriptive characteristics of participants.
N All N Men N Women
Age (years) 73 53.7 (5.1) 34 54.6 (5.2) 39 53 (5.0)
Body composition parameters
Body mass index (kg/m2) 73 26.7 (3.8) 34 28.3 (3.6) 39 25.3 (3.3) *
Lean mass (kg) 73 43.2 (11.7) 34 53.9 (6.5) 39 34.1 (5.8) *
Lean mass index (kg/m2) 73 15.2 (2.9) 34 17.5 (2.0) 39 13.2 (1.8) *
Fat mass (%) 73 40.1 (8.9) 34 34.7 (8.0) 39 44.5 (7.4) *
Fat mass (kg) 73 30.1 (8.5) 34 30.9 (9.8) 39 29.2 (7.1)
Fat mass index (kg/m2) 73 10.8 (3.1) 34 10.0 (3.2) 39 11.4 (2.9)
Bone mineral density (g/cm2) 73 1.1 (0.1) 34 1.2 (0.1) 39 1.0 (0.1) *
Dietary intake
Total Energy intake (kcal/day) 72 2071.7 (455.4) 34 2312.1 (402.9) 38 1854.6 (390.3) *
Vitamin D intake (μg/day) 72 5.0 (6.0) 34 3.8 (3.3) 38 6.1 (7.6)
Calcium intake (mg/day) 72 763.4 (340.5) 34 867.3 (396.9) 38 670.5 (251.4) *
Phosphorus intake (mg/day) 72 1324.7 (558.9) 34 1507.6 (689.6) 38 1161.0 (342.2) *
Physical activity parameters
LPA (min/day) 70 173.7 (45.4) 33 169.9 (52.7) 37 178.0 (40.7)
MVPA (min/day) 70 95.8 (35.6) 33 96.4 (37.1) 37 96.6 (35.7)
Total PA (min/day) 70 269.5 (75.1) 33 265.2 (79.3) 37 273.3 (72.0)
Blood parameters
1,25 Dihydroxyvitamin D (pg/ml) 73 40.3 (14.1) 34 38.3 (13.4) 39 42.0 (14.6)
Dara are presented as means (standard deviation). Abbreviations: LPA, light physical activity; MVPA,
moderate-vigorous physical activity; PA, physical activity. * Significance differences between sexes (p < 0.05)
obtained by the independent sample T test.
Figure 1 shows the associations between 1,25(OH)2D and body composition related parameters.
There was a significant negative association of 1,25(OH)2D with BMI (β = −0.274, R2 = 0.075, p = 0.019,
Figure 1A), LMI (β = −0.268, R2 = 0.072, p = 0.022, Figure 1B) and BMD (β = −0.325, R2 = 0.105,
p = 0.005, Figure 1D), which persisted after including age, sex, and age and sex in the model (all
p ≤ 0.042, Table 2). 1,25(OH)2D was not significantly associated with FMI (β = −0.080, R2 = 0.006,
p = 0.502; Figure 1C), which did not change adjusting for age, sex, and age and sex (all p ≥ 0.35,
Table 2). The results remained unchanged after further adjusting for total energy, vitamin D, calcium,
phosphorus intake and/or physical activity levels (i.e., light, moderate-vigorous and total physical
activity) (data not shown, all p > 0.1).
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Figure 1. Simple linear regression graphs between 1,25-Dihydroxyvitamin D (1,25(OH)2D) and body
mass index (BMI) (A), lean mass index (LMI) (B), fat mass index (FMI) (C), and bone mineral density
(BMD) (D) in middle-aged sedentary adults. β (standardized regression coefficient), R2, and P from a
simple linear regression analysis.
Table 2. Association of 1,25-Dihydroxyvitamin D with body mass index, lean mass index, fat mass
index and bone mineral density.
1,25-Dihydroxyvitamin D
Model 1 Model 2 Model 3
p value β p value β p value β
Body mass index (kg/m2) 0.020 −0.274 0.040 −0.263 0.042 −0.262
Lean mass index (kg/m2) 0.023 −0.269 0.030 −0.383 0.032 −0.383
Fat mass index (kg/m2) 0.505 −0.080 0.354 −0.112 0.356 −0.113
Bone mineral density (g/cm2) 0.005 −0.325 0.009 −0.370 0.009 −0.377
Model 1 was adjusted for age; Model 2 was adjusted for sex; and Model 3 was adjusted for age and sex. p value of
multiple-regression analysis. β (standardized regression coefficient). Values in bold indicate significance differences
(p < 0.05).
ANOVA revealed no significant differences in 1,25(OH)2D across body weight status
(45.3 ± 13.3 pg/mL in normal-weight, 37.8 ± 13.1 pg/mL in overweight and 38.4 ± 16.7 pg/mL in obese
individuals; Figure 2), which persisted after including age and sex as a covariate (44.8 ± 13.1 pg/mL in
normal-weight; 37.9 ± 12.3 pg/mL in overweight and 38.9 ± 14.0 in obese individuals; p = 0.2).
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Figure 2. 1,25-Dihydroxyvitamin D (1,25(OH)2D) by body weight status categories in middle-aged
adults. Values are presented as means and standard error. p value obtained from the analysis of the
variance to compare 1,25(OH)2D across weight status (normal-weight, over-weight, and obese).
4. Discussion
The main results of the present study suggest that 1,25(OH)2D is negatively associated with BMI,
LMI and BMD independently of age and sex, whereas no association was found between 1,25(OH)2D
and FMI in middle-aged sedentary adults.
There is a controversy in the scientific literature regarding the 1,25(OH)2D status of obese
individuals. It has been described in classical studies that there are greater levels of 1,25(OH)2D
(~20 to 30%) in both obese men and women [25–28,46]. However, although we did not find any
significant differences between BMI groups, we observed that overweight and obese individuals have
~16.6% and ~15.3% lower 1,25(OH)2 than normal-weight individuals, which agrees with a previous
large cohort that reported a ~18% lower 1,25(OH)2D in the obese group compared with their lean
counterparts [23,24]. These discrepancies between studies cannot be attributed to the individual´s age,
sex and/or BMI, since the participants had similar biological characteristics. A seasonal effect might
explain these controversial results as the 1,25(OH)2D assessment was conducted in winter months [46]
or spring months [27] in some studies, while others did not control the season in which the blood
samples were taken [24]. Given that the effects of ultraviolet ray exposure on 25(OH)D could be
different for obese and lean individuals, the time of the year when the study was conducted may
be of importance. However, previous studies have suggested that the season of the year does not
present the same influence on 1,25(OH)2D as it has on 25(OH)D [47]. The different 1,25(OH)2D assay
methods used across the studies could be one important factor to consider. While older studies applied
radioreceptor assays [25–28,46] in which lipid interferences have been described when samples are
not pure enough [48], more recent studies including our own study used modern immuno assays for
the assessment of 1,25(OH)2D [30,32]. Taken all together, it is likely that obese subjects present low
1,25(OH)2D. This fact could be explained because obesity is associated with poor levels of 25(OH)D,
and it has been demonstrated that 1,25(OH)2D depends on substrate availability [23,49]. A higher fat
body mass offers a greater distribution space for both fat-soluble compounds. Additionally, obese
individuals are usually exposed to negative lifestyle factors (i.e., unhealthy dietary habits and sedentary
behaviour, among others), [50] and to lower sunlight exposure [51]. These lifestyle factors have been
shown to have a negative influence on vitamin D status [52,53].
The use of 25(OH)D as a key marker of vitamin D status has logical advantages summarized as
greater serum stability and a longer half-life than other markers (e.g., 1,25(OH)2D) [22]. However,
it is important to consider that it is biologically inactive and therefore could not be the best vitamin
D function indicator [54]. The shorter half-life of 1,25(OH)2D could be one of the reasons why the
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relationship of 1,25(OH)2D and lean body mass has not been deeply studied. Hassan-Smith et al.
reported a positive association between 1,25(OH)2D and lean body mass [29]. These findings differ
from those observed in our study in which we obtained higher 1,25(OH)2D in individuals with lower
lean body mass. These discrepancies could be explained by the different biological characteristics of
the subjects of the study (i.e., our cohort was older than the Hassan-Smith et al. study [29]) and by
the different assay methods used to determine 1,25(OH)2D. New studies measuring 1,25(OH)2D are
necessary to clarify this issue.
We also found a negative association between 1,25(OH)2D and BMD in our study cohort which
concurs with a previous study that reported a positive association of 1,25(OH)2D and the bone
resorption marker β-cTX [32]. These results are consistent with the notion that 1,25(OH)2D increases
bone resorption via stimulating intestinal calcium absorption after calcium intake [32]. Moreover,
recent animal and in vitro studies have proposed that 1,25(OH)2D has a direct effect on osteoclasts
inducing bone resorption by its interaction with the receptor activator of nuclear factor-κβ/receptor
activator of nuclear factor-κβ ligand signaling pathway [55,56]. Taking this into consideration, an
inverse association would be expected between 1,25(OH)2D and bone mineral density. In addition, it
seems plausible that 1,25(OH)2D is produced when BMD is low and once BMD is recovered 25 (OH)D
is transformed into the inactive 24,25(OH)2D. Although this argument could explain our findings,
further intervention studies are needed to understand this issue.
Our study has some limitations. The cross-sectional design does not allow ascribing causality to the
observed relationships. Further, our study population was limited to sedentary healthy middle-aged
adults (45–65 years old) and hence these results may not be generalizable to younger, older, and/or
physically active individuals. This study, like most clinical studies, was based on a single assay of
1,25(OH)2D. We did not assess the 24-hydroxyvitamin D2 plasma levels. In addition, a whole-body
DXA scan was conducted, so future studies are necessary to investigate whether spine and hip bone
mineral density have the same association pattern. Finally, due to the relatively small sample size of
the current study, the data should be interpreted with caution. One of the strengths of this study is
that body composition was measured using a gold-standard technology, such as dual-energy X-ray
absorptiometry. In addition, the measurement of objective physical activity data and dietary intake to
be used as covariates represent further strengths.
5. Conclusions
In conclusion, our results suggest that 1,25(OH)2D could be negatively associated with BMI,
LMI and BMD independently of age and sex, while no significant relationship was obtained
between 1,25(OH)2D and FMI in middle-aged sedentary adults. Intervention studies are needed to
understand whether changes in body composition status are associated with changes in 1,25(OH)2D in
this age-population.
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Abstract: The association between vitamin D [25(OH)D] and bone health has been widely studied in
children. Given that 25(OH)D and bone health are associated with muscular fitness, this could be the
cornerstone to understand this relationship. Hence, the purpose of this work was to examine if the
relation between 25(OH)D and areal bone mineral density (aBMD) was mediated by muscular fitness
in children with overweight/obesity. Eighty-one children (8-11 years, 53 boys) with overweight/obesity
were included. Body composition was measured with dual energy X-ray Absorptiometry (DXA),
25(OH)D was measured in plasma samples and muscular fitness was assessed by handgrip and
standing long jump tests (averaged z-scores were used to represent overall muscular fitness). Simple
mediation analyses controlling for sex, years from peak height velocity, lean mass and season were
carried out. Our results showed that muscular fitness z-score, handgrip strength and standing long
jump acted as mediators in the relationship between 25(OH)D and aBMD outcomes (percentages of
mediation ranged from 49.6% to 68.3%). In conclusion, muscular fitness mediates the association
of 25(OH)D with aBMD in children with overweight/obesity. Therefore, 25(OH)D benefits to bone
health could be dependent on muscular fitness in young ages.
Keywords: Vitamin D; strength; bone health; mediation; childhood; obesity
1. Introduction
The World Health Organization defines osteoporosis as a systemic skeletal disease characterized
by low bone density and microarchitectural deterioration of bone tissue [1]. Acquiring an optimal
bone mineral accrual during childhood (i.e., late childhood and peripubertal years) is considered
an important factor for reducing the risk of osteoporosis later in life [2]. In general, children with
overweight/obesity usually have a greater areal bone mineral density (aBMD) than normal-weight
children as they mature earlier, tend to be taller and have greater lean mass [2]. Notwithstanding,
Nutrients 2019, 11, 2760; doi:10.3390/nu11112760 www.mdpi.com/journal/nutrients39
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Rokoff et al. [3] recently showed central adiposity to be inversely associated with aBMD Z-score at the
total body less head (TBLH) in children with high levels of abdominal fat.
Childhood obesity is associated with a deficient 25(OH)D status in Spain [4]. Vitamin D status is
reflected by 25-hydroxyvitamin D (25(OH)D) levels and its concentration in children with obesity is
influenced by vitamin D intake, season, ethnicity/race, decreased exposure to sunlight as a consequence
of the sedentary lifestyle, or by 25(OH)D sequestration through adipose tissue [5]. This prohormone
is essential for bone development and remodeling processes, as well as for normal calcium and
phosphorus homeostasis [6]. Some studies evidenced that 25(OH)D-deficient children had lower
aBMD Z-score at the lumbar spine (LS) and the total body, probably influenced by the consequent
increase in parathormone levels [7,8].
Moderate-to-high muscular fitness at a young age is a powerful determinant of health [9].
In this regard, Torres-Costoso et al. [10] found that children with good performance in handgrip and
standing long jump had better and worse bone health, respectively. The latter associations were fully
mediated by lean mass, whose function seems to be influenced by 25(OH)D levels [11]. When calcitriol
(1,25(OH)2D, an active metabolite of vitamin D) activates the nuclear vitamin D receptor (VDR), several
slow pathways are activated leading to cytoskeletal protein synthesis important for muscle function
(i.e., calmodulin, calbindin D-9K or insulin-like growth factor binding protein-3) [12–14]. Moreover,
the activation of the nuclear VDR also increases phosphate metabolism via increases in the uptake and
accumulation of phosphate and ATP, resulting in positive effects on muscle contraction [15]. In addition,
the 1,25(OH)2D activation of the membranous VDR stimulates rapid actions that affect Ca2+ handling
and muscle cell proliferation and differentiation [16].
Although the relationship between 25(OH)D and muscular fitness has been described in youth, no
study has jointly examined the association of these predictors with aBMD outcomes. Most published
studies have been conducted using statistical multivariate procedures in order to control for potential
confounders, but these statistical procedures are unable to distinguish between confounding and
mediating variables. Mediation analysis allows us to clarify the process underlying the relationship
between two variables and the extent to which this relationship can be modified or confounded by a
third variable [17]. Therefore, the aim of this study was to examine whether the relationship between
25(OH)D and aBMD outcomes is mediated by muscular fitness in children with overweight/obesity.
2. Materials and Methods
2.1. Design
A cross-sectional analysis was conducted of the baseline measurements of the ActiveBrains project
(registered at Clinicaltrials.gov, number NCT02295072). A detailed description of the study has been
published elsewhere [18]. The ActiveBrains project measured 110 children with overweight/obesity
aged 8–11 years from Granada (south of Spain) according to the following inclusion criteria: (1) to be
overweight or obese based on the World Obesity Federation (formerly named International Obesity
Task Force) cut-off points (2) to be 8 to 11 years old, (3) not to have any physical disabilities or
neurological disorder that affects their physical performance, and (4) in the case of girls, not to have
started the menstruation at the moment of the assessments.
A total of 81 children with overweight/obesity (10.0 ± 1.2 years old, 65% boys) with valid data
on 25(OH)D, muscular fitness variables, body composition (i.e., bone, fat and lean mass) and sexual
maturation were included in this report. Participants were recruited from the Pediatric Unit of the
“San Cecilio” and “Virgen de las Nieves” University Hospitals in the province of Granada, Spain.
Furthermore, we contacted several schools of Granada and we advertised the study in the local media,
inviting any child meeting the inclusion criteria. The study protocol was approved by the Ethics
Committee on Human Research (CEIH) of the University of Granada (Reference: 848, February 2014).
Written consent was obtained from parents for the participation of their children.
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2.2. Measures
2.2.1. Anthropometrics and Sexual Maturation
Participants were weighed using an electronic scale (SECA 861, Hamburg, Germany) with an
accuracy of 100 g. A precision stadiometer was used to assess height (cm) and sitting height (SECA
225, Hamburg, Germany) to the nearest 0.1 cm. BMI was calculated as body mass (kg)/height (m2) and
the participants were classified as overweight or obese according to sex- and age-specific BMI cut-offs
defined by Cole et al. [19].
Somatic maturity offset was assessed as years from peak height velocity (PHV) from age, height
and sitting height using validated algorithms for children [20]. In boys: −8.128741 + (0.0070346 × (age
× sitting height)), where R2 = 0.906 and the standard error of the estimate = 0.514. In girls: −7.709133 +
(0.0042232 × (age × height)), where R2 = 0.898 and the standard error of the estimate = 0.528. PHV is
the period of time of maximum growth in stature and therefore, years from PHV are considered in
terms of time before and time after the PHV.
2.2.2. Vitamin D
Venous blood samples were obtained between 8:00 a.m. and 9:00 a.m. by venipuncture after an
overnight fast (at least 12 h) from September 2015 to February 2016 (Autumn and Winter). Blood
samples in tubes containing EDTA were spun immediately at 30,000 g for 10 min. Plasma was isolated
and stored at −80 ◦C until assayed. Plasma 25(OH)D was analyzed by immunoturbidimetry (Alinity i
25-OH Vitamin D Reagent Kit ref. 08P4522, Abbot, IL, USA) with a sensitivity of 3.5 ng/mL and an
intra-assay coefficient of variation of 2.5%.
2.2.3. Muscular Fitness
Upper-body muscular fitness was assessed using the handgrip strength test through a
dynamometer with an adjustable grip (TKK 5101 Grip D, Takey, Tokyo Japan). Participants were
instructed to squeeze continuously for ≥2 s with the elbow in full extension position. The test was
repeated twice (right and left hands alternately). The best score of the 2 attempts for each hand was
chosen and averaged [21]. Finally, relative upper-body muscular fitness was expressed per kg of body
mass (Handgrip strength (kg/kg)). Lower-body muscular fitness was assessed by the standing long
jump test. Participants were instructed to push off vigorously and jump as far forward as possible,
trying to land on both feet. The distance reached was taken in centimeters from the take-off line and
the heel of the nearest foot at landing. The longest attempt from 3 was recorded (cm). The scientific
rationale for the selection of these tests, as well as their validity and reliability, has previously been
demonstrated in children and adolescents [21].
A muscular fitness score (muscular fitness z-score) was computed by combining the standardized
values of handgrip strength (kg/kg) and standing long jump (cm). Each of these variables was
standardized as follows: z-score = (ith value −mean)/SD. The muscular fitness z-score was calculated
as the mean of the 2 standardized scores (handgrip strength and standing long jump).
2.2.4. Body Composition
Children were scanned with dual-energy X-ray Absorptiometry (DXA) using the Hologic Discovery
Wi (Hologic Series Discovery QDR, Bedford, MA, USA). The DXA equipment was calibrated at the
start of each testing day by using a lumbar spine phantom as recommended by the manufacturer.
All DXA scans and analyses were performed using the GE encore software (version 4.0.2) following
the same protocol by the same researcher. The positioning of the participants and the analyses of
the results were undertaken following recommendations from the International Society of Clinical
Densitometry [22]. The total body scan was used to obtain fat mass, lean mass, and aBMD at the TBLH,
arms, and legs.
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2.3. Statistical Analysis
Descriptive characteristics of the participants are presented as mean ± standard deviation (SD) or
percentages. All variables were checked for normality using visual check of histograms, Q-Q and box
plots. Interaction analyses were performed for sex and since no significant interactions were found
(p ≤ 0.28), analyses were performed for boys and girls together.
A partial correlation analysis controlling for sex and years from PHV was performed to examine
the relationship between 25(OH)D, muscular fitness variables, TBLH lean mass, and TBLH fat mass.
We carried out a mediation analysis controlling for sex, years from PHV, TBLH lean mass
and season to test whether the association between 25(OH)D and aBMD outcomes was mediated
by muscular fitness. These covariates were selected because of their well-known association with
aBMD [23,24]. The PROCESS macro version 3.1, model 4, with 10,000 bias-corrected bootstrap samples
and 95% confidence intervals was used for these analyses. In a nutshell, the mediation analysis is
composed of ordinary least squared regression-based equations (paths) that allow us to answer the
question of how a predictor transmits its effect (total effect) on an outcome being partitioned into
direct (c’ path) and indirect effect (a × b path). Most contemporary analysts focus on the indirect
effect by stating 2 steps in establishing mediation [25]: (1) show that the causal variable is correlated
with the mediator (path a); (2) show that the mediator affects the outcome variable controlling for the
predictor (path b). Thus, mediation is assessed by the indirect effect of the 25(OH)D (predictor) on
aBMD (outcome) through muscular fitness (mediator). The total (c path), direct (c′ path), and indirect
effects (a × b paths) are presented (Figure 1). Indirect effects with confidence intervals not including
zero were interpreted as statistically significant [25] regardless of the significance of the total effect (the
effect of 25(OH)D on aBMD outcomes) and the direct effect (the effect on aBMD outcomes when both
25(OH)D and muscular fitness are included as independent variables). The percentage of mediation
(PM) was calculated as “(indirect effect/total effect) × 100” to know how much of the total effect was
explained by the mediation when the following assumptions were achieved: the total effect is larger
than the indirect effect and of the same sign. All the analyses were performed using the IBM SPSS
Statistics for Windows version 20.0 (IBM Corp: Armonk, NY, USA), and the level of significance was
set to p < 0.05.
Figure 1. Causal diagram reflecting the simple mediation analyses. Path c shows the association
between the predictor and the outcome. Arrows a × b show the natural indirect effect pathway, and c′
shows the natural direct effect pathway. aBMD: areal bone mineral density.
3. Results
Table 1 shows the raw descriptive characteristics of the participants at baseline (mean ± SD).
Briefly, the mean age of the participants was 10.0 ± 1.2 years and they were 2.4 ± 0.9 years below PHV,
overweight and obesity was evident in 28.4% and 71.6% of them, respectively; the mean 25(OH)D
concentration was 31.5 nmol/L and only 6.2% of the children measured fell above the suggested cut-off
of 50 nmol/L [26].
42
Nutrients 2019, 11, 2760
Table 1. Characteristics of the study sample by sex.
Variables All (n = 81) Boys (n = 53) Girls (n = 28)
Age (years) 10.0 ± 1.2 10.2 ± 1.2 9.7 ± 1.2
Years from PHV (years) −2.4 ± 0.9 −2.6 ± 0.9 −1.8 ± 1.1
Height (cm) 143.9 ± 8.7 144.5 ± 8.1 142.7 ± 9.8
Body mass (kg) 54.8 ± 10.7 55.8 ± 10.7 53.1 ± 10.8
TBLH fat mass (kg) a 21.9 ± 5.8 22.1 ± 5.9 21.5 ± 5.8
TBLH lean mass (kg) a 26.6 ± 5.2 27.3 ± 4.9 25.5 ± 5.3
BMI (kg·m−2) 26.3 ± 3.4 26.5 ± 3.4 25.9 ± 3.3
Overweight (%) 28.4 26.4 32.1
Obesity (%) 71.6 73.6 67.9
Autumn (%) 91.4 90.6 92.9
Winter (%) 8.6 9.4 7.1
25(OH)D (nmol/L) a,* 31.5 ± 9.5 32.7 ± 9.6 29.2 ± 8.9
Deficiency (%) 46.9 43.4 53.6
Insufficiency (%) 46.9 49.1 42.9
Sufficiency (%) 6.2 7.5 3.6
Muscular fitness z-score b 0.000 ± 1.000 0.032 ± 0.098 −0.061 ± 1.037
Handgrip strength (kg)/body mass (kg) a 0.307 ± 0.059 0.309 ± 0.058 0.303 ± 0.059
Standing long jump (cm) a 106.2 ± 17.8 106.5 ± 17.9 105.7 ± 17.9
TBLH (g·m−2) a 0.772 ± 0.059 0.775 ± 0.059 0.766 ± 0.058
Arms (g·m−2) a 0.607 ± 0.041 0.613 ± 0.041 0.596 ± 0.040
Legs (g·m−2) a 0.913 ± 0.079 0.917 ± 0.082 0.906 ± 0.074
PHV peak height velocity; TBLH total body less head; BMI body mass index; 25(OH)D 25-hydroxyvitamin D;
aBMD areal bone mineral density; a Values were Blom-transformed before analysis, but non-transformed values
are presented; b Z-score mean computed from handgrip strength (kg/kg) and standing long jump (cm) tests;
* Vitamin D status was defined as follows [26]: Sufficiency, > 50 nmol·L−1; Insufficiency, 30–50 nmol/L−1; Deficiency,
<30 nmol/L−1.
Partial correlations between 25(OH)D, muscular fitness variables, TBLH fat mass and TBLH lean
mass after adjustment for sex and years from PHV are presented in Table 2. 25(OH)D was positively
correlated with muscular fitness z-score and handgrip strength (r = 0.28 and r = 0.29, respectively).
Muscular fitness z-score was positively correlated with TBLH aBMD and arms aBMD (r = 0.24 and
r = 0.35, respectively), whilst handgrip strength was positively correlated with arms aBMD (r = 0.32).
Finally, standing long jump was positively correlated with aBMD at TBLH, arms and legs (r = 0.27,
r = 0.29 and r = 0.23, respectively).
Table 2. Partial coefficients of the independent variable with muscular fitness variables and aBMD















25(OH)D 0.275 * 0.285 * 0.186 0.039 0.043 −0.011
Muscular fitness z-score b - 0.881 ** 0.869 ** 0.244 * 0.352 * 0.182
Handgrip strength/body mass - 0.540 ** 0.165 0.320 * 0.089
Standing long jump - 0.266 * 0.295 * 0.233 *
TBLH aBMD - 0.764 ** 0.894 **
Arms aBMD - 0.577 **
PHV peak height velocity; 25(OH)D 25-hydroxyvitamin D; TBLH total body less head: aBMD areal bone mineral
density; b Z-score mean computed from handgrip strength (kg/kg) and standing long jump (cm) tests; Boldface
indicates statistical significance: * p < 0.050, ** p < 0.001.
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Mediation Analysis
Mediation analysis models are depicted in Figure 2. 25(OH)D was not significantly associated with
any of the aBMD outcomes (c, total effect). Regarding path a, 25(OH)D was positively associated with
muscular fitness z-score (Figure 2A, β = 0.277, p = 0.023) and handgrip strength (Figure 2B, β = 0.252,
p = 0.038). In the path b, in all mediation models, muscular fitness was positively associated with TBLH
aBMD (Figure 2A, β = 0.210, p = 0.004), arms aBMD (Figure 2B, β = 0.319, p < 0.001) and legs aBMD
(Figure 2C, β = 0.204, p = 0.007). Finally, when 25(OH)D and muscular fitness were simultaneously
included as independent variables (c’, direct effect), aBMD outcomes were not predicted. There was
a significant mediating effect of muscular fitness on the relationship of 25(OH)D with TBLH aBMD,
arms aBMD and legs aBMD (PM ranged from 49.6 to 68.3%).
Figure 2. Simple mediation models of the relationship between 25(OH)D and aBMD outcomes using
muscular fitness as a mediator, controlling for sex, years from PHV, TBLH lean mass and season.
Muscular fitness z-score was used as a mediator in panel (A), handgrip strength/body mass was used
as mediator in panel (B) and standing long jump was used as a mediator in panel (C). Z-score mean
computed from handgrip strength (kg/kg) and standing long jump (cm) tests; PHV peak height velocity;
TBLH total body less head; 25(OH)D 25-hydroxyvitamin D; aBMD areal bone mineral density
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4. Discussion
In the present study, we revealed a mediating effect of muscular fitness on the relationship between
25(OH)D levels and aBMD at the TBLH, arms, and legs after controlling for sex, years from PHV,
TBLH lean mass and season. To the best of our knowledge, this is the first study in children with
overweight/obesity analyzing whether muscular fitness acts as mediator in the association between
25(OH)D and aBMD outcomes.
Our results show no significant association between 25(OH)D and aBMD outcomes after adjusting
for sex, years from PHV, TBLH lean mass and season (path c, total effect). This finding agrees with
Hauksson et al. [27] who found no significant association between 25(OH)D levels and bone mineral
accrual in Icelandic children at ages 7 and 9. On the contrary, Pekkinen et al. [7] reported that 25(OH)D
status was a key determinant of aBMD in children and adolescents. In this regard, 25(OH)D status
has been highlighted as a significant predictor of peak bone mass in males but not in females during
childhood [28]. Likewise, non-significant associations between 25(OH)D and bone outcomes have
been reported in American prepubertal girls after adjusting for potential cofounders [29] and in
Finnish prepubertal girls after adjustment for maturation and BMI [8]. This could be explained by the
differences in sex hormone effects on bone since estrogens may counteract the effects of lower 25(OH)D
levels in females, whereas in males this compensatory effect is absent [28]. Nevertheless, we did not
find sex interaction between 25(OH)D and aBMD outcomes, suggesting that these sex differences
in hormonal effects on bone might not occur in prepubertal children with overweight/obesity since
estradiol levels may be high in both boys and girls [30,31].
A few studies have assessed the effect of 25(OH)D in relation to muscular fitness in children [32–34].
In addition, the present study does so, taking into account different ways of measuring muscular
fitness in the upper and lower limbs. The results of the present investigation confirm a relationship
between 25(OH)D levels and muscular fitness z-score, handgrip strength and standing long jump
(path a). These results agree with Foo et al. [32] who observed that adolescent girls with sufficient
25(OH)D status performed significantly better in handgrip strength compared with those with deficient
or severely deficient status. Moreover, our results partly concur with Ward et al. [33] who found a
positive association between 25(OH)D levels and the performance in countermovement jump in British
adolescent girls. Otherwise, a study carried out with children did not find any relationship between
handgrip strength and 25(OH)D status [34].
In this study, muscular fitness z-score, handgrip strength, and standing long jump were positively
associated with TBLH aBMD, arms aBMD and legs aBMD, respectively (path b). Torres-Costoso
et al. [10] reported a positive association between handgrip strength and aBMD outcomes in children
aged 8–11 years, although a negative association between standing long jump and aBMD outcomes
was found. The latter inverse association contrasts with our results. A possible explanation for these
differences could be the different weight status of the participants included in both studies (BMI,
18.8 ± 3.8 vs. 26.3 ± 3.4). In addition, the fact that our results were adjusted for TBLH lean mass (but
not in Torres-Costoso’s study) could modify the direction of the association. Our findings agree with
the literature and support the fact that bones adapt their resistance to the mechanical stimuli (i.e., body
mass and muscle contractions) placed on them [35]. Moreover, it should be noted that the performance
in the standing long jump test may be affected by the coordination skills [9], which might not be fully
developed in 8–11-year-old children.
Our results show that the total effect of 25(OH)D on aBMD outcomes was mediated by muscular
fitness z-score, handgrip strength and standing long jump (PM ranged from 49.6 to 68.3%). Since the
mediation analysis assumes that the predictor variable causes the mediator [17], muscular fitness
may be an intermediate step in the causal pathway of 25(OH)D with aBMD. There is consistent
evidence regarding the bivariate association of muscular fitness with both 25(OH)D [36] and aBMD
outcomes [37,38]. Otherwise, the relationship between 25(OH)D and bone in children remains
controversial [27,32]. In addition, a recent study has reported that the association between muscular
fitness and aBMD is fully mediated by lean mass, whose function appears to be affected by 25(OH)D
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levels [11]. Together with our results, this evidence indicates that increasing 25(OH)D levels may
increase muscular fitness and, ultimately, the aBMD. As an optimal bone mineral accrual is critical
during childhood in order to prevent osteoporosis later in life [2], public health policies should start at
an early age. Therefore, school-based interventions aiming at improving outdoor physical activity
levels are justified among children to synthesize 25(OH)D and, ultimately, improve muscular fitness.
Strengths and Limitations
The current study has several limitations that should be acknowledged. First, our cross-sectional
design rules out the possibility of identifying cause-effect relationships. Thus, the reported findings
need to be confirmed prospectively. Second, the number of participants with complete data in all
studied variables is relatively small. Third, although we did not find interaction by sex, our results
need to be confirmed by studying boys and girls separately. Finally, calcium intake was not available
and therefore, we did not include it in the model as a cofounder (i.e., vitamin D interacts with calcium
affecting bone health [6]).
The present study has also several strengths, such as the use of relevant sets of cofounders (i.e., sex,
years from PHV, TBLH lean mass and season) that are crucial to analyze the association of 25(OH)D
with bone outcomes in children. Furthermore, valid and reliable tests for assessing muscular fitness
were chosen from the ALPHA-Fitness battery [21]. Finally, we used DXA for assessing aBMD bone
outcomes which are the gold standard for measuring bone outcomes and have been used worldwide
in the pediatric population [22].
5. Conclusions
Muscular fitness plays a key role in the relationship between 25(OH)D levels and aBMD at the
TBLH and arms. Increasing 25(OH)D levels may improve muscular fitness and, ultimately, aBMD in
children with overweight/obesity. Future longitudinal studies must be conducted in order to confirm
these findings.
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Abstract: The purpose of this work was to describe changes in metabolic activity in the bones of young
male competitive cyclists (CYC) as compared with age-matched controls (CON) over a one-year period
of study. Eight adolescent male cyclists aged between fourteen and twenty, and eight age-matched
controls participated in this longitudinal study. Serum osteocalcin (OC), amino-terminal propeptide
of type I procollagen (PINP), beta-isomerized C-telopeptides (β-CTx) and plasma 25 hydroxyvitamin
D [25(OH)D], were investigated by an electrogenerated chemiluminescence immunoassay. Analysis
of variance revealed no significant differences in formation and resorption markers between cyclists
and controls. Within the groups, both CYC and CON showed decreased OC at −30% and −24%,
respectively, and PINP where the figures were −28% and −30% respectively (all p < 0.05). However,
only the CYC group showed a decrease in [25(OH)D], lower by 11% (p < 0.05). The similarity in the
concentrations of markers in cyclists and controls seems to indicate that cycling does not modify the
process of bone remodeling. The decrease in vitamin D in cyclists might be detrimental to their future
bone health.
Keywords: cyclists; adolescence; bone turnover; osteocalcin; vitamin D
1. Introduction
Osteoporosis is a serious skeletal disease which continues to grow in our society, characterized
by low bone mineral density (BMD) and microarchitectural deterioration of bone tissue, affected by
the peak of bone mass obtained before 20 years of age [1]. People affected by osteoporosis present
bone fragility and fracture risk, with a consequent deterioration in quality of life [2], and increased
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Nutrients 2019, 11, 1178
mortality [3]. Therefore, the prevention of the development of the disease is crucial and it should start
during adolescence [4].
Several studies suggested that maximizing bone mineral acquisition during growth might reduce
the risk of osteoporosis in later life [5–8]. Bone health and positive metabolic balance are influenced
by genetic and environmental factors, including physical activity. Exercise during adolescence may
contribute to the prevention of osteoporosis, although it needs to be a weight-bearing activity to be
osteogenic [5,9]. In this sense, cycling may adversely affect bone mass during adolescence [10], and
several studies have diagnosed osteopenia and osteoporosis in professional and master cyclists [11–13].
Bone development depends mainly on bone turnover, which includes bone formation and
resorption [14], and may be estimated by different biochemical markers, osteocalcin (OC) and
amino-terminal propeptide of type I procollagen (PINP) as markers of bone formation, and serum or
urine beta-isomerized C-telopeptides (β-CTx) as a marker of bone resorption. The bone metabolism
markers have been widely used to determinate the variations in the bone remodeling process as a
consequence of physical activity [15–17], and indicate modeling and remodeling of bone tissue during
pubertal growth and maturation [18].
Higher values of bone formation and resorption markers have been found in adolescent
athletes [10,19], although similar results among athletes and controls have also been determined [20].
Additionally, it is important to know the vitamin D status because of the influence that this
nutrient has on bone mass and bone loss [21]. Positive and direct associations between plasma
25 hydroxyvitamin D [25(OH)D] (active form of vitamin D) and bone mineral content (BMC) were
previously described [21–24], however, there is a scarce amount of information on young cyclists,
a population that may be at a higher risk due to their non-osteogenic sport participation.
Despite the importance of assessing bone metabolism in adolescents, there has been little research
on the association between biochemical markers and sport participation, and most are cross-sectional
studies. However, longitudinal studies may help us to understand how sport can influence bone
metabolism, and how this is translated to bone development, which is crucial information to cyclists
who seem to be at a higher risk of not achieving optimal peak bone mass [25,26].
The purpose of our longitudinal study was to measure the effect of cycling on bone metabolism in
adolescent cyclists and to compare it to active age-matched peers.
2. Materials and Methods
2.1. Study Design
A one-year longitudinal design was used, with repeated measurements performed at the beginning
and at the end of the season, in November and in October.
2.2. Ethics Statement
Written informed consent was obtained from parents and adolescents. The study was performed
following the ethical guidelines of the Declaration of Helsinki 1961 (revision of Fortaleza 2013) and the
Ethics Committee of Clinical Research from the Government of Aragón (CEICA; Spain) approved the
study protocol. REF: CEICA: PI09/00063.
2.3. Participants
A total of eight young elite male road cyclists (CYC) from different cycling teams in Spain,
and eight physically active controls (CON), recruited from secondary schools and colleges, agreed
to participate in the study (Table 1). Cyclists and controls were excluded if they were aged over
twenty-one, or if they were unhealthy, with any chronic disease, musculoskeletal condition, or bone
fracture, if they regularly took medicines, or if they had other habits affecting bone development.
One of the cyclists presented extreme values for most bone markers and was consequently deemed an
outlier, and excluded.
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Table 1. Descriptive characteristics of the sample. BMI, body mass index; SD, standard deviation.
PRE POST
Cyclists n = 7 Controls n = 8 Cyclists n = 7 Controls n = 8
Mean SD Mean SD Mean SD Mean SD
Age (years) 16.3 ± 0.9 15.8 ± 1.5 17.6 ± 1.2 16.9 ± 1.5
Height (cm) 171.1 ± 7.5 173.3 ± 8 173.6 ± 8 174.5 ± 6.6
Weight (kg) 57 ± 5.8 66.1 ± 15.1 62.8 ± 6.6 67.1 ± 15.1
BMI (kg/m2) 19.5 ± 1.7 22 ± 4.1 20.9 ± 1.8 22 ± 4.8
Years of cycling
training (years) 2.6 ± 2.8 3.6 ± 2.8
Hours of cycling
training (h/week) 10.5 ± 7 13.5 ± 5.2
BMI: Body mass index; SD: Standard deviation.
These young road cyclists were regular participants in regional competitions, and had trained
under supervision for an average of 13.5 h per week (h/week) over a minimum of two and a maximum
of seven years prior to the study. Control subjects were involved in recreational sports (rugby, tennis,
handball, or football) for at least 2 h/week with occasional weekend matches, however, none of them
cycled for more than one hour per week.
Subjects were asked to complete a medical and physical activity questionnaire, and to provide
additional information in respect to physical activity, past injuries, medicines taken and known diseases.
2.4. Anthropometric Measurements
While the subjects were barefoot and clad in light indoor clothing, their body weight (kg) and
height (cm) were measured with an electronic weighing scale (Type SECA 861; precision 100 g, range 0
to 150 kg) and a stadiometer (Type Seca 225; precision 0.1 cm, range 70 to 200 cm). Body mass index
(BMI) was calculated as weight (kg) divided by height squared (m2).
2.5. Blood Collection and Biochemical Analysis
Fasting blood samples (10 mL) were drawn at 8:00 a.m., after 10 h overnight, through an indwelling
venous catheter placed in a forearm vein. Then, serum was separated and stored at −20 ◦C for later
analysis. In order to avoid diurnal variations in plasma levels of total [25(OH)D], blood samples were
obtained at the same time of the day [27].
2.6. Bone Turnover Markers
The concentrations of serum OC, PINP and β-CTx were determined by an electrogenerated
chemiluminescence immunoassay using an Elecsys 2010 analyzer from Roche Diagnostics GmbH
(Germany). The kits used were also purchased from Roche Diagnostics GmbH. The measuring range
for serum osteocalcin was 0.50 μg/L to 300 μg/L (defined by the lower detection limit and the maximum
of the calibration curve). Values below the detection limit were reported as <0.50 μg/L. Values above
the measuring range were diluted with Elecsys Diluent Universal at a concentration below 60 μg/L.
Osteocalcin presented coefficients of variation (CV) of 4.0% and 6.5% at 15.5 μg/L and 1.4% and 1.8% at
68.3 μg/L. The measurement range for total PINP in serum ran over from 5 μg/L to 1200 μg/L. Intra-
and inter-assay CVs were 1.8% and 2.3% at 274 μg/L and 2.9% and 3.7% at 799 μg/L. Values below the
detection limit were reported as <5 μg/L. Values above the measuring range of 1200 μg/L were diluted
with Elecsys Diluent Universal at a recommended concentration of 1100 μg/L. Analytical sensitivity
(the lower detection limit) was <5 μg/L. β-CTx had intra- and inter-assay CVs of 1.0% and 1.6% at
3.59 μg/L and 4.6% and 4.7% at 0.08 μg/L. The range for measurements was between 0.010 μg/L and
6.00 μg/L, the analytical sensitivity or lower detection limit was 0.01 μg/L, and the functional sensitivity
was 0.07 μg/L.
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2.7. Vitamin D Status
Plasma [25(OH)D] was analyzed by ELISA using a kit (Octeia® 25-Hydroxy vitamin D) from
Immuno Diagnostic Systems (Germany) and measured with a Sunrise™ Photometer by Tecan
(Mannheim, Germany). The sensitivity of this method is 5 nmol/L 25(OH)D and the variation
was under 6%. The CV for the method was below 1%. The complete methodology has been described
elsewhere [15].
2.8. Statistics
The normality of the data distribution was evaluated with the Kolmogorov–Smirnov test.
All variables presented normal distributions, except PINP. Thus, this was logarithmically transformed
although the original data are also reported.
The characteristics of the subjects were described using averages and standard deviation (SD)
values for continuous variables. Independent t-tests were performed to evaluate differences between
groups for descriptive variables. To determine how bone turnover markers and vitamin D status
differed between groups, analyses of covariance (ANCOVAs) were applied, and adjusted for age.
ANCOVAs for repeated measures ×2 (time) were performed between pre- and post-evaluation to
determine the effects of cycling on bone metabolic markers and vitamin D status.
The probability value for the significance level was fixed at 0.05. Data were analyzed using the
SPSS 19.0 statistical program (SPSS Incorporated, Chicago, IL, USA).
3. Results
Table 1 summarizes the descriptive characteristics of participants of the sample as a whole (cyclists
and controls), before and after evaluation. The results showed no differences in any of the variables.
3.1. Bone Metabolism Markers and Vitamin D
Figure 1 shows the OC, PINP, β-CTx and the [25(OH)D] concentrations in cyclists (CYC) and
controls (CON), before and after evaluation. No difference was observed between the groups for the












Figure 1. Panels (A–D) concentrations in cyclists (n = 8) and controls (n = 8), at pre- and post-evaluation.
(A) Amino-terminal propeptide of type I precollagen (PINP). (B) Osteocalcin (OC). (C) beta-isomerized
C-telopeptides (β-CTx). (D) Plasma 25 hydroxyvitamin D [25(OH)D]. Values are presented as the mean
and SD. For final statistical analysis one cyclist has been removed (statistical outlier). The p values
calculated with one-way analysis of covariance (ANCOVA), adjusting for age. * p < 0.05 compared to
control group. $ p < 0.05 compared to cyclists group.
3.2. Changes within Group
Figure 1 shows intra-group results. With regard to bone metabolism, formation markers (OC and
PINP) decreased in both the CYC and the CON groups (all p < 0.05). However, neither group showed
changes in β-CTx (both p > 0.05). Nevertheless, [25(OH)D] decreased significantly in the CYC group
(p < 0.01).
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3.3. Group-by-Time Interactions
No group-by-time interactions were found in any parameters. This suggests that both groups
evolved similarly (all p > 0.05).
4. Discussion
The results of this one-year longitudinal study showed similar decreases in bone formation
markers for both the CYC and CON groups over time, just as had been described in previous long-term
studies relating to bone turnover markers in young female athletes [20,28,29]. Thus, the results suggest
that this trend seems to be similar in athletes of both sexes, and in accordance with the results recorded
by García-Marco et al. [30] in a study with an adolescent population (aged between 12 and 17), which
detected a decrease in markers as puberty progressed in both boys and girls. As previously noted, bone
remodeling decreases with age independently of whatever sport may be practiced, so growth may
perhaps mask the effects of physical activity at these ages. The relationship between bone metabolism
markers and bone mineral parameters in children and adolescents is not clear. Hence, further studies
are needed to determine the role of bone turnover markers and physical activity on bone mineral
acquisition during puberty.
No differences were found between them, when adult cyclists and runners were investigated
in one piece of research [13], and other authors have determined normal ranges of bone markers
in a group of young cyclists [31]. However, adult cyclists presented lower values for bone alkaline
phosphatase (BAP) as compared to triathletes, swimmers, and controls, but yielded similar values for
OC and β-CTX in another study [16].
Although there has been no previous investigation of changes in bone metabolism markers in
adolescent cyclists, some researchers have analyzed BMD and BMC amongst this population, finding
that cyclists had lower values for both variables than the controls did [10,25]. Moreover, Olmedillas et
al. [10] reported greater differences in BMC and BMD between cyclists and controls in adolescents
over 17 years of age. Since bone mass can be defined as the net product of bone formation and
bone resorption [14], the present results for bone metabolic markers cannot provide support for the
lower bone mass described previously [10]. This may be because bone metabolism markers are not
site-specific and reflect bone remodeling of the whole skeleton [32]. It is not clear how metabolic
markers reflect bone changes during growth and this topic requires further research.
Although we have not found significant differences in bone remodeling markers between cyclists
and controls, other researchers show that cycling compromises the acquisition of peak bone mass
throughout life [12–14,25,26]. One possible explanation for these differences might be the limited
number of participants in the two groups in this study. Longitudinal investigations with adolescent
cyclists would be needed to gain an understanding of the causes of this decrease in bone mass, and to
act to prevent osteoporosis in these subjects in the future. A conceivable hypothesis would be that, even
with the same metabolic activity, metabolic efficiency may be compromised because of physiological or
nutritional interactions [33–35]. For instance, a major finding in this work was that 25(OH)D decreased
significantly in the CYC group, but not in the CON group. Vitamin D deficiency is associated with
decreased bone mass, because it compromises calcium absorption and impairs bone accumulation [21].
A direct association between 25(OH)D and BMC has been described previously [22–24]. In children,
vitamin D deficiency is associated with demineralized bones and with rickets [22], so an adequate
consumption of vitamin D is essential in preventing this disease. Low intakes of vitamin D, relative to
the recommended dietary allowance (RDA) in Spanish children were observed by Gómez-Bruton et
al. [36]. In particular, active adolescents did not consume the amount of vitamin D set for their age
group, with cyclists being the group farthest away from meeting the recommendations. On the basis of
their results, these low intakes are of concern in cyclists, because they showed lower values of BMC
and BMD than controls. It is possible that an insufficient intake of vitamin D is among the principal
causes of decreased bone mass in adolescent cyclists, as previously described by Olmedillas and
colleagues [10]. Potential diurnal variation in plasma levels of total [25(OH)D], due mainly to variations
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in plasma volume previously described [27], have been taken into consideration. Therefore, in our
study, blood extractions were collected at the same time in the morning, under the same conditions for
all participants in pre- and post-evaluation.
The main limitation of our study is a relatively small number of subjects, however, the practice
level of the participants should be taken into account. These cyclists were training for at least the
last two years for a mean time of 13.5 h/week and participating in competitions during this time.
An additional issue, is the range of age of the participants (mean, 17 years), as it is a challenge for
their trainers to maintain the adherence of this level of training for long periods with a high level of
commitment. Actually, we enrolled 25 cyclists in the first evaluation, however, due to most of them
abandoning the training and to specific abandonments of the study, the final sample is the one that is
represented in this study. The study’s principal strength is its longitudinal design (a one-year long-term
design with two measurements in the season) and the specificity of the sample according to age and
level of training. To date, there have been very few longitudinal studies that have analyzed the effects
on biochemical markers in boys derived from practicing sport including cycling and gymnastics [37,38].
Further research, with dual energy X-ray absorptiometry (DXA) measurements and the assessment of a
wider spectrum of bone osteoanabolic and catabolic parameters could provide a better understanding
of the net process of bones.
5. Conclusions
The similar concentration of markers in cyclists and controls seems to indicate similar metabolic
activity. As different levels of bone mass had previously been recorded in these cyclists, metabolic
efficiency may have been compromised by other concurrent factors. Decreased vitamin D levels were,
in fact, noted in the cyclists over this one-year period, which in the end could be detrimental to the
future bone health of these individuals.
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Abstract: The aim was to investigate the associations between different physical activity (PA) patterns
and sedentary time (ST) with vitamin D deficiency (<12 ng/mL) in a large sample of Chilean women.
In this cross-sectional study, the final sample included 1245 adult and 686 older women. The PA
levels, mode of commuting, ST, and leisure-time PA were self-reported. Vitamin D deficiency was
defined as <12 ng/mL and insufficiency as <20 ng/mL. A higher ST was associated with vitamin D
deficiency (odds ratio (OR): 2.4, 95%: 1.6–4.3) in adults, and passive commuting was associated with
vitamin D deficiency in older (OR: 1.7, 95%: 1.1–2.7). Additionally, we found a joint association in the
high ST/passive commuting group in adults (OR: 2.8, 95%: 1.6–4.9) and older (OR: 2.8, 95%: 1.5–5.2)
with vitamin D deficiency, in respect to low ST/active commuting. The PA levels and leisure-time
PA were not associated with vitamin D deficiency. In conclusion, mode of commuting and ST seems
important variables related to vitamin D deficiency. Promoting a healthy lifestyle appears important
also for vitamin D levels in adult and older women. Further studies are needed to establish causality
of this association and the effect of vitamin D deficiency in different diseases in this population.
Keywords: Vitamin D; females; exercise; sedentary lifestyle; nutrition; elderly
1. Introduction
Vitamin D was first characterized as a vitamin in the 20th century and nowadays it is recognized
as a prohormone [1]. Vitamin D has two major forms, vitamin D2 (ergocalciferol) and vitamin D3
(cholecalciferol). The first is derived from plant sources, is not largely human-made, and added to
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foods, and the latter is synthesized in human skin and is consumed in diets via animal-based foods
intake, mainly fish oils [1]. The active form of vitamin D generates a number of extraskeletal biological
responses including inhibition of breast, colon, and prostate cancer cell progression; effects on the
cardiovascular system; and protection against a number of autoimmune diseases including multiple
sclerosis and inflammatory bowel disease [2].
Vitamin D is important in biological process related with women’s health, such as fertility,
pregnancy outcomes, and lactation at young age [3]. Some observational studies have revealed that a
decrease in the vitamin D levels in women is related with reduced fertility [4], antenatal and postpartum
depression [3]; as well high parathyroid hormone, the increasing risk of suffering sarcopenia and
impaired glucose metabolism in the general population [5,6]. Moreover, supplementation with
vitamin D probably might reduce the rate of falls but not risk of falling in older people [4,7]. Normal
levels of vitamin D are associated to a low frequency of pathogenesis and neoplasm progressions,
as well as hypertension, diabetes, immune disorders such as multiple sclerosis, musculoskeletal
conditions [8,9], or bone mass status, especially in women [10]. Although vitamin D deficiency is
rare in developed countries, subclinical forms occur, and they have public health relevance since low
vitamin D concentrations are highly prevalent among population living in high latitudes, mainly
indoors, and among those who are older or dark skinned [11]. Sunlight is the primary source of
vitamin D [12], a very rough general estimation indicates that about 80% of vitamin D supply comes
from skin ultraviolet-B-induced production, whereas only 20% comes from dietary intake; however,
this varies considerably depending on different factors such as seasonal/sun exposure habits, latitude,
nutrition/supplement intake or ethnicity [13].
In 2013, a review identified 243 studies related with vitamin D status in Caribbean and Latin
American countries. The final analysis only included 28 studies with two major characteristics: small
samples sizes and low national representativeness. Countries with available data have shown that
vitamin D insufficiency was classified in the range of mild, moderate, or severe public health problem,
and the only country with a nationally representative sample in this study was Mexico [14]. In Chile,
a study conducted in 2007 with 555 post-menopausal women showed a vitamin D deficiency in 47.5%
of the population, defined as less than 17 ng/mL [15]. Recommendations of normal levels of vitamin
D in plasma are above of 30 ng/mL, and different cut-points have been used to classify insufficiency
or deficiency, according the population [16,17]. For instance, recent data from the Chilean population
showed that 80% of older subjects with a low-energy hip fracture have presented insufficient vitamin
D levels (less than 20 ng/mL) [18]. Moreover, in healthy older populations, vitamin D values were
very similar, 83% of women and 55.3% of men presented parameters below 20 ng/mL [19].
Regular physical activity (PA) and low sedentary time (ST) have significant benefits for health
at all ages [20]. The principal recommendation is some PA is better than doing none [21]. The adult
population (aged from 18–64 years) and older population (aged 65 years and above) should do
150 minutes of moderate-intensity PA throughout the week or at least 75 minutes of vigorous-intensity
PA throughout the week, or an equivalent combination of moderate- and vigorous-intensity activity
(e.g., walking, cycling, or doing sports) [20]. Globally, around 23% of adults aged from 18 and above,
were not active enough in 2010 (men 20% and women 27%) [4,7,22–25]. Physical activity increase
may be about general PA level, leisure PA, mode of commuting, organized sports, among others and
independently reducing ST [20].
Previously, low serum vitamin D levels have been associated with lower PA level, gait speed,
and balance. Vitamin D level below 30 ng/mL was not associated to an increased risk of fractures;
however, a subgroup of women with serum vitamin D levels below 20 ng/mL showed an increased risk
tendency of fractures, which may be associated to an inferior PA and postural stability [26]. Another
report demonstrates that serum vitamin D concentrations below 20 ng/mL are associated to a poor
physical performance, that is to say to a decreased physical performance in older men and women [27].
On the other hand, evidence shows that cycling is associated to high UV exposure, and thus, to high
serum vitamin D levels compared to most other outdoors activities that are practiced, including
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walk [28,29]. It has been established that not all activities are equivalent regarding to sunlight exposure.
Thus, whereas some patterns of PA have been associated with vitamin D levels, there is a lack of
studies considering ST of mode of commuting. Interestingly, it is necessary to establish a relationship
of the aforementioned according to the different population, since it has been shown that older people
would be at risk [30]. Furthermore, a better understanding of the effects, according to the population,
could help to provide valuable lifestyle recommendation.
Finally, data from general Chilean population regarding vitamin D levels are scarce, and
associations with PA patterns and ST might be important factors in the status of vitamin D and
maintenance of health [22]. Therefore, the aim of the present study was to investigate associations
between self-reported PA patterns, ST, and different serum vitamin D levels in a large sample of
Chilean adults and older women, adjusting for a number of potential confounders.
2. Material and Methods
2.1. Study Population
The 2016–2017 Chilean National Health Survey was a representative household survey with
a stratified multistage probability sample of 6233 non-institutionalized participants over 14 years
old from the 15 regions in Chile, both urban and rural. This survey represents the first, largest,
and representative measurement of serum vitamin D levels in Chilean people. Sample size was
calculated with a relative sampling error of less than 30%, and absolute sampling error of 2.6% to
national level. The participation rate was 90.2%. Detailed information about the survey has been
described elsewhere [31]. Vitamin D measurement was taken from a subsample of fertile age women
(15 to 49 years) and older people. In this cross-sectional study were included those who have complete
vitamin D measurement, valid response in PA questions and correct anthropometric parameters. Final
sample was divided in adults (≥18 to <65 years) and older (≥65 years) groups, both for Chilean
women. The ethics committee of the Pontificia Universidad Católica de Chile and the Chilean Ministry
of Health approved the study protocol and ethical consent forms.
2.2. Survey and Sample
Standardized protocols were used and all investigators (nurses and research technicians)
underwent joint training sessions prior to implementation of the survey. The fieldwork for this
survey was conducted between August 2016 and March 2017; while blood samples and laboratory
tests were made between September 2016 and February 2017.
2.3. Serum Vitamin D Levels
A nurse took venous blood samples in morning hours. Serum was extracted from 1 mL of total
blood. Standardized liquid chromatography-tandem mass spectrometry (LC–MS/MS) method was
used for measurement of 25(OH)-Vitamin D3 for Chilean National Health Survey 2016–2017, which
allows laboratories and surveys to compare 25(OH)-Vitamin D3 measurements [32]. Vitamin D levels
were categorized according two different criteria: (i) specific criteria for Chilean population according
to the Health Ministry of Chile [33] of deficiency as <12 ng/mL [34], and (ii) internationally frequent
cut-points used criteria corresponding to insufficiency of <20 ng/mL) [16,17]. This method has better
analytical specificity and sensitivity compared to immunoassay methods, and fixed analytical goals for
imprecision (≤10%) and bias (≤5%) [35].
2.4. Physical Activity
The Global PA Questionnaire (GPAQ) (version 2) to measure PA was used. The physical active
categories were defined according to standard criteria of the questionnaire. Those who had less of
600 metabolic equivalent of task (METS) per week were considered inactive and those who had 600 or
more METS per week were considered active [36].
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2.5. Leisure-Time Physical Activity
A question was made in the visit, the question was (i) In the last month, Did you practice sport or did
any PA out of work time, during 30 minutes or more each time? The response options were: (i) Yes, three
times a week or more; (ii) Yes, one or two times a week; (iii) Yes, less of four times per month; (iv) I do
not practice sport. The responses then were categorized in “Yes” for those who exercise three times a
week or more, and “no” for those who did not practice sport at least three times a week.
2.6. Commute Mode
A question was made in order to inquire the commute mode of every surveyed, (i) which is
the mode of commuting that you use (at least one time per week?) The response options were:
(i) drive a light car; (ii) drive a heavy car; (iii) light car passenger; (iv) heavy car passenger; (v) bicycle;
(vi) walk; (vii) and other. The responses were categorized in “active commuting” for those had mode
of commuting bicycle or walk, and “passive commuting” for the rest.
2.7. Sedentary Time
A question of the GPAQ to estimate ST was asked to every participant of the study. The question
was (i) How much time do you usually spend sitting or reclining on a typical day? The participant had to
respond in minutes and hours per day. This question was categorized according to low ST (<4 hours
per day); middle ST (≥4 and <8 hours per day); and high ST (>8 hours per day) [37].
2.8. Covariates
Socio-demographic data were collected for all participants, including age (years), menopausal
status (yes/no), achieved education level (primary/secondary/beyond secondary), region (I to XV)
and dairy consumption (three times a day or less, once each day, each two days, once a week, once a
month or definitely never). Further, participants were asked according their sunlight exposure during
the last week, (i) How much sunlight have you been exposed to in the last week? The responses were:
(i) much; (ii) little.
2.9. Statistical Analysis
Data were presented as mean, standard deviation (SD), and percentages (%). Independent
t-test and chi-square test were used to compare differences between adults and older women for
continuous and categorical variables, respectively. Firstly, separated multivariable logistic regression
model were employed to obtain odds ratio (OR) and confidence interval (CI 95%) in respect to
different cut-points, adjusted by age (years), menopausal status (yes/no), achieved education level
(primary/secondary/beyond secondary), region (I to XV), dairy consumption (three times a day or less,
once each day, each two days, once a week, once a month or definitely never), and sunlight exposure
(much/little). Finally, joint associations of ST and commute mode according to different criteria were
tested. Here, ST was categorized as low ST (<4 hours per day) and high ST (≥4 hours per day) and
it was combined with active and passive commuting. Thus, low ST/active commuting was used as
reference group, high ST/active commuting, low ST/passive commuting, high ST/active commuting
were second, third, and fourth groups, respectively. The performed model was adjusted by the same
covariates mentioned previously plus PA level (active/inactive). For the interpretation of odds ratio,
the effect size cut points of 1.68, 3.47, and 6.71 were used, according to small, medium, and large effect
size [38]. Analyses were performed using SPSS-IBM (Software, v.21.0 SPSS Inc., Chicago, IL, USA),
and a value of p < 0.05 was considered statistically significant. The Figure 1 was performed using the
ggplot2 package in R and Supplementary Materials Figure S1 with leaflet package.
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Figure 1. Odds ratio of the joint association between sedentary time (ST) and mode of commuting with
different cut-points of vitamin D deficiency in adults and older women. The reference categories are
groups with low ST (<4 hours/day) in combination with active commuting.
Figure 1 (bottom panels) shows joint OR for vitamin D deficiency for older women according
the sedentary group and mode of commuting group. It can be appreciated from Figure 1 that for the
cut-points of <12 ng/mL, compared to the reference group, the high ST/active group presents an OR
of 1.476 (CI: 0.877–2.487, p = 0.143) the low ST/passive group presents an OR of 1.25 (CI: 0.444–3.514,
p = 0.673) and high ST/passive group presents an OR of 2.875 (CI: 1.584–5.218, p = 0.001) for vitamin D
deficiency. Furthermore, according to cut-points of <20 ng/mL, it can be appreciated in Figure 1 an
OR of 1.712 9CI: 1.116–2.627, p: 0.014) for high ST/active, OR of 1.531 (CI: 0.638–3.676, p = 0.34) low
ST/passive and OR of 1.905 (CI = 1.119–3.242, p = 0.018) high ST/active groups.
3. Results
The present study included only those who had a complete vitamin D measurement, valid
responses in PA questions, and correct anthropometric measurements. The sample with serum
vitamin D measurement was 2326. The final sample was divided into adults (≥18 years) and older
(≥65 years) Chilean women groups. The final sample with complete data of physical activity patterns
and covariates included was 1931 women. Table 1 shows descriptive characteristics of participants
separated by group of age.
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Table 1. Descriptive characteristic of the adults and older women.
Variables, Mean ± SD Adults Women (1245) Older Women (686)
Age (years) 35.4 ± 8.5 73.6 ± 6.6
Body mass index (kg/m2) 29.2 ± 5.7 29.3 ± 5.3
Vitamin D levels (ng/mL) 20.2 ± 8.0 18 ± 8.5
Nutritional Status (n: %)
Underweight 7 (0.6) 6 (0.9)
Normal weight 297 (23.9) 139 (20.3)
Overweight 455 (36.5) 245 (35.7)
Obese 486 (39.0) 296 (43.1)
Physical activity (n: %)
Inactive 532 (42.7) 393 (57.3)
Active 713 (57.3) 293 (42.7)
Sedentary time (n: %)
Low Sedentary time 868 (69.7) 508 (74.1)
Middle Sedentary time 260 (20.9) 138 (20.1)
High Sedentary time 117 (9.4) 40 (5.8)
Leisure-time physical activity (n: %)
30 min, 3 times per week 153 (12.3) 34 (5.0)
Less than 30 min, 3 times per week 1092 (87.7) 652 (95.0)
Commute mode (n: %)
Active Commuting 291 (23.4) 157 (22.9)
Passive Commuting 954 (76.6) 529 (77.1)
Educational Level (n: %)
Primary 96 (7.7) 415 (60.4)
Secondary 725 (58.2) 224 (32.7)
Beyond secondary 424 (34.1) 47 (6.9)
Dairy consumption (n: %)
Three times a day 84 (6.7) 46 (6.7)
Less than three times a day 79 (6.3) 55 (8)
Once a day 428 (34.4) 293 (42.7)
Every two days 223 (17.9) 124 (18.1)
At least once a week 242 (19.4) 104 (15.2)
At least once a month 73 (5.9) 22 (3.2)
Never 116 (9.3) 42 (6.1)
Menopausal status (n: %)
Yes 48 (3.9) 693 (93.1)
No 1197 (96.1) 47 (6.9)
Vitamin D deficiency (<12 ng/mL) (n: %)
<12 ng /mL 204 (16.4) 181 (26.4)
≥12 ng /mL 1041 (83.6) 505 (73.6)
Vitamin D insufficiency (<20 ng/mL) (n: %)
<20 ng /mL 642 (51.6) 445 (64.9)
≥20 ng /mL 603 (48.4) 241 (35.1)
Sunlight exposure (n: %)
Little 722 (58) 502 (73.2)
Much 523 (42) 184 (26.8)
Region (latitude *) (n: %)
XV. Arica y Parinacota (−18.474) 94 (7.6) 30 (4.4)
I. Tarapacá (−20.213) 64 (5.1) 27 (3.9)
II. Antofagasta (−23.652) 57 (4.6) 23 (3.4)
III. Atacama (−27.366) 70 (5.6) 20 (2.9)
IV. Coquimbo (−29.953) 61 (4.9) 45 (6.6)
V. Valparaíso (−33.035) 125 (10) 85 (12.4)
XIII. Metropolitana (−33.456) 186 (14.9) 104 (15.2)
VI. L. Bdo. O’Higgins (−34.170) 74 (5.9) 33 (4.8)
VII. Maule (−35.426) 88 (7.1) 60 (8.7)
VIII. Bíobío (−36.826) 138 (11.1) 59 (8.6)
IX. La Araucanía (−38.739) 66 (5.3) 27 (3.9)
XIV. Los Ríos (−39.814) 56 (4.5) 48 (7)
X. Los Lagos (−41.469) 55 (4.4) 40 (5.8)
XI. Aysén (−45.575) 64 (5.1) 38 (5.5)
XII. Magallanes y Antártica (−53.154) 47 (3.8) 47 (6.9)
SD, standard deviation. * Coordinates have been calculated based on the world geodetic system (standard WGS84).
64
Nutrients 2019, 11, 300
The anthropometric and nutritional values show similar results in both groups. The distribution
of underweight, normal weight, overweight, and obese was the same for adult and older women.
Vitamin D levels expressed as ng/mL were 20.2 for adult women and 18.0 for older women. Adult
women exhibited higher vitamin D levels compared with older women, as well as higher PA patterns,
leisure-time PA, educational level, and sunlight exposure. In contrast, ST, dairy consumption and
menopausal status were lower in adult women compared to older population. Finally, the commute
mode was similar in both groups. Table 2 shows the results of logistic regression analysis for each PA
pattern according different cut-points and separated by adults and older women.
3.1. Adults
Table 2 (left side) shows the OR of vitamin D deficiency for adults. It can be seen that middle and
high ST groups are associated with vitamin D deficiency (OR between 1.7 to 2.6, all p < 0.001) in both
cut-points. Furthermore, Table 2 shows that passive commuting are also associated with vitamin D
deficiency only for cut-points less than 20 ng/mL. PA level pattern and leisure-time PA pattern were
not associated with vitamin D deficiency (all p > 0.05).
Figure 1 was constructed using two variables, ST and commute mode. These variables were
categorized as low and high, and passive or active, respectively. The OR of the joint association
between ST and mode of commuting was determined with different cut-points of vitamin D deficiency
in adult women (Figure 1, upper panels) and older women (Figure 1, bottom panels). Reference
categories were groups with low ST (<4 hours/day) in combination with active commuting. It can be
appreciated from Figure 1 that for the cut-points of <12 ng/mL, compare to reference group, the high
ST/active group presents OR of 1.231 (CI: 0.735–2.060, p = 0.43), the low ST/passive group presents OR
of 3.754 (CI: 1.761–8.000, p = 0.001) and high ST/passive group presents OR of 2.821 (CI: 1.614–4.931,
p = <0.001) for vitamin D deficiency. Furthermore, according to cut-points of <20 ng/mL, it can be
appreciated an OR of 1.555 (CI: 1.120–2.158, p = 0.008), OR of 1.980 (CI: 1.102–3.558, p = 0.022) and
OR of 2.689 (CI: 1.822–3.967, p = <0.001), for high ST/active, low ST/passive and high ST/active
groups, respectively.
3.2. Older
Table 2 (right side) shows the OR of vitamin D deficiency for older women. Middle ST group
shows a high vitamin D deficiency and high ST group showed a tendency association (p = 0.004 and
0,074, respectively) only in <12 ng/mL cut-points. Passive commuting is associated with vitamin D
deficiency in both cut-points. PA level group and leisure-time PA group were not associated with
vitamin D deficiency (all p > 0.005).
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4. Discussion
We examined the association between PA patterns and ST with vitamin D deficiency and
insufficiency in a nationally representative sample of Chilean women. The results showed that
passive commuting is associated with vitamin D deficiency and insufficiency in older women, whereas
high ST is associated with vitamin D deficiency and insufficiency in adult women. Additionally,
we identify a joint effect of high ST/passive commuting on vitamin D deficiency and insufficiency in
both groups. The magnitude of the effect was between small to medium.
To our knowledge, this is the first study that analyzes how different patterns of PA and ST are
related with vitamin D levels in Chilean population. Interestingly, active adult women and inactive
older women shares the same value, as well as inactive adult women correspond to active older
women, creating a mirror effect. The vitamin D levels expressed as ng/mL was 20.2 for adult women
and 18.0 for older women. These results were similar to another study in a little sample of Chilean
older people (n = 57 participants); the aforementioned study have reported that women presented
lower levels than men 15.6 ± 5.8 and 19.2 ± 6.0 ng/mL, respectively.
In Europe, vitamin D insufficiency (<20 ng/mL) is present in 36.0% of younger and 24.4% of
older participants [39], while there is a high variability between countries. Contrary, to our results,
the prevalence of vitamin D insufficiency was higher in young people compared to older participants;
an explanation given by the authors is that older population are healthier and quite more active than
younger participants. These differences are connected, in some cases, to institutionalization factors,
especially combined with concurrent health and mobility problems, such as reduced skin efficiency
to produce endogenous vitamin D levels [40], poor dietary vitamin D intake as well poor general
nutritional status [41]. Thus, the evidence is not conclusive regarding vitamin D levels according to
age, since other risk factors have been identified as skin pigmentation, latitude, health status, vitamin
D intake by fortified food or any behavior related to sunlight exposure such as the use of lighter-weight
clothes, or indoor working [42–44].
Physical Activity has been proposed to be an important determinant of vitamin D status in
Caucasian adults. Jerome et al. [45] showed that sedentary students possessed significantly lower
vitamin D levels compared to trained athletes’ students that live at high latitudes, even if these
sedentary students had a higher vitamin D food intake. Furthermore, leisure-time PA has also been
associated to vitamin D levels in cancer survivor patients; however, differences between outdoor
and indoor PA were found [46]. In our sample, self-report PA levels, as well as leisure PA, were not
associated to vitamin D deficiency or insufficiency. A previous study showed that people who practice
mountain sports are associated to a lower risk of serum vitamin D deficiency, while this association was
not observed for people who practice nautical sports [47]. Moreover, a previous study of US population
reported similar results, although the association was strongest to PA measure by accelerometers than
by self-report [48]. Therefore, this could be a reason of non-association in our data. Our data were
self-reported and does not discriminate between outdoor or indoor physical activities, therefore the
method of measure of PA, outdoor/indoor factor and the different population (cancer patients versus
healthy women) could explain these findings.
Hibler was one of the first in to associate ST with serum vitamin D levels. Their results support
that PA is positively associated to high vitamin D levels, nonetheless they do not show associations
between ST and vitamin D levels [49]. Furthermore, it was not found in association with between
ST and vitamin D levels in a Brazilian sample. These contradictory findings could be due to the
differences between analyzed populations, since the Brazilian study considered adolescents and
participants suffering colorectal adenoma [22,49]. On the other hand, no previous studies that correlate
the commute mode with vitamin D deficiency or insufficiency were found, only some activities that
increase the UV-light exposition. In this sense, our results provide valuable information that shows
the beneficial effect of active commuting on vitamin D levels, since the commute mode has been
related positively with better health [50], low type 2 diabetes risk [51], cancer, cardiovascular disease,
and all-mortality causes [52].
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The joint association between commute mode, ST, and serum vitamin D levels has not been
studied. Physical Activity time and ST were jointly evaluated in the previous Chilean national health
survey, in order to estimate cardiovascular risk. The active/low sedentary behavior group presented
lower cardiovascular risk factors such as hypertension, obesity, and type 2 diabetes [53]. Collectively,
active commuting changes were associated to better PA patterns [54]. Therefore, both active commuting
as low ST could be an important strategy to increase serum vitamin D levels and avoid the deficiency,
considering the arguments exposed above where PA pattern has been estimated as a determinant
variable, specifically in postmenopausal women [55].
Vitamin D deficiency is related to musculoskeletal diseases such as rickets and osteomalacia,
or several infectious and metabolic processes [56]. Thus, it has been recommended the increase
of vitamin D intake [57]. Indeed, in a Chilean population it has been demonstrated the combined
beneficial effect of vitamin D supplementation plus exercise on vitamin D serum levels, bone density
and functional capacity [58]. Despite this, two recent systematic-reviews, shows that vitamin D
supplementation do not have a significant effect on fracture incidence [59] and musculoskeletal
health [60]. On the other hand, aging is associated to a progressive bone mass decrease, thus remain
physically active is one of the main strategies to combat this continuous loss [13,61]. An alternative
to PA is the active commuting, most prevalent behavior associated to active commuting in older
population is walking; especially in this population, the benefits of active commuting represents the
possibility of independence and autonomy [62,63]. That allows increased sunlight exposure, and
therefore, a greater possibility of vitamin D absorption. These results could have important public
health implications, since several health problems are associated to low vitamin D levels. In this sense,
decrease ST and increase active commuting could be useful strategies against these problems.
The mechanism implicated in this relationship remains unclear, physical activity has been related
to sun exposure and vitamin D levels. Nevertheless, this report, as well as other works, has found this
same association regardless of sun exposure [47,64]. Another hypothesis is related to physical activity
effect and bone metabolism, suggesting an interaction between calcium and vitamin D absorption [65].
Additionally, it has been proposed a close link between sedentary time and increase adiposity, since
adiposity is related to decline vitamin D levels [66,67]. Hence, in light to support these hypotheses,
more researches are needed.
Important strengths in this study include the population-based sampling method and the wide
consideration of potential confounders. However, this study has some limitations. The principal
limitation is that cross-sectional study design does not allow to draw causal relationships as was
addressed above. Thus, it is not possible to establish whether PA can lead to a vitamin D deficiency or
participants with vitamin D deficiency have less PA. Another limitation is about sunlight exposure;
despite having considered a question about sunlight exposure, self-report nature and dichotomy
response do not grant accurate information about the real amount exposure. On the other hand,
the specific vitamin D intake estimation could not be obtained from the used questionnaire and PA
questionnaires utilized in our paper often fail to provide sufficient detail on activity type, frequency,
duration, and intensity, especially in older adults. Finally, another limitation was the lack of calorie
measures of total energy, fat and sugar intake, which could not be obtained from the questionnaire used.
5. Conclusions
We found that high ST is associated with vitamin D deficiency in adult women as well as, passive
commuting is associated with vitamin D deficiency. Moreover, there is a joint association of high
ST/passive commuting on vitamin D deficiency and insufficiency in both groups. These novel results
may add key information for public policy in Chile related to health system approach. In this sense,
lifestyle recommendations are needed in order to establish specific recommendations, since the patterns
of PA and ST could affect differentially vitamin D status according to age. Further research directions
should establish the causal effect of PA and ST patterns, as well as establish the vitamin D deficiency
implications in different pathologies in the studied Chilean population.
68
Nutrients 2019, 11, 300
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/2/300/s1,
Figure S1: Vitamin D levels of all survey participants along Chilean territory. Population from North of Chile
exhibit higher serum vitamin D levels compared to the population from the south territory, being rather deficient
for the latter. It is noteworthy, that no region’s present population hold the recommended serum vitamin D levels,
which is higher than 30 ng/mL.
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Abstract: While observational studies show an association between 25(OH)vitamin D concentrations
and depressive symptoms, intervention studies, which examine the preventive effects of vitamin D
supplementation on the development of depression, are lacking. To estimate the role of lowered
25(OH)vitamin D concentrations in the etiology of depressive disorders, we conducted a two-sample
Mendelian randomization (MR) study on depression, i.e., “depressive symptoms” (DS, n= 161,460) and
“broad depression” (BD, n = 113,769 cases and 208,811 controls). Six single nucleotide polymorphisms
(SNPs), which were genome-wide significantly associated with 25(OH)vitamin D concentrations
in 79,366 subjects from the SUNLIGHT genome-wide association study (GWAS), were used as an
instrumental variable. None of the six SNPs was associated with DS or BD (all p > 0.05). MR analysis
revealed no causal effects of 25(OH)vitamin D concentration, either on DS (inverse variance weighted
(IVW); b = 0.025, SE = 0.038, p = 0.52) or on BD (IVW; b = 0.020, SE = 0.012, p = 0.10). Sensitivity
analyses confirmed that 25(OH)vitamin D concentrations were not significantly associated with DS or
BD. The findings from this MR study indicate no causal relationship between vitamin D concentrations
and depressive symptoms, or broad depression. Conflicting findings from observational studies
might have resulted from residual confounding or reverse causation.
Keywords: vitamin D; depression; depressive symptoms; Mendelian randomization
1. Introduction
Depressive disorders are the most common mental disorders worldwide, with more than
300 million people having been affected, in 2015 [1]. Considering that major depressive disorders (MDD)
recently became the third leading cause of disability worldwide [1], effective preventive approaches
are urgently needed. Interventions aiming at the prevention of mental disorders should ideally focus
on youth, since the first onset of mental disorders is frequently seen during childhood/adolescence [2].
Diet as one modifiable lifestyle factor could be a target for such preventive interventions.
Considering the increasing evidence for an inverse association between diet quality and mental
disorders, it was recently claimed to consider “nutritional medicine as mainstream in psychiatry” [3].
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At the same time, vitamin D deficiency was suggested to be linked with increased depressive
symptoms [3]. In fact, a number of studies have confirmed a relationship between vitamin D levels and
mental health already in childhood and adolescence. The majority of such studies focused on the autism
spectrum disorders and ADHD [4]. The few observational studies on depression in adolescence seemed
to confirm the suggested inverse association between 25(OH)vitamin D concentrations (recommended
biomarker for vitamin D status), and depression or emotional problems [5–7]. However, findings from
observational studies are not sufficient to draw conclusions on cause–effect relationships.
In childhood and adolescent depression, randomized controlled trials (RCTs)—the gold standard to
imply causality—are currently missing [4,8]. In adults, RCTs have examined vitamin D supplementation
effects on the course of an already existing depression, but meta-analyses of these studies have revealed
conflicting results [9–11]. Furthermore, these RCTs have focused on the therapeutic effects, but have
not examined a preventive role of vitamin D, prior to the development of depression. The few RCTs
on preventive effects had only been conducted in postmenopausal women [12] or women older than
70 years [13], without showing any beneficial effects. Transferability of these results to the general
population remains unclear. However, such preventive RCTs would require long-term interventions
and follow-up periods of several years, to cover a critical time frame of disorder pathogenesis,
and very large sample sizes, to provide sufficient statistical power. In contrast, two-sample Mendelian
Randomization (MR) studies based on summary data from large-scale genome-wide association studies
(GWAS) are a time-effective approach to examine the causal effect of an exposure (e.g., 25(OH)vitamin
D concentration) on an outcome (e.g., depression), by using genetic markers as instrumental variables
(IVs) [14]. The concept of MR studies implies a natural “quasi randomization”, since the individual
composition of alleles and, thus, of IVs are determined randomly at conception, resulting in a reduced
risk of confounding [15]. Bias from reverse causation, another limitation of observational studies,
is also precluded in MR studies, as the individual genotype is determined at conception, and cannot be
modified by the outcome of interest [15].
Recently, a two-sample MR study was conducted which focused on the causal effects of
25(OH)vitamin D on MDD. Using data from the most recent MDD GWAS with 59,851 cases and
113,154 controls, this MR study did not reveal a causal association between 25(OH)vitamin D
concentrations and the risk of MDD [16]. However, the phenotype of MDD does not completely cover
the complex dimensional and transitional aspects in the etiology of depression, ranging from single
depressive symptoms to a depressive syndrome, and finally a diagnosis of MDD or other subtypes
of depressive disorders [17]. To include both the dimensional aspects of depression and different
depression subtypes as outcomes, our two-sample MR study examined the effects of 25(OH)vitamin D
concentrations on depressive symptoms (DS) and broad depression (BD), using summary-level data of
the most recent large-scaled GWAS.
2. Materials and Methods
2.1. Data Sources for MR Analyses
This two-sample MR study relied on publicly available summary statistics of three different GWAS
meta-analyses on 25(OH)vitamin D concentration [18], DS [19], and BD [20,21]. For the definition of
the genetic instrument we used the most recent GWAS on serum 25(OH)vitamin D (i.e., the exposure
in this MR analysis) from the SUNLIGHT consortium with 79,366 participants of European ancestry,
including 31 studies from Europe, Canada, and USA [18]. The following studies were included
in the SUNLIGHT GWAS: 1958 British Birth (1956BC), the Cardiovascular Health Study (CHS),
the Framingham Heart Study (FHS), Gothenburg Osteoporosis and Obesity Determinants (GOOD),
the Health, Aging, and Body Composition study (Health ABC), the Study of Indiana Women (Indiana),
the Northern Finland Birth Cohort 1966 (NFBC), the Old Older Amish Study (OOA), the Rotterdam
Study, the Twins UK registry, the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC),
the Atherosclerosis Risk in Communities Study (ARIC), the AtheroGene registry, B-vitamins for
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the Prevention of Osteoporotic Fractures (B-PROOF), Epidemiology of Diabetes Interventions and
Complications (EDIC), the Case-Control Study for Metabolic Syndrome (GenMets), the Helsinki Birth
Cohort Study (HBCS), the Health Professional Follow-Up Study (HPFS, nested coronary heart disease
case-control study), the Invecchiare in Chianti Study (InChianti), the Cooperative Health Research
in the region Augsburg (KORA), the Leiden Longevity Study (LLS), the Ludwigshafen Risk and
Cardiovascular Health Study (LURIC), the Multi-Ethnic Study of Atherosclerosis (MESA), the Nijmegen
Biomedische Studie (NBS), the Nurses’ Health Study (NHS, nested breast cancer case-control study,
and type2 diabetes case-control study), the Orkney Complex Disease Study (ORCADES), the Prostate,
Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), the PROspective Study of Pravastatin
in the Elderly at Risk (PROSPER), the Study of Health in Pomerania (SHIP), the Scottish Colorectal
Cancer Study (SOCCS), and the Cardiovascular Risk in Young Finns Study (YFS). The majority
of these 31 studies used radioimmunoassay techniques, HPLC-MS, or LC-MS for the detection of
serum 25(OH)vitamin D. Detailed information about ethical approvals of the respective studies,
as well as the sample characteristics, are given in the supplementary files of the SUNLIGHT GWAS
meta-analysis [18,22]. For our MR study we used independent single nucleotide polymorphisms
(SNPs) of all six loci as genetic instruments, which were genome-wide significantly associated with
the exposure of interest (i.e., serum 25-hydroxyvitamin D concentrations) [18]. The effect sizes of the
six genetic variants on the exposure were derived from the publicly available summary statistics of
the GWAS meta-analysis (Table 1). Overall, these six SNPs explained 2.8% of the variance of serum
25(OH)vitamin D concentrations [18].
Effect estimates of these six genetic instruments on the two outcomes DS and BD were obtained
from the summary statistics of the two GWAS, including 161,460 individuals with European descent
for DS [19] and 113,769 “white British” BD cases, along with 208,811 controls from the UK Biobank for
BD [20,21]. The GWAS on DS [19] used data of the following cohorts: (1) UK Biobank (information
about ethics: https://www.ukbiobank.ac.uk/wp-content/uploads/2011/05/EGF20082.pdf.) (2) GERA,
Resource for Genetic Epidemiology Research on Adult Health and Aging; Subsample of the longitudinal
cohort enrolled in the Kaiser Permanente Research Program on Genes, Environment, and Health
(RPGEH) [23]. The institutional review boards of both, KPNC and the University of California San
Francisco approved the project. (3) The Psychiatric Genetics Consortium (PGC) data on MDD [24]
also relied on the GERA cohorts. The UK Biobank included people who were currently aged 40–69,
participants of RPGEH were all adult (≥18 years old). Okbay et al. (2016) considered only persons with
European ancestry (UK Biobank: “White-British” ancestry) and constructed a continuous phenotype
for DS, by combining the responses to two questions about the experienced feelings of disinterest and
feelings of depression with case-control data on MDD [19].
The GWAS on BD [20] used data from the UK Biobank study [25], which was conducted
under the generic approval from the NHS National Research Ethics Service (approval letter dated
17th June 2011, Ref 11/NW/0382). According to the study protocol, the UK Biobank aimed to
include 500,000 people from all over UK, who were currently aged 40–69 and were living within a
reasonable travelling distance to an assessment center. While the study protocol of the UK Biobank
(https://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf) did not list any
criterion for exclusion, Howard et al. excluded individuals which were not recorded as “white British”
as well as the outliers (e.g., based on heterozygosity, shared relatedness of up to the third degree,
etc.) [20]. Howard et al. defined BD via self-reported help-seeking behavior for non-specific mental
health difficulties, which might reflect the beginning of a depressive episode [20]. They hypothesized
that genetic variants identified in cohorts using self-reported measures of depression are known to be
highly correlated with those obtained from cohorts using clinically diagnosed depression phenotypes,
but at the same time offer the opportunity to analyze large cohorts rather than smaller studies with a
clinically defined phenotype [20]. Accordingly, BD represents the broadest of the examined phenotypes
in this GWAS, including different depression diagnoses (e.g., single episode depression, recurrent
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depressive disorder), which resulted in the largest number of, both, subjects for analysis and identified
significant SNPs [20].
Using summary data of these three GWAS, two separate two-sample MR studies were conducted
for BD and DS, including analyses of pleiotropy, sensitivity, and power.
2.2. Testing Mendelian Randomization Assumptions
MR studies require fulfillment of three core assumptions [15]: (1) The first assumption states
that the selected genetic instrument has to be truly associated with the exposure of interest, i.e.,
25(OH)vitamin D. By selecting our instrument based on large-scaled GWAS and focusing only on
genome-wide significant SNPs for 25(OH)vitamin D, we ensured that this first assumption was fulfilled.
(2) If there is an effect of the genetic instrument on the outcome, besides the effect of 25(OH)vitamin D,
it ss no longer possible to distinguish between the effects in an MR study. Accordingly, the second
assumption states that the genetic instrument has to be independent of the outcome, conditional on the
exposure and confounders of the exposure–outcome association [26]. (3) The third assumption states
that the genetic instrument must not be associated with any confounder of the exposure–outcome
relationship. Assumptions 2 and 3 are difficult to test, because it also includes associations with
unknown confounders. Therefore, we investigated whether there was horizontal pleiotropy, i.e.,
genetics had an effect on DS or BD, besides its effect on 25(OH)vitamin D, by estimating the coefficients
of Egger’s regression for MR, and checking whether the intercept was significantly unequal to zero.
2.3. Statistical Analysis
All tests were performed using the statistical software “R” version 3.5.2 (R Foundation for
Statistical Computing, Vienna, Austria). Since the two outcomes were analyzed separately, the overall
significance level of 0.05 was applied for each outcome, in order to control for multiple testing in the
sense of a family-wise error rate.
To ensure that our analyses were not based on weak instruments, the F-statistics were computed.
Following general recommendations, F-statistics above 10 indicate that the instruments were sufficiently
strong. Given no evidence for horizontal pleiotropy, the summary data were analyzed for the single
SNPs, as well as the combination of all SNPs as IV, using two MR methods (inverse variance weighted
regression (IVW) and Egger’s regression). Other MR methods (simple mode, weighted mode and
weighted median) were applied, with similar results (not shown). To visualize the results, forest and
scatter plots were used, which combined the results of single and multi SNP analyses. In the forest
plots, the single SNP effect estimates were displayed beside the multi SNP effect estimates, with the
corresponding 95% confidence intervals. In the scatter plots, the single SNP effects on the exposure
were plotted against the single SNP effects on the outcome (with corresponding standard deviation in
both directions) and the estimated regression lines of the multi SNP analyses were added.
To examine whether the analyses were driven by any single SNP, sensitivity analyses using a
leave-one-out approach were conducted. For this purpose, all SNPs but one were analyzed, using the
IVW regression. In general, if the analyses are not driven by one single SNP, the regression coefficients
remain relatively stable. Finally, we estimated the power to detect a true causal effect of a relative
difference between 1% and 20%, per 1 standard deviation in 25(OH)vitamin D, which corresponded to
the odds ratio values between 0.8 and 1.2 in 0.01 steps, with the approach proposed by Brion et al. [27].
Results from our analysis of the German representative KiGGS study might give a crude impression
on the standard deviation of 25(OH)vitamin D in a healthy sample. In this analysis, we observed a
standard deviation of 25.0 nmol/l and 25.5 nmol/l, in boys and girls aged 3–17 years [5].
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3. Results
The information on the association of the six selected SNPs with 25(OH)vitamin D concentrations,
DS, and BD are presented in Table 1. None of the six 25(OH)vitamin D-lowering alleles were either
associated with DS or with BD. With F = 381.0103 the F-statistic indicated strong instrumental
variables. The overall estimates, calculated by IVW or MR Egger, did not reveal associations between
25(OH)vitamin D concentrations and DS or BD (Table 2, Figures 1 and 2). Sensitivity analyses using the
leave-one-out approach confirmed the lack of associations (Supplemental Tables S1 and S2). There was
no evidence for pleiotropy either for DS (MR-Egger intercept: 0.0002; p = 0.949) or BD (MR-Egger
intercept: −0.0001; p = 0.886). Power analyses revealed that our MR analyses had a 100% power to
detect an OR of 1.1 for BD per 1 standard deviation decrease in natural-log transformed 25(OH)vitamin




Figure 1. Results of the single and multi SNP analyses for the SNP effect of natural-log transformed
25(OH)vitamin D on (a) broad depression, and (b) depressive symptoms. The black lines visualize the
results of single SNP analyses, the red lines visualize the results of the multi SNP analysis.
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Figure 2. Results of the single and multi SNP analyses on the association between natural-log
transformed 25(OH)vitamin D concentration and (a) broad depression and (b) depressive symptoms.
A SNP effect of 0.025 means that carrying an alternative allele at this SNP was associated with an
expected increase in the natural-log transformed 25(OH)D by 0.025; eˆ(beta) gives the change in
25(OH)vitamin D in percentage. Accordingly, a SNP effect of 0.025 was associated with an expected
increase of 25(OH)D by 2.5% (eˆ0.025 = 1.025), while a SNP effect of 0.1 was associated with an expected
increase of 25(OH)D by 10.5% (eˆ0.1 = 1.105).
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4. Discussion
Using data from the large-scaled GWAS in subjects from European descent, this MR study did not
provide evidence for the suggested role of (genetically determined) 25(OH)vitamin D concentrations
in the onset of DS or BD. Combined with the results from a previous MR study, based on a subsample
of the data sets used for this current study, which showed no association with MDD, it might be
hypothesized that raising of vitamin D concentrations seems to have no discernible preventive effect
on the onset of depressive disorders in individuals of European descent.
In contrast to this conclusion, a meta-analysis of observational studies that compared the lowest
and the highest category of vitamin D concentrations in adults, revealed an OR of 1.31 (95% confidence
interval (CI) 1.0–1.71, p = 0.05) for depression derived from nine cross-sectional studies and a hazard
ratio of 2.21 (95% CI 1.40–3.49, p = 0.0007) from three cohort studies [28]. We recently confirmed these
findings in children using cross-sectional data of the representative KiGGS study in Germany, which
illustrated an inverse association between 25(OH)vitamin D concentrations and emotional problems,
measured by the Strengths and Difficulties Questionnaire (SDQ) [5]. A prospective analysis of the
Avon longitudinal study for parents and children (ALSPAC) also seemed to indicate a preventive role
of vitamin D in adolescence. While 25(OH)vitamin D concentrations at the age of 10 years were not
associated with self-reported DS at the age of eleven years, long-term analyses revealed that those
participants with 25(OH)D <50 nmol/l at ten years had a 20% increased risk of self-reported depressive
symptoms at 14 years [7]. Overall, these associations from observational studies stand in contrast to
the MR study on MDD [16], and stand also in contrast to our findings on DS and BD. As suggested by
König and Del Greco, reverse causation and residual confounding should be considered as alternative
explanations, if MR studies do not support findings from observational studies [15]. In fact, low vitamin
D levels could well be a consequence of an already developing depression, e.g., in case of social
withdrawal and reduced sunlight exposure (reverse causation). Residual confounding also seems
reasonable considering that decreasing vitamin D concentrations were discussed to be a biomarker for
impaired general health [29]. Accordingly, low vitamin D concentrations could be associated with a
number of potential confounds, which hamper a complete adjustment in the statistical analyses of
observational studies.
A limitation of our MR study was that the analyzed SNPs only explained 2.8% of the variance of
vitamin D concentrations. Accordingly, the lacking association between the respective SNPs and the
development of depression might be confounded by the weak effect of these genetic determinants
on the vitamin D level (weak instrument bias). However, the F-Statistics indicated that the genetic
instruments used were sufficiently strong.
The considered GWAS meta-analyses for vitamin D, DS, and BD for MR analysis were all restricted
to individuals of European descent. Since our MR analysis relied on the provided information in the
underlying GWAS meta-analyses, it was, for example, not possible to conduct stratified analyses for
different countries, ethnicities, or age groups. Accordingly, the effects of vitamin D concentrations
observed in this MR study might not be transferable to populations with other specific characteristics
(e.g., ethnicity and age). Furthermore, horizontal pleiotropy, i.e., an association between the MR
instrument and the outcome of interest via pathways other than the suggested exposure, is a general
issue in MR studies and is a source of bias [14]. Although pleiotropy cannot be completely ruled out
in our MR study, the MR Egger intercept revealed no indication of pleiotropy. Another limitation is
that the statistical power only allowed the detection of OR > 1.1 per 1 standard deviation decrease
in the natural-log transformed 25(OH)vitamin D with a statistical power of 100% (OR > 1.07 with
80% power). Accordingly, small preventive effects below this threshold could not completely be
ruled out. Additionally, it must be kept in mind that DS and BD represent a broad definition of
depression. As depression is a heterogenic disorder, vitamin D might still be effective in specific
subtypes of depression. Finally, it has to be considered that vitamin D represents only one of
numerous etiological factors in the complex etiological model of depression, including endocrinology,
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inflammation, and neurotransmission pathways [17]. At least, at the population level, the role of
vitamin D in this process might be of minor importance.
5. Conclusions
This MR study did not support the suggested preventive role of 25(OH)vitamin D concentrations
in the development of depression. Other health and lifestyle factors related to low 25(OH)vitamin
D concentrations, such as insufficient sunlight exposure as a consequence of an already beginning
depression, could explain the observed associations from observational studies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/5/1085/s1,
Table S1: Sensitivity analyses using the leave-one-out approach on the association of natural-log transformed
25(OH)vitamin D concentrations with broad depression, Table S2: Sensitivity analyses using the leave-one-out
approach on the association of natural-log transformed 25(OH)vitamin D concentrations with depressive symptoms.
Figure S1. Calculated power to detect a true causal effect of a relative difference between 1% and 20% per 1
standard deviation in 25(OH)vitamin D.
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Abstract: Vitamin D (VitD) insufficiency is common in multiple sclerosis (MS). VitD has possible
anti-inflammatory effects on the immune system. The ratio between VitD metabolites in MS patients
and the severity of the disease are suggested to be related. However, the exact effect of the bone-derived
hormone fibroblast-growth-factor-23 (FGF23) and VitD binding protein (VDBP) on this ratio is not
fully elucidated yet. Therefore, the aim is to study differences in total, free, and bioavailable VD
metabolites and FGF23 between MS patients and healthy controls (HCs). FGF23, vitD (25(OH)D),
active vitD (1,25(OH)2D), inactive 24,25(OH)D, and VDBP were measured in 91 MS patients and 92
HCs. Bioavailable and free concentrations were calculated. No difference in FGF23 (p = 0.65) and
25(OH)D/24.25(OH)2D ratio (p = 0.21) between MS patients and HCs was observed. Bioavailable
25(OH)D and bioavailable 1.25(OH)2D were lower (p < 0.01), while VDBP concentrations were higher
in MS patients (p = 0.02) compared with HCs, specifically in male MS patients (p = 0.01). In conclusion,
FGF23 and 25(OH)D/24.25(OH)2D did not differ between MS patients and HCs, yet bioavailable VitD
concentrations are of potential clinical relevance in MS patients. The possible immunomodulating
role of VDBP and gender-related differences in the VD-FGF23 axis in MS need further study.
Keywords: multiple sclerosis; fibroblast growth factor 23; vitamin D metabolites; vitamin D
binding protein
1. Introduction
Multiple sclerosis (MS) is a chronic, progressive disease of the central nervous system characterized
by an inflammatory, demyelinating, and neurodegenerative process, which can result in varying levels
of disability. Consequently, MS has a negative effect on the daily life of patients, resulting from fatigue,
muscle weakness, and imbalance to immobility, which all negatively affect bone health [1–4]. Earlier
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studies showed that decreased bone mineral density (BMD) is prevalent already shortly after clinical
onset even in physically active patients with MS [2,4–6]. Lower BMD combined with impaired mobility
can result in an increased fracture risk in MS patients and accompanying disability and economic
burden [7]. The specific aetiology of MS is still unknown, but strong evidence exists regarding viral,
genetic, and immunological causes of the disease [8,9].
Vitamin D is thought to play a role in the pathogenesis of MS, as it is known that the prevalence
of MS increases with latitude, which in turn is associated with lower serum concentrations of
vitamin D (25(OH)D) [10,11]. Vitamin D possibly modulates T-lymphocyte subset differentiation and,
therefore, a lower concentration is thought to lead to an increased risk of MS [12]. In line with this,
associations between lower serum concentrations 25(OH)D and an increased risk of MS are shown
in several studies [13–15]. As a result, vitamin D supplementation is often advised to MS patients,
although contra-dictionary effects regarding the beneficial effects of increased 25(OH)D concentrations
on, for example, the recurrence rate of relapses, deterioration of number of brain laesions, and
improvement of disability are described [16–20]. Because of the potential role of vitamin D in MS,
other vitamin D metabolites have been studied in MS patients. 25(OH)D needs to be metabolized to
the biologically active 1.25(OH)2D, and both metabolites are predominantly bound to their carrier
vitamin D binding protein (VDBP). Previous research showed a higher plasma VDBP concentration in
MS patients compared with healthy controls (HCs) [21]. VDBP is known to play an important role in
the intracellular actin scavenging system by removing actin derived from damaged tissue and also
promotes inflammation [22–26]. Polymorphisms of both VDBP and also of the vitamin D receptor
(VDR) can result in a changed equilibrium between active and inactive vitamin D metabolites [24,27,28].
Interestingly, lower concentrations of the vitamin D metabolite 24.25(OH)2D were associated with a
higher grade of disability based on the Expanded Disability Status Scale (EDSS) score in MS patients [29].
Moreover, the ratio of 25(OH)D/24.25(OH)2D was strongly inversely associated with brain parenchymal
function [29].
A key player in vitamin D metabolism is the bone-derived hormone fibroblast growth factor 23
(FGF23), as it inhibits the enzyme 1-alpha hydroxylase and stimulates the enzyme 24-hydroxylase,
resulting in the conversion of 25(OH)D into 24.25(OH)2D instead of into 1.25(OH)2D. We thus
hypothesize that plasma FGF23 concentrations differ between MS patients and healthy controls.
The primary aim of this study is to further elucidate the vitamin D-FGF23 axis by measuring
multiple D metabolites and FGF23 using accurate state-of-the art analytical methods in a well-defined
cohort of MS patients and healthy controls. The second aim of our study is to assess bone turnover
markers (BTMs) in our cohort MS patients and healthy controls and to study the possible associations of
BTMs with vitamin D metabolites, as vitamin D deficiency is associated with increased bone turnover
and lower bone mineral density [30–32]. Lastly, it is known that MS affects more women than men and
that women have higher VDBP concentrations compared with men [13,21,33–36]. Therefore, possible
gender-related differences of vitamin D metabolites and BTMs between MS patients and healthy
controls will be studied.
2. Materials and Methods
2.1. Subjects and Study Protocol
The subjects and study protocol were described earlier by Kragt et al. [13]. Patients were eligible
to participate in the study if they provided informed consent and were between 18 and 75 years of
age. Three subtypes of MS were identified: relapsing-remitting MS (RRMS), secondary progressive
MS (SPMS), and primary progressive MS (PPMS). Patients with all subtypes of MS were eligible to
participate. In addition, patients with clinically isolated syndrome (CIS) were also included, which
refers to a single episode of symptoms that are suggestive for MS. Patients were recruited between July
and September 2003, to ensure that all blood samples were drawn during summer season. Patients
were asked to bring a healthy control with them to the outpatient clinic if possible, preferably their
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partner in order to match the patients based on age and environmental factors. If a healthy control
was lacking, hospital personnel volunteered to participate as controls. Patients were excluded if they
were diagnosed with osteomalacia, hyperparathyroidism, hyperthyroidism, or hypercortisolism, or if
they had been receiving glucocorticoid treatment in the previous three weeks (daily oral treatment or
intravenous methylprednisolone treatment), anti-epileptic drugs, or vitamin D supplementation of
more than 200 IU/day. The controls were excluded if they had MS or had a first-degree family member
with MS. In addition, study participants were excluded in the case of suspicion of concomitant bone
disease based on their laboratory results. All subjects gave their informed consent for inclusion before
they participated in the study. The study was conducted in accordance with the Declaration of Helsinki,
and the protocol was approved by the Medical Ethical Committee of the Amsterdam UMC, location
VU University Medical Center (code 2003.029).
2.2. Measurements
2.2.1. General
The functional disability of MS patients was evaluated using the Expanded Disability Status
Scale (EDSS) [37]. EDSS quantifies disability in MS patients, which ranges from 0 to 10, with higher
scores representing higher levels of disability. Blood samples were collected before 00:00 and after
an overnight fast. Samples were collected in 2003 and stored (both as serum and EDTA plasma in
several aliquots) in minus 80 degrees Celsius. Analyses were performed in 2011 (parathyroid hormone
(PTH), alkaline phosphatase (ALP), albumin, calcium, phosphate, estimated glomerular filtration rate
(eGFR)) and in 2017 (25(OH)D, 24.25(OH)2D, 1.25(OH)2D, VDBP, FGF23, c-terminal telopeptide (CTX),
osteocalcin, procollagen type 1 N-terminal propeptide (P1NP)) in the various aliquots.
2.2.2. Vitamin D Metabolites
In the current study, 25(OH)D and 24.25(OH)2D were measured in serum using a dedicated
isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) [38]. Total serum
concentrations of 25(OH)D were calculated by the sum of 25(OH)D2 and 25(OH)D3. For 25(OH)D2,
the lower limit of quantitation (LLOQ) was 0.36 nmol/L and the inter-assay coefficient of variation
(CV) was 6%. For 25(OH)D3, LLOQ was 1.19 nmol/L and the inter-assay CV was 6%. For 24.25(OH)2D,
LLOQ was 0.12 nmol/L and the inter-assay CV was 5% [37,39]. A two-dimensional isotope dilution
ultra-pressure liquid chromatography tandem mass spectrometry (2D ID-UPLC-MS/MS) was used
to measure serum 1.25(OH)2D with an LLOQ of 3.4 pmol/L and inter-assay CV of 11% [40]. It is of
note that, in the earlier study of Kragt et al., a radioimmunoassay was used for the measurement of
25(OH)D and 1.25(OH)2D [13], but the concentrations shown in the current study are obtained using
an LC-MS/MS method. VDBP was measured using a polyclonal ELISA (Immundiagnostik AG) with a
LLOQ of 2.2 μg/L and an inter-assay CV of <13%.
2.2.3. Free and Bioavailable Vitamin D Metabolites
Vitamin D metabolites bound to protein are not biologically active, whereas the unbound hormones
are. Free 25(OH)D was calculated using equations and affinity constants according to Malmstroem
et al. [41] and free 1.25(OH)2D was calculated using equations and affinity constants according to
Bikle et al. [42]. Bioavailable 25(OH)D and 1.25(OH)2D were calculated using equations adapted from
Vermeulen et al. [43] and the supplement of Powe et al. [44].
2.2.4. Bone Turnover Markers (BTMs)
FGF23 was measured in EDTA plasma using a c-terminal immunoassay (Immutopics) with an
LLOQ of 20 RU/mL and inter-assay CV of <10% [45]. CTX and P1NP were measured in EDTA plasma
using an immunoassay (Cobas, Roche Diagnostics, Almere, The Netherlands), with an LLOQ of 10 ng/L
and inter-assay CV of <6.5% for CTX and an LLOQ of 5 μg/L and inter-assay CV of <8% for P1NP,
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respectively. Osteocalcin was measured in EDTA plasma using an immunometric-assay (Biosource,
Nivelles, Belgium) with an LLOQ of 0.4 nmol/L and inter-assay CV of 8–15%.
2.2.5. Other Measurements
PTH was measured in EDTA plasma using an immunoassay (Architect, Abbott Diagnosher,
Chicago, IL, USA) with an LLOQ 0.5 pmol/L and inter-assay CV of <9%. ALP, eGFR, calcium,
phosphate, and albumin were measured in heparin plasma using the chemistry module of the Cobas
(Roche Diagnostics).
2.3. Statistical Analysis
Baseline characteristics between MS patients and healthy controls were compared using a Student’s
t-test or chi-square test. The Mann–Whitney U test was used in the case of non-parametric variables.
To detect differences between patients and controls in biochemical indices of the vitamin D metabolites
and BTMs, the Mann–Whitney U test was used as well. In addition, separate analyses for men and
women were performed. Lastly, correlations between serum vitamin D metabolites, BTMs, and EDSS
were calculated using Spearman correlations owing to non-parametric variables. All statistical analyses
were carried out using SPSS software, version 23.0.
3. Results
3.1. General
A total of 213 participants were eligible to be included in this study. After applying the in- and
exclusion criteria, a total of 30 participants were excluded; see Figure 1. The final study population
that was included in the analyses consisted of 183 participants based on 91 MS patients and 92 healthy
controls. Table 1 summarizes the baseline characteristics of all participants. In total, 61% of the MS
patients were female. Relapsing remitting MS was the most predominant subtype of MS (57%).
 
Figure 1. Flow chart of study population selection. PTH = parathyroid hormone, ALP = alkaline
phosphatase, eGFR = estimated glomerular filtration rate FGF23 = fibroblast growth factor 23,
MS =multiple sclerosis.
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Table 1. Baseline characteristics, vitamin D metabolites, FGF23, and bone turnover markers of multiple
sclerosis (MS) patients and controls displayed as median with corresponding interquartile range (IQR),
unless specified otherwise, of MS patients and controls.
Patients (n = 91) Controls (n = 92) p Value a Reference Range
Age, yr (mean ± SD) 45 ± 11 42 ± 11 0.30
Female of total population (%) 67 41 <0.01 *
Postmenopausal of total population (%) 34 16 0.04 *
Caucasian (%) 98 95 0.44







Disease duration, yr (median, IQR) 10 (5–16) n.a.
EDSS (median, IQR) 4 (3–6) n.a.
Use of vitamin D supplements b, (%) 40 14 <0.01 *
Use of using disease modifying therapy, (%) 32 n.a.
Total 25(OH)D, nmol/L 75 (59–93) 77 (67–98) 0.06 # >50
Total 1.25(OH)2D, pmol/L 105 (74–143) 99 (79–133) 0.57 59–159
25(OH)D2, nmol/L 1.1 (0.8–1.5) 1.2 (0.9–1.5) 0.66
25(OH)D3, nmol/L 73 (58–92) 76 (66–96) 0.05 #
24.25(OH)D, nmol/L 6.5 (4.4–9.0) 7.1 (5.4–9.6) 0.08 # 0.4–8.9
Free 25(OH)D (* 10−2), nmol/L 1.2 (1.0–1.5) 1.4 (1.2–1.7) <0.01 *
Albumin bound 25(OH)D, nmol/L 4.5 (3.5–5.6) 5.1 (4.1–6.1) <0.01 *
Bioavailable 25(OH)D, nmol/L 4.5 (3.5–5.6) 5.1 (4.1–6.1) <0.01 *
Free 1.25(OH)2D (* 10−1), pmol/L 2.0 (2.2–2.8) 2.5 (0.2–3.1) <0.01 * #
Albumin bound 1.25(OH)2D, pmol/L 7.3 (5.7–9.1) 8.4 (6.7–9.9) <0.01 *
Bioavailable 1.25(OH)2D, pmol/L 7.5 (5.9–9.4) 8.6 (7.0–10.2) <0.01 *
Ratio total 25(OH)D/24.25(OH)2D 11.2 (9.9–13.6) 11.4 (9.5–12.9) 0.21 10–33
VDBP, μg/L 408 (374–445) 388 (361–427) 0.02 * # 200–550
Albumin, g/L 42 (39–44) 42 (40–43) 0.86 35–52
Calcium, mmol/L 2.4 (2.3–2.4) 2.4 (2.3–2.4) 0.73 2.2–2.6
Corrected calcium, mmol/L 2.3 (2.3–2.4) 2.3 (2.3–2.4) 0.81
FGF23, RU/mL 88 (72–113) 89 (69–106) 0.65 <125
PTH, pmol/L 5.2 (4.0–6.6) 5.3 (3.8–6.7) 0.94 <10
Phosphate, mmol/L 1.0 (0.9–1.1) 0.8 (0.8–0.9) <0.01 * 0.7–1.4
CTX, ng/L 256 (183–379) 307 (212–418) 0.10 <580
P1NP, μg/L 37 (27–54) 39 (29–56) 0.37 22–87
ALP, U/L 74 (53–89) 67 (56–79) 0.14 <115
Osteocalcin, nmol/L 1.5 (1.1–2.1) 1.5 (1.1–2.0) 0.99 0.4–4.0
eGFR = estimated glomerular filtration rate, RRMS = relapsing remitting MS, SPMS = secondary progressive MS,
PPMS = primary progressive MS, CIS = clinically isolated syndrome, SP + R = secondary progressive + remitting,
EDSS = Expanded Disability Status Scale, VDBP = vitamin D binding protein, PTH = parathyroid hormone, ALP =
alkaline phosphatase, FGF23 = fibroblast growth factor 23, CTX = c-terminal telopeptide, P1NP = procollagen type 1
N-terminal propeptide. a p values of Student’s t-test, chi-square test, or Mann–Whitney U test. b Maximum allowed
dose of vitamin D supplements was 200 IU/day. * Bold, significance level p ≤ 0.05. # Significant difference between
male and female; details can be found in Table 2.
3.2. Vitamin D Metabolites, FGF23, and Bone Turnover Markers
Biochemical indices of vitamin D metabolism and bone turnover of the study population are
displayed in Table 1. Again, it is of note that, in contrast to the earlier study of Kragt et al., current
25(OH)D and 1.25(OH)2D measurements are reported based on the ID-LC-MS/MS measurements [13].
Overall, no significant difference between total serum concentrations of 25(OH)D (p = 0.06) was found
between MS patients and the healthy controls. MS patients had significant lower serum concentrations
of free, albumin bound, and bioavailable 25(OH)D and 1.25(OH)2D compared with healthy controls
(p < 0.01). In addition, MS patients had higher concentrations of phosphate and VDBP compared with
controls, whereas no significant differences in BTMs were found. Plasma FGF23 concentrations did not
differ between MS patient and the healthy controls (p = 0.65) (Figure 2).
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Table 2 shows the significant results of separate analyses for men and women. In contrast to
male patients, female MS patients had lower serum concentrations of total 25(OH)D, 25(OH)D3,
24.25(OH)2D, free 25(OH)D, and free 1.25(OH)2D compared with healthy female controls (p = 0.04).
Male MS patients had higher serum concentrations of VDBP compared with male controls (p = 0.01).
No other significant differences were found between male MS patients and healthy male controls.
Regarding BTMs, no significant differences were found between males and females (data not shown).
Lastly, EDSS scores did not differ between male and female MS patients (p = 0.77, data not shown).
Table 2. Vitamin D metabolites of MS patients and controls stratified for gender, only shown in the
case of significant differences between male and females, displayed as median with corresponding
interquartile range (IQR).
Men (n = 84) Women (n = 99)
Patients (n = 30) Controls (n = 54) p values a Patients (n = 61) Controls (n = 38) p values a
Total 25(OH)D, nmol/L 74 (56–97) 75 (66–90) 0.62 77 (60–90) 88 (68–106) 0.02 *
25(OH)D3, nmol/L 73 (55–96) 74 (64–89) 0.64 75 (58–89) 86 (67–104) 0.01 *
24.25(OH)2D, nmol/L 6.5 (4.5–8.8) 6.9 (5.4–8.7) 0.48 6.5 (4.4–9.1) 7.1 (5.6–11.0) 0.04 *
Free 25(OH)D (* 10−2), nmol/L 0.013 (0.010–0.017) 0.014 (0.012–0.017) 0.17 0.012 (0.010–0.015) 0.013 (0.011–0.017) 0.03 *
Free 1.25(OH)2D (* 10−1), pmol/L 0.23 (0.17–0.30) 0.25 (0.22–0.31) 0.18 0.21 (0.17–0.27) 0.24 (0.21–0.31) 0.03 *
Phosphate, mmol/L 1.0 (0.9–1.0) 0.8 (0.8–0.9) <0.01 * 1.0 (0.9–1.1) 0.8 (0.8–0.9) <0.01 *
VDBP = vitamin D binding protein, PTH = parathyroid hormone. a p values of Mann–Whitney U test are shown as
medians with interquartile ranges in parentheses. * bold significance level p ≤ 0.05.
Figure 2. Vitamin D metabolites and FGF23 in MS patients versus healthy controls, * p ≤ 0.05.
3.3. Associations
3.3.1. Associations between Vitamin D Metabolites, FGF23, Bone Turnover Markers, and EDSS in
MS Patients
In MS patients, all vitamin D metabolites correlated strongly with each other (all r > 0.77; p < 0.01,
data not shown). EDSS showed negative correlations with bioavailable 1.25(OH)2D, bioavailable
25(OH)D, and 24.25(OH)2D (r −0.30, p < 0.01; r −0.30, p < 0.01; and r −0.23, p = 0.03, respectively).
No correlations between EDSS and FGF23 or BTMs in MS patients were found (data not shown).
As shown in Table 3, FGF23 correlated positively with serum 25(OH)D and serum 24.25(OH)2D
(r 0.22, p= 0.04 and r 0.22, p= 0.04, respectively), and CTX correlated negatively with serum 24.25(OH)2D
and 25(OH)D (r −0.31, p < 0.01 and r −0.23, p = 0.03, respectively) in MS patients. Phosphate showed
a positive correlation with osteocalcin (r 0.22, p 0.04). Negative correlations for osteocalcin with
1.25(OH)2D, and P1NP with 24.25(OH)2D, were observed in MS patients only (r −0.24, p = 0.02 and
r −0.25, p = 0.02, respectively), as were positive correlations of the ratio between total serum 25(OH)D
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and 24.25(OH)2D with P1NP and CTX (r 0.27, p = 0.01 and r 0.31, p < 0.01, respectively). In addition,
in MS patients, ALP showed a positive correlation with osteocalcin, CTX, and P1NP (r 0.36, p < 0.01;
r 0.44, p < 0.01; and r 0.43, p < 0.01, respectively); P1NP showed a positive correlation with osteocalcin
and CTX (r 0.75, p < 0.01 and r 0.74, p < 0.01, respectively); and CTX correlated positively with
osteocalcin (r 0.67, p < 0.01).
Table 3. Correlation between vitamin D metabolites, bone turnover markers (BTMs), and EDSS in
MS patients.
N = 90 ALP FGF23 Osteocalcin CTX P1NP EDSS
Free 1.25(OH)2D
r −0.03 r 0.10 r 0.01 r −0.10 r −0.07 r −0.28
p 0.78 p 0.33 p 0.95 p 0.33 p 0.54 p 0.01
Bioavailable 1.25(OH)2D
r −0.04 r 0.10 r 0.04 r −0.06 r −0.03 r −0.30
p 0.71 p 0.33 p 0.72 p 0.59 p 0.77 p < 0.01
Total 1.25(OH)2D
r −0.12 r −0.05 r −0.24 r −0.09 r −0.19 r −0.08
p 0.25 p 0.65 p 0.02 p 0.41 p 0.08 p 0.47
Free 25(OH)D r −0.02 r 0.10 r 0.01 r −0.10 r −0.06 r −0.28
p 0.82 p 0.34 p 0.93 p 0.36 p 0.57 p 0.01
Bioavailable 25(OH)D r −0.03 r 0.11 r 0.05 r −0.05 r −0.02 r −0.30
p 0.77 p 0.33 p 0.66 p 0.67 p 0.84 p < 0.01
Total 25(OH)D r −0.16 r 0.22 r −0.12 r −0.23 r −0.19 r −0.23
p 0.14 p 0.04 p 0.28 p 0.03 p 0.08 p 0.03
24.25(OH)D r −0.20 r 0.22 r −0.16 r −0.31 r −0.25 r −0.22
p 0.06 p 0.04 p 0.14 p < 0.01 p 0.02 p 0.04
Ratio
25(OH)D/24.25(OH)2D
r 0.18 r −0.13 r 0.16 r 0.31 r 0.27 r 0.10
p 0.09 p 0.23 p 0.13 p <0.01 p 0.01 p 0.34
PTH
r 0.09 r −0.04 r −0.04 r 0.04 r −0.08 r 0.16
p 0.40 p 0.69 p 0.97 p 0.69 p 0.46 p 0.13
Phosphate r 0.10 r 0.03 r 0.22 r 0.13 r 0.16 r −0.03
p 0.35 p 0.78 p 0.04 p 0.24 p 0.15 p 0.76
ALP = alkaline phosphatase, FGF23 = fibroblast growth factor 23, CTX = c-terminal telopeptide, P1NP = procollagen
type 1 N-terminal propeptide, EDSS = Expanded Disability Status Scale, PTH = parathyroid hormone. Bold text
indicates a significance level of p ≤ 0.05. r: Spearman correlation coefficient.
3.3.2. Associations Based on Gender of MS Patients
Looking at gender differences, in female MS patients, the same correlations were found as
described above, except for the correlations of FGF23 with serum 25(OH)D and 24.25(OH)2D (r 0.12,
p = 0.37 and r 0.10, p = 0.44, respectively). In male MS patients, however, FGF23 correlated positively
with total (r 0.50, p < 0.01), free (r 0.43, p = 0.02), and bioavailable 25(OH)D (r 0.43, p = 0.02); free (r 0.43,
p 0.02) and bioavailable 1.25(OH)2D (r 0.43, p 0.02); and 24.25(OH)2D (r 0.46, p = 0.01), respectively.
Furthermore, EDSS showed negative correlations with CTX (r −0.53, p < 0.01), P1NP (r −0.48, p < 0.01),
and osteocalcin (r −0.40, p 0.03) in male MS patients only.
3.3.3. Associations in Healthy Controls
Lastly, in healthy controls, similar correlations of osteocalcin, CTX, and P1NP were found (data
not shown). FGF23 correlated significantly with serum 1.25(OH)2D (r −0.35, p < 0.01; data not shown),
and CTX correlated significantly with serum 25(OH)D (r −0.24, p = 0.05; data not shown). In addition,
PTH showed a positive correlation with ALP (r 0.21, p 0.04; data not shown) and phosphate showed a
negative correlation with P1NP (r −0.27, p 0.03; data not shown) in the healthy control group.
4. Discussion
This study examined differences in total, free, and bioavailable vitamin D, FGF23 and bone
turnover markers in patients with MS compared with healthy controls and possible gender differences.
Although positive correlations between FGF23 and total 25(OH)D and 24.25(OH)2D in MS patients
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were seen, no differences in plasma FGF23 concentrations between MS patients and healthy controls
were observed. No differences between serum concentrations of BTMs in MS patients and healthy
controls were found. Yet, we did observe a negative correlation between CTX and total 25(OH)D and
24.25(OH)2D. EDSS showed negative correlations with bioavailable 1.25(OH)2D, bioavailable 25(OH)D,
and 24.25(OH)2D. We found gender differences in vitamin D metabolism: serum concentrations of
total 25(OH)D, 25(OH)D3, 24.25(OH)2D, free 25(OH)D, and free 1.25(OH)2D were lower in female MS
patients compared with female healthy controls. Serum concentrations of VDBP were higher in male
MS patients compared with healthy male controls.
The main aim of this study was to further elucidate the vitamin D-FGF23 axis by measuring
multiple D metabolites and FGF23 using accurate state-of-the art analytical methods in a well-defined
cohort of MS patients versus healthy controls. We confirmed the finding of an earlier study that the
serum 24.25(OH)2D concentration is negatively correlated with EDSS [29]. Although we found a
significant positive correlation between FGF23 and 25(OH)D and 24.25(OH)2D, we did not observe
a difference in FGF23 concentration between MS patients and healthy controls. A previous study
described comparable plasma concentrations of FGF23 in MS patients compared with healthy controls
as well [46], although two other studies found higher serum concentrations of FGF23 in MS patients
compared with healthy controls [47,48]. However, the latter study was performed in patients with
RRMS only and these differences were found during autumn (September–November) and winter
time, respectively. Therefore, seasonal effects or the use of different FGF23 assays measuring either
intact or c-term FGF23 could have resulted in these different findings. We found a higher phosphate
concentration in MS patients; nevertheless, no differences in PTH or eGFR compared with healthy
controls were found. Lastly, no correlations between FGF23 and 1.25(OH)2D or EDSS were found in
MS patients, which is in line with two other recent studies [46,48]. Summarized, these findings do not
support our hypothesis that FGF23 differs between MS patients and healthy controls.
Regarding the various vitamin D metabolites, we found similar concentrations of 25(OH)D and
1.25(OH)2D between MS patients and healthy controls, as some showed earlier [13,49,50], whereas
others found lower serum concentrations of 25(OH)D or 1.25(OH)2D in MS patients compared
with healthy controls, respectively [15,51–57]. These differences between studies might be caused
by differences in sample size, analysis of both male and female participants in different seasons
of the year, use of different assays to measure vitamin D and its metabolites, and possible VDBP
polymorphisms [24,27,28]. In addition, a number of studies did report a relationship between lower
serum concentrations of 1,25(OH)2D and an increased risk of MS [51,52]. Furthermore, our study
showed that MS patients were using supplementation of vitamin D more often compared with their
healthy controls. However, the maximal supplementation dosage was <200 IU of vitamin D per day, of
which no clinical relevant effect on the vitamin D metabolites is expected, as a higher supplementation
dosage is normally advised [18,19,29]. Moreover, controls had similar baseline concentrations of
25(OH)D.
As suggested in recent studies, bioavailable 25(OH)D might be preferred above total 25(OH)D as a
marker for vitamin D status, and might thus be a better marker of mineral metabolism [58–62]. The sum
of the albumin bound fraction of 25(OH)D plus the freely circulating 25(OH)D results in the bioavailable
25(OH)D, which can be calculated similarly for bio-available 1.25(OH)2D, respectively [58,60]. In the
circulation, VDBP and albumin bind over 99% of the 25(OH)D and 1.25(OH)2D [60], whereas the
binding affinity of vitamin D to albumin is much lower than the binding affinity to VDBP [63]. We found
lower serum concentrations of both free and bioavailable 25(OH)D and 1.25(OH)2D, respectively,
in MS patients compared with healthy controls, in contrast to comparable serum concentrations of
total 25(OH)D and 1.25(OH)2D between MS patients and healthy controls. In contrast to our findings,
Behrens et al. found no difference in free and bioavailable 25(OH)D between MS patients and controls,
yet 1.25(OH)2D was not measured in this study [64]. However, their study included patients with
CIS only (not yet diagnosed with MS), used non-parametrical statistical tests, and a de-seasonalized
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concentration of vitamin D was calculated afterwards. Our study measured summer concentrations of
vitamin D only and included all subtypes of MS, which may explain the different findings.
The second aim of our study was to assess BTMs in MS patients versus healthy controls and
to study the possible associations of BTMs with vitamin D metabolites, as vitamin D deficiency is
associated with increased bone turnover [32]. Our study did not show any differences between BTMs
and FGF23 in MS patients and their healthy controls. This finding is in line with earlier studies,
where similar serum concentrations of CTX, P1NP, or osteocalcin between MS patients and healthy
controls were found, and similar concentrations of cross-linked N terminal telopeptide type 1 collagen
(NTX) and bone ALP in newly diagnosed MS patients and healthy controls were found [18,32,65–67].
The current study shows that, despite differences in vitamin D metabolites, bone turnover in MS
patients seems to not be affected compared with healthy controls.
Lastly, possible gender-related differences of vitamin D metabolites and BTMs between MS patients
and healthy controls were studied; as known, MS affects more women than men and, in general, women
have higher VDBP concentrations compared with men [13,21,33–36]. Indeed, our study showed more
female MS patients, of which the largest part was post-menopausal. Further analyses based on pre- or
postmenopausal status was not possible because of small groups. Our study showed lower total and
free 25(OH)D, free 1.25(OH)2D, and 24.25(OH)2D only in female MS patients compared with healthy
female controls, but no difference in this respect between male MS patients compared with healthy men.
No differences between FGF23 in male and female MS patients were found. Interestingly, in our study,
VDBP was higher in MS patients compared with controls, but after further analysis, this difference was
found in male MS patients only. An earlier study found that serum VDBP concentrations were higher
in MS patients compared with healthy controls as well; however, this study included both female
and males [21]. In contrast, other studies showed no difference in VDBP concentrations between MS
patients and controls [64,68]. The differences between VDBP concentrations in the various studies
could be the result of variation between numbers of male and female patients and controls included in
these studies or by using either a polyclonal or monoclonal assay. It is known that VDBP can affect
inflammatory processes [22,23,25,26,61,69,70]. As we found higher VDBP in male MS patients, in the
presence of a similar EDSS score as in female MS patients, this suggests a possible modulating effect
of VDBP in male MS patients. It was shown before that higher concentrations of VDBP restrict the
uptake of free vitamin D metabolites and reduce anti-inflammatory responses of immune cells [71–74].
Moreover, VDBP can act as a chemotactic cofactor, which enhances chemotaxis of neutrophils and
macrophages by complement factor C5a [23]. These macrophages are known to contribute to laesion
formation and axonal damage [22,26]. Previous experimental studies showed that T-lymphocytes,
glia cells, and neurons express 1-α-hydroxlyase and VDR, which enables them to convert 25(OH)D
to 1.25(OH) [75–77]. Normally, in the central nervous system, focal inflammation is initiated by
auto-reactive T-helper cells type 1 (Th 1) and T-helper cells type 17 (Th 17) [78]. The activated vitamin D
is thought to induce anti-inflammatory effects in glia cells and neurons and affects vitamin D responsive
genes in T-helper cells [76,79–82], thereby inhibiting pro-inflammatory T-helper cell activity (Th1 and
Th 17) and promoting anti-inflammatory T-helper cell activity (Th2 and regulatory T-cells) [51,83].
However, whether vitamin D affects the T-cell response also depends on concentrations of VDBP [84,85].
On the basis of these studies, the elevated concentrations of VDBP found in our study strengthen the
pro-inflammatory role of VDBP in enhancing neuronal damage in MS.
Lastly, EDSS scores were comparable between male and female MS patients, which is consistent
with previous research [86,87]. In female MS patients, however, EDSS showed negative correlations
with free and bioavailable 1.25(OH)2D; free, bioavailable, and total 25(OH)D; and 24.25(OH)2D, which
is in line with earlier studies, which reported a negative correlation between EDSS and 1.25(OH)2D or
25(OH)D, respectively [46,88]. In contrast, in male MS patients, negative correlations between EDSS
and CTX, P1NP, and osteocalcin were observed, which differs from previous studies, which found no
correlations between EDSS and BTMs or only a positive correlation between EDSS and CTX [67,89].
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The strengths of this study are the relative large study population and the broad spectrum
of vitamin D metabolites, FGF23, and BTMs that was measured. Accurate and well-standardized
LC-MS/MS assays were used to measure vitamin D metabolites. In addition, to minimize seasonal
changes known to affect vitamin D metabolism [48], only blood samples drawn during summertime
were used. There are also some possible limitations of this study. First, owing to the cross-sectional
study design, the described differences between MS patients and controls in serum concentrations of
vitamin D metabolites are not necessarily causal. In addition, 97% of our study population is Caucasian,
which reduces the generalizability of the results, as it is known that vitamin D metabolism differs
between races [53]. Moreover, our study was not primarily designed to study gender difference, so the
differences we found in this respect should be studied further in other cohorts. No data on fractures
were available. Lastly, dual energy X-ray absorptiometry (DXA) scans were not available to compare
vitamin D metabolites and bone turnover markers with BMD.
5. Conclusions
In conclusion, this study provides additional knowledge of vitamin D-FGF 23 axis and bone
turnover markers in MS patients compared with healthy controls, as well as gender-related differences.
Similar serum concentrations of total 25(OH)D and 1.25(OH)2D in MS patients and healthy controls were
found. Furthermore, no differences in plasma FGF23 concentrations and other bone turnover markers
between MS patients and healthy controls were observed. The ratio total 25(OH)D/ 24.25(OH)2D did
not differ between MS patients and healthy controls. However, this study suggested a relevant gender
difference as serum concentrations of total 25(OH)D, 24.25(OH)2D, free 25(OH)D, and free 1.25(OH)2D
were lower in female MS patients compared with female healthy controls, while serum concentrations
of VDBP were higher in male MS patients compared with male controls. This study thus shows that
only a total 25(OH)D measurement probably does not reflect all changes in vitamin D metabolism
in MS patients. The exact role of VDBP and its polymorphisms in MS needs further studies. Finally,
given the high incidence of reduced bone mineral density and the still partially unknown mechanisms
that affect bone turnover in MS patients [66], further studies should be performed to evaluate the
relationship between change in the vitamin D-FGF23 axis, BMD, and fracture risk in both male and
female MS patients.
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Abstract: 25-hydroxyvitamin D (25(OH)D) is commonly measured to assess vitamin D status. Other
vitamin D metabolites such as 24,25-dihydroxyvitamin D (24,25(OH)2D) provide additional insights
into vitamin D status or metabolism. Earlier studies suggested that the vitamin D metabolite ratio
(VMR), calculated as 24,25(OH)2D/25(OH)D, could predict the 25(OH)D increase after vitamin
D supplementation. However, the evidence for this additional value is inconclusive. Therefore,
our aim was to assess whether the increase in 25(OH)D after supplementation was predicted by
the VMR better than baseline 25(OH)D. Plasma samples of 106 individuals (25(OH)D < 75 nmol/L)
with hypertension who completed the Styrian Vitamin D Hypertension Trial (NC.T.02136771) were
analyzed. Participants received vitamin D (2800 IU daily) or placebo for 8 weeks. The treatment
effect (ANCOVA) for 25(OH)D3, 24,25(OH)2D3 and the VMR was 32 nmol/L, 3.3 nmol/L and 0.015 (all
p < 0.001), respectively. Baseline 25(OH)D3 and 24,25(OH)2D3 predicted the change in 25(OH)D3
with comparable strength and magnitude. Correlation and regression analysis showed that the VMR
did not predict the change in 25(OH)D3. Therefore, our data do not support routine measurement of
24,25(OH)2D3 in order to individually optimize the dosage of vitamin D supplementation. Our data
also suggest that activity of 24-hydroxylase increases after vitamin D supplementation.
Keywords: vitamin D metabolites; vitamin D supplementation; vitamin D metabolite ratio;
randomized controlled trial; 24,25-dihydroxy vitamin D
Nutrients 2019, 11, 2539; doi:10.3390/nu11102539 www.mdpi.com/journal/nutrients101
Nutrients 2019, 11, 2539
1. Introduction
Vitamin D plays an essential role in calcium and phosphate homeostasis [1]. Vitamin D status
is most commonly assessed by determining the 25-hydroxyvitamin D (25(OH)D) concentration in
serum or plasma. However, several other vitamin D-related metabolites can be measured to provide a
better understanding of individual vitamin D status and metabolism. Among them, 24,25(OH)2D has
emerged as a metabolite with potentially high utility [2].
In the kidneys, 25(OH)D is converted by 1-alpha-hydroxylase (CYP27B1) into
1,25-dihydroxyvitamin D (1,25(OH)2D; also called active vitamin D or calcitriol) (Figure 1). 1,25(OH)2D
can bind to the vitamin D receptor (VDR) with high affinity. The subsequent signaling results in an
increase in serum calcium and phosphate concentrations, mainly mediated by an increased intestinal
uptake. In addition, 1,25(OH)2D has effects on the parathyroid gland, kidneys and bones, all resulting
in an increase in serum calcium and phosphate concentrations [1]. Furthermore, 1,25(OH)2D has major
effects on modulating the immune system, which might be relevant for the treatment of autoimmune
diseases, infections, cancer and cardiovascular diseases [3]. An excess of both 1,25(OH)2D and/or
25(OH)D lead to their catabolism by the enzyme 24-hydroxylase (CYP24A1). This results in the
formation of metabolites 1,24,25(OH)2D and 24,25(OH)2D, respectively [4]. It is still unclear whether
24,25(OH)2D has a physiological role in humans [5].
 
Figure 1. Metabolism of vitamin D. Vitamin D3 (cholecalciferol) is produced in the skin when exposed
to sunlight. The hepatic enzyme CYP2R1 then converts this into 25(OH)D3 (calcifediol). In the kidneys,
25(OH)D3 can be converted into the active form, 1,25(OH)2D3 (calcitriol), by CYP27B1 (1-α-hydroxylase).
In the kidneys, CYP24A1 (24-hydroxylase) can catabolize the 25(OH)D3 into 24,25(OH)2D3.
Using an LC-MS/MS method, 25(OH)D and 24,25(OH)2D can be measured simultaneously, which
allows for determination of the 24,25(OH)2D/25(OH)D ratio, also known as the vitamin D metabolite
ratio (VMR) [2]. The VMR is an indicator of CYP24A1 activity and thereby of vitamin D catabolism.
It is currently used for diagnosing idiopathic infantile hypercalcemia, a rare genetic disorder in which
a mutation in CYP24A1 results in severe hypercalcemia and suppressed parathyroid hormone (PTH)
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levels [5]. The VMR may also reflect vitamin D receptor (VDR) activity since CYP24A1 expression is
upregulated in response to 1,25(OH)2D [2].
In recent years, there has been an increasing interest in the use of the VMR when assessing vitamin
D status. For example, it has been postulated to better reflect vitamin D deficiency [6]. In addition,
it has been speculated that the ratio could provide useful information regarding bone health [7].
Interestingly, several studies show that the VMR can predict the change seen in 25(OH)D after vitamin
D supplementation, although results are inconclusive [6,8–11]. The CYP24A1 activity could be partially
responsible for the individual differences seen in the effect of vitamin D supplementation on serum
levels of 25(OH)D. Theoretically, if CYP24A1 activity is a major predictor of the effect of vitamin D
supplementation, the VMR could be used to personalize the treatment dosage. At present, 25(OH)D
concentrations at the start of supplementation, as well as BMI, age, ethnicity and genetic background
have been most commonly studied in regard to predicting the response to vitamin D supplementation,
and studies involving 1,25(OH)2D, 24,25(OH)2D, free and bioavailable 25(OH)D and the VMR are
scarce [12].
Therefore, we set out to determine whether baseline VMR measurements can predict changes in
vitamin D-related metabolite levels after vitamin D supplementation. To that extent, we measured
25(OH)D3, 1,25(OH)2D and 24,25(OH)2D3 in a randomized clinical trial of patients (25(OH)D < 75
nmol/L) receiving vitamin D supplementation [13]. We hypothesized that measurements of baseline
VMR would be advantageous over baseline 25(OH)D measurements for the prediction of the change
in 25(OH)D upon supplementation.
2. Materials and Methods
2.1. Study Cohort
The present post-hoc analysis was conducted in adults (>18 years old) with 25(OH)D levels <75
nmol/L and hypertension, who completed the randomized, placebo-controlled Styrian Vitamin D
Hypertension Trial (NC.T.02136771). The participants of this trial were treated with either placebo or
2800 IU daily of vitamin D3 (Oleovit D3, Fresenius Kabi, Graz, Austria) for 8 weeks. A total of 188
study participants completed the original study and sufficient material for analysis from both study
visits was available for 106 of these subjects. The details regarding the study, including inclusion and
exclusion criteria, can be found in the publication of the original study by Pilz et al. [13].
Study participants provided written informed consent. The study complied with the Declaration
of Helsinki and was approved by the ethics committee of the Medical University of Graz, Austria.
2.2. Measurements
For the original study by Pilz et al, the 25(OH)D levels were determined with the
ChemiLuminescence assay (IDS-iSYS 25-hydroxyvitamin D assay; Immunodiagnostic Systems Ltd.,
Boldon, UK) on an IDS-iSYS multidiscipline automated analyser [13]. The intra- and inter-assay CVs
were 6.2% and 11.6%, respectively.
In the present study, 25(OH)D3 and 24,25(OH)2D3 were measured in plasma samples by isotope
dilution liquid chromatography-tandem mass spectrometry at the Endocrine Laboratory of the
Amsterdam UMC, as described previously [14]. For 25(OH)D3, the lower limit of quantitation (LLOQ)
was 1.2 nmol/L and the inter- and intra-assay coefficients of variation (CV) were 6% and 3%, respectively.
For 24,25(OH)2D3, the LLOQ was 0.1 nmol/L and the inter- and intra-assay coefficients of variation
(CV) were 9% and 5%, respectively. 25(OH)D2 was also measured, but as the concentrations were all
very low (<7.9 nmol/L) and supplementation was given as vitamin D3, these data were not taken into
account in this paper. In order to calculate the VMR and as it is the golden standard, the LC/MS-MS
method was used for the current study. Using this method, 7 subjects had 25(OH)D levels >75 nmol/L
at baseline. Measurements of other study parameters have been described previously [13].
To calculate free and biologically available 25(OH)D3 we used the equations from Powe et al. [15].
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2.3. Statistical Analysis
Continuous data following a normal distribution are reported as means with standard deviations
(SD). Variables with a skewed distribution are shown as medians with interquartile ranges. Categorical
variables are shown as percentages of observations. Groups at baseline were compared using the
unpaired Students t-test, the Mann–Whitney U test or the chi-squared test. Skewed variables were log
transformed before being used in parametric analyses.
The changes from baseline for 25(OH)D3, 1,25(OH)2D and 24,25(OH)2D3 in the vitamin-D-treated
group were calculated as the difference between the value at the final study visit and the value
at baseline. They are depicted as Δ25(OH)D3, Δ1,25(OH)2D and Δ24,25(OH)2D3. The VMR was
calculated as the ratio between 24,25(OH)2D3 and 25(OH)D3.
Analysis of covariance (ANCOVA) was used to calculate the treatment effects with adjustment for
baseline values. Pearson correlation analysis was used to determine the strength of associations between
vitamin-D-related parameters and Δ25(OH)D3, Δ1,25(OH)2D, as well as Δ24,25(OH)2D3. Bonferroni
correction was applied to account for multiple testing. Univariate linear regression analysis was used
to determine the relation between Δ25(OH)D3 and baseline 25(OH)D3, 24,25(OH)2D3 and VMR.
Using the LC/MS-MS method, 7 subjects had 25(OH)D levels >75 nmol/L at baseline. Therefore,
we explored whether inclusion of these subjects had an effect on the analyses. In addition, we also
investigated whether the inclusion of only subjects with 25(OH)D levels <50 nmol/L at baseline would
affect the analyses.
If outliers were detected in the analyses by the software, defined as cases with standardized
residuals greater than 3 standard deviations for ANCOVA analyses or as cases with values higher or
lower than 1.5*IQR (interquartile range) for correlation analyses, they were removed and the analysis
repeated to determine their potential effect on the analysis. In the case of Pearson correlation analyses,
one extreme outlier was removed (25(OH)D > 4xSD at baseline) because of its significant effect on all
of the analyses. This is marked in the results section. If the outliers had no significant effect on the
analysis, the results including the outliers are reported. A p-value < 0.05 was considered statistically
significant. All analyses were performed using S.P.SS version 25 (S.P.SS, Chicago, IL, USA).
3. Results
The baseline characteristics of study participants can be found in Table 1. There were no differences
between the placebo and vitamin-D-treated groups in any of the parameters at baseline.
Table 1. Baseline characteristics.
Parameter All (n = 106) Placebo (n = 54) Vitamin D (n = 52) p-value
Age (years) 62.0 (51.3–68.7) 64.8 (50.8–70.2) 59.6 (52.4–66.6) 0.318
Body mass index (kg/m2) 30.0 ± 5.4 29.7 ± 5.9 30.3 ± 4.9 0.562
Gender (% female) 57 57 56 0.865
24,25(OH)2D3 (nmol/L) 3.5 ± 1.6 3.4 ± 1.5 3.6 ± 1.5 0.419
25(OH)D3 (nmol/L) 48 ± 18 46 ± 19 49 ± 18 0.401
VMR ((nmol/L)/(nmol/L)) 0.073 ± 0.017 0.072 ± 0.018 0.073 ± 0.017 0.768
PTH (pmol/L) 5.5 (4.1–6.7) 5.5 (4.0–6.7) 5.3 (4.1–6.7) 0.779
1,25(OH)2D (pmol/L) 126 ± 53 118 ± 52 133 ± 52 0.142
Serum phosphate (mmol/L) 0.94 ± 0.17 0.96 ± 0.17 0.92 ± 0.16 0.282
Serum calcium (mmol/L) 2.26 (2.21–2.33) 2.26 (2.21–2.34) 2.26 (2.20–2.33) 0.773
eGFR (mL/min/1.73m2) 72 ± 17 69 ± 16 74 ± 18 0.152
24h urinary calcium excretion (mmol/24h) 3.30 (1.90–5.00) 2.95 (1.83–4.78) 3.70 (2.10–6.30) 0.222
Calculated free 25(OH)D3 (pmol/L) 15 (9–21) 12 (8–21) 17 (11–20) 0.153
Vitamin D binding protein (μg/mL) 247.1 ± 109.5 254.8 ± 110.6 239.3 ± 109.0 0.772
Calculated bioavailable 25(OH)D3 (nmol/L) 5.9 (3.9–8.2) 5.2 (3.2–8.5) 6.6 (4.1–8.0) 0.149
1,25(OH)2D /25(OH)D3 ((nmol/L)/(nmol/L)) 0.0023 (0.0019–0.0036) 0.0027 (0.0018–0.0039) 0.0028 (0.0021–0.0035) 0.753
1,25(OH)2D /24,25(OH)2D3 ((nmol/L)/(nmol/L)) 0.036 (0.025–0.05) 0.036 (0.024–0.051) 0.035 (0.026–0.050) 0.893
The calculated treatment effects after vitamin D supplementation are depicted in Table 2.
We observed significant treatment effects for all included vitamin-D-related parameters. For 25(OH)D3,
the treatment effect was 32 nmol/L (95% CI: 26 to 39; p < 0.001), for 1,25(OH)2D 26 pmol/L (9 to 42;
p = 0.003), for 24,25(OH)2D3 3.3 nmol/L (2.7 to 3.9; p < 0.001), for the VMR 0.015 (nmol/L)/(nmol/L)
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(0.010–0.019; p < 0.001), for calculated free 25(OH)D3 12 pmol/L (6 to 18; p < 0.001), for calculated
bioavailable 25(OH)D3 4.66 nmol/L (2.63 to 6.68; p < 0.001), for the 1,25(OH)2D/25(OH)D3 ratio −0.0010
(nmol/L)/(nmol/L) (−0.0013 to −0.0006; p < 0.001) and for the 1,25(OH)2D/24,25(OH)2D3 ratio −0.020
(nmol/L)/(nmol/L) (−0.026 to −0.015; p < 0.001). In the subgroup of subjects with 25(OH)D3 levels
below 50 nmol/L, the treatment effects and p-values were comparable for all parameters.
Table 2. Analysis of covariance (ANCOVA) analysis for the effect of vitamin D or placebo treatment on
vitamin-D-related parameters.





Placebo, n=54 46 ± 19 45 ± 20 32 (26 to 39) <0.001Vitamin D, n=52 49 ± 18 79 ± 19
1,25(OH)2D (pmol/L)
Placebo, n=52 118 ± 52 114 ± 39 26 (9 to 42) 0.003Vitamin D, n=52 133 ± 52 150 ± 63
24,25(OH)2D3 (nmol/L)
Placebo, n=54 3.4 ± 1.5 3.3 ± 1.8 3.3 (2.7 to 3.9) <0.001Vitamin D, n=52 3.6 ± 1.6 6.8 ± 1.7
VMR
Placebo, n=54 0.072 ± 0.018 0.071 ± 0.017 0.015 (0.010 to 0.020) <0.001Vitamin D, n=52 0.073 ± 0.017 0.087 ± 0.018
Calculated free
25(OH)D3 (pmol/L)*
Placebo, n=53 12 (8–21) 12 (8–18) 12 (6 to 18) <0.001Vitamin D, n=51 17 (11–20) 21 (17–31)
Calculated bioavailable
25(OH)D3 (nmol/L) *
Placebo, n=53 5.22 (3.15–8.51) 4.99 (2.95–6.83) 4.66 (2.63 to 6.68) <0.001Vitamin D, n=51 6.60 (4.10–8.02) 8.69 (6.58–12.51)
1,25(OH)2D/ 25(OH)D3 *
Placebo, n=52 0.0027 (0.0018–0.0039) 0.0026 (0.0019–0.0036) −0.0010 (−0.0013 to
−0.0006) <0.001Vitamin D, n=52 0.0028 (0.0021–0.0035) 0.0019 (0.0014–0.0026)
1,25(OH)2D
/24,25(OH)2D3 *
Placebo, n=52 0.036 (0.024–0.051) 0.037 (0.026–0.052) −0.020 (−0.026 to
−-0.015) <0.001Vitamin D, n=52 0.035 (0.026–0.050) 0.022 (0.016–0.028)
* Log-transformed parameters.
The overall correlation between 25(OH)D3 and 24,25(OH)2D3 at baseline was r = 0.815, p < 0.001.
Results of the regression analyses of the Δ25(OH)D3 in the vitamin-D-supplemented group are
shown in Figure 2. The slope of the linear regression, p-values and R2 values are highly similar for
baseline 25(OH)D3 and 24,25(OH)2D3. The VMR, however, could not predict the increase in 25(OH)D3
concentration. The results of the correlation analyses in the vitamin-D-treated group are summarized
in Table 3. None of the vitamin-D-related parameters correlated significantly with Δ25(OH)D3 or
Δ1,25(OH)2D after Bonferroni correction. Also, in the subgroup of subjects with 25(OH)D levels
below 50 nmol/L, none of the parameters correlated significantly with Δ25(OH)D3 or Δ1,25(OH)2D
after Bonferroni correction. For Δ25(OH)D3, a trend was seen for baseline 25(OH)D3 and baseline
24,25(OH)2D3 (r = −0.388, p = 0.056 and r = −0.374, p = 0.056). This trend with Δ25(OH)D3 was also
observed for calculated free 25(OH)D3 and calculated bioavailable 25(OH)D3 (r = −0.373, p = 0.056
and r = −0.375, p = 0.056). Δ24,25(OH)2D3 was significantly associated with baseline 25(OH)D3,
24,25(OH)2D3, calculated free 25(OH)D3 and calculated bioavailable 25(OH)D3 (r = −0.562, p < 0.001;
r = −0.476, p = 0.003; r = −0.382, p = 0.048 and r = −0.393, p = 0.032, respectively), but not with other
parameters. In the subgroup of subjects with 25(OH)D3 levels below 50 nmol/L, none of the parameters
correlated significantly with Δ24,25(OH)2D3 after Bonferroni correction.
Correlation analyses after adjustment for gender, age, BMI, PTH, eGFR, serum phosphate and
serum calcium showed that none of the vitamin-D-related parameters were significantly associated
with Δ25(OH)D3 or Δ1,25(OH)2D after Bonferroni correction (Table A1). However, when corrected
for the above-mentioned parameters, only baseline 25(OH)D3 was still significantly associated
with Δ24,25(OH)2D3 (r = −0.657, p = 0.008). In the subgroup of subjects with 25(OH)D3 levels
below 50 nmol/L, none of the parameters correlated significantly with Δ25(OH)D3, Δ1,25(OH)2D or
Δ24,25(OH)2D3 after Bonferroni correction.
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Figure 2. Univariate linear regression analysis for the change in 25(OH)D3 concentration in the vitamin
D intervention group and (a) baseline 25(OH)D3, (b) baseline 24,25(OH)2D3 and (c) baseline VMR
(Vitamin D Metabolite Ratio).
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Table 3. Pearson correlations with unadjusted p-values and Bonferroni adjusted p-values of
baseline vitamin-D-related parameters with the changes from baseline of 25(OH)D3, 1,25(OH)2D
and 24,25(OH)2D3 after vitamin D supplementation.
Baseline Parameters Δ25(OH)D3 Δ1,25(OH)2D Δ24,25(OH)2D3
25(OH)D3
r −0.388 −0.142 −0.562
p-value 0.005 0.322 <0.001
Adjusted p-value 0.056 1.000 <0.001
1,25(OH)2D
r −0.287 −0.260 −0.272
p-value 0.041 0.065 0.053
Adjusted p-value 0.328 0.520 0.424
24,25(OH)2D3
r −0.374 −0.122 −0.476
p-value 0.007 0.392 <0.001
Adjusted p-value 0.056 1.000 0.003
VMR
r −0.109 −0.027 −0.015
p-value 0.448 0.850 0.916
Adjusted p-value 1.000 1.000 1.000
Calculated free
25(OH)D3 *
r −0.373 −0.281 −0.382
p-value 0.007 0.046 0.006
Adjusted p-value 0.056 0.368 0.048
Calculated bioavailable
25(OH)D3 *
r −0.375 −0.280 −0.393
p-value 0.007 0.047 0.004
Adjusted p-value 0.056 0.376 0.032
1,25(OH)2D/25(OH)D3 *
r −0.004 −0.058 0.176
p-value 0.980 0.687 0.216
Adjusted p-value 1.000 1.000 1.000
1,25(OH)2D
/24,25(OH)2D3 *
r 0.053 −0.028 0.181
p-value 0.711 0.843 0.204
Adjusted p-value 1.000 1.000 1.000
* Log-transformed parameters.
4. Discussion
The goal of our study was to assess whether vitamin D metabolites can predict the increase of
25(OH)D after vitamin D supplementation. As elaborated above, CYP24A1 activity (24-hydroxylase)
is reflected by the ratio of 24,25(OH)2D over 25(OH)D, i.e. the VMR. In addition, the ratio between
1,25(OH)2D and 24,25(OH)2D3 was recently proposed as part of a three-dimensional model for assessing
vitamin D metabolic pathways [16]. It was previously suggested that vitamin D metabolites and
their ratios could provide additional information for predicting vitamin D treatment response [8,9].
The findings in this vitamin D RC.T. in patients with 25(OH)D levels <75 nmol/L and hypertension do
not support this hypothesis.
In our study, the VMR did not predict Δ25(OH)D3 in the treatment arm of the RC.T.. In a regression
model, baseline 24,25(OH)2D3 and baseline 25(OH)D3 did, with comparable strength and magnitude,
predict the increase in 25(OH)D3 upon treatment. When adjusting for multiple testing in correlation
analyses, no correlations of any of the included parameters with Δ25(OH)D3 retained significance. Yet,
we did observe trends for Δ25(OH)D3 with baseline 25(OH)D3, 24,25(OH)2D3, free 25(OH)D3 and
bioavailable 25(OH)D3. Notwithstanding their borderline significance, the strength of the correlations
is highly similar between these parameters and they do not seem to be superior to baseline 25(OH)D.
According to these data, we can infer that CYP24A1 activity, measured by the VMR, does not predict
the individual differences in the increase in 25(OH)D after vitamin D supplementation.
Concerning the VMR, the results of this study are in accordance with several other published
reports. Saleh et al. performed an RC.T. of 4 weeks with 107 participants receiving a single 100,000 IU
dose of vitamin D or placebo [11]. The VMR could not predict the increase of 25(OH)D after 4 weeks,
whereas 25(OH)D did predict this increase with a similar R2-value to our data. However, their data
indicated that 24,25(OH)2D3 could not predict the Δ25(OH)D3, whereas in our study it did. Aloia et al.
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reported on the predictive properties of the VMR in four different small samples (between 14 and
16 participants per group) of placebo or 800, 2000 or 4000 IU vitamin D daily for 10 weeks [6]. They
did not show an advantage of the VMR as a predictor, compared to baseline 25(OH)D, 24,25(OH)2D3
or free 25(OH)D. Binkley et al. investigated the effect of 1800IU of vitamin D in 62 postmenopausal
women after 4 months and measured vitamin D metabolites [10]. They observed that neither VMR,
25(OH)D, 24,25(OH)2D3 nor free 25(OH)D was related to the observed increase in 25(OH)D.
On the contrary, other published studies did suggest a predictive role for the VMR. The study
by Wagner et al. included young adults with a mean age of around 27 years that received 28,000 IU
(equivalent to 4000 IU per day) of vitamin D once per week for 8 weeks in the form of a supplement or
fortified cheese. Wagner et al. showed that the VMR predicted the increase in vitamin-D-receiving
subjects (R2 = −0.38, p = 0.004, n = 60) [8]. Also, Cashman et al. reported a significant correlation
between the VMR and the change after vitamin D supplementation (R2 = 0.15, p < 0.01) in a study
including subjects above 50 years of age that were treated for 15 weeks by 20 μg vitamin D (800 IU) per
day [9]. Of note, both studies did not report the R2-value of baseline 25(OH)D with its increase after
supplementation. Therefore, it is not possible to conclude whether the VMR was superior to 25(OH)D
in this aspect.
Changes in other vitamin-D-related parameters after vitamin D treatment were also studied.
To that end, we assessed if Δ1,25(OH)2D and Δ24,25(OH)2D3 could be predicted by baseline parameters
included in the study. We found no correlation between any tested baseline parameter and Δ1,25(OH)2D.
1,25(OH)2D levels are mainly regulated by calcium levels, which could explain this observation [12].
On the other hand, baseline 25(OH)D3, 24,25(OH)2D3, calculated free 25(OH)D3 and calculated
bioavailable 25(OH)D3 all showed a significant correlation with Δ24,25(OH)2D3. The clinical relevance
of this observation is, in our opinion, unclear and should be further studied.
In our study, we observed an increase in the VMR upon vitamin D treatment. This suggests an
increase in CYP24A1 activity and catabolism of 25(OH)D upon supplementation. A concurrent decrease
in the 1,25(OH)2D/25(OH)D3 ratio implies a reduced conversion of 25(OH)D to 1,25(OH)2D. Indeed,
this suggests the physiological shift from anabolic to catabolic pathways when an excess of vitamin D
exists. This is also supported by the significant decrease in the 1,25(OH)2D/24,25(OH)2D3 ratio. In the
present study, and all aforementioned studies, the correlation coefficients between baseline 25(OH)D
and Δ25(OH)D3 after supplementation were negative, which implies that the change in 25(OH)D3
after vitamin D treatment is smaller in individuals with higher baseline 25(OH)D3 levels [8–10].
We acknowledge that this study has several limitations. First, the results are derived from
post-hoc analyses. Second, the study population consisted of hypertensive subjects with 25(OH)D
levels <75 nmol/L; therefore, the findings might not be readily extrapolated to the general population.
Furthermore, for the vitamin D level inclusion criterion, the 25(OH)D concentrations were measured at
study baseline using a chemiluminescence assay, while mass-spectrometry-based methods are currently
the gold standard [2]. However, for the current study, 25(OH)D and 24,25(OH)2D were re-measured
using a dedicated LC-MS/MS method. In addition, the intervention period of 8 weeks was relatively
short and only a small number of subjects were severely vitamin D deficient. Vitamin D deficiency was
defined as a 25(OH)D of <75 nmol/L in the original study by Pilz et al. [13]. There is still an ongoing
debate as to whether the cut-off levels should be set at <50 nmol/L or <75 nmol/L [17,18]. In addition,
vitamin D sufficiency was defined by measurements of baseline 25(OH)D3, which is currently the
critical measurement for defining vitamin D status [19]. Some studies suggest that free 25(OH)D3
could be a better marker for assessing vitamin D status [20]. In our study, calculated free 25(OH)D3 did
not predict Δ25(OH)D3 after supplementation better than baseline 25(OH)D3. The RC.T. design and
the successful vitamin D intervention are strengths of this study. Also, a high number of parameters
were measured with gold-standard methods. In contrast to the majority of exploratory studies on the
VMR, p-values of the correlations were adjusted for multiple testing.
In summary, we show that 25(OH)D3, 24,25(OH)2D3 and the VMR increase after vitamin D
treatment. However, 24,25(OH)2D3 and the VMR could not predict 25(OH)D3 levels after vitamin
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D treatment in this cohort better than baseline 25(OH)D3. As this has been corroborated by other
studies, it implicates the routine measurement of 24,25(OH)2D3 will probably be of no added value
when personalizing the treatment dosage of vitamin D.
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Appendix A
Table A1. Pearson correlations of baseline vitamin-D-related parameters adjusted for gender, age,
BMI, PTH, eGFR, serum phosphate and serum calcium, with the changes from baseline of 25(OH)D,
1,25(OH)2D and 24,25(OH)2D after vitamin D supplementation. p-values without and with Bonferroni
adjustment are shown.
Baseline Parameters Δ25(OH)D3 Δ1,25(OH)2D Δ24,25(OH)2D3
25(OH)D3
r −0.508 −0.277 −0.657
p-value 0.013 0.201 0.001
Adjusted p-value 0.104 1.000 0.008
1,25(OH)2D
r −0.350 −0.171 −0.430
p-value 0.102 0.435 0.040
Adjusted p-value 0.816 1.000 0.320
24,25(OH)2D3
r −0.490 −0.129 −0.597
p-value 0.018 0.559 0.003
Adjusted p-value 0.440 1.000 0.096
VMR
r −0.064 0.137 −0.516
p-value 0.773 0.534 0.012
Adjusted p-value 1.000 1.000 0.096
Calculated free
25(OH)D3 *
r −0.451 −0.363 −0.399
p-value 0.031 0.089 0.059
Adjusted p-value 0.248 0.712 0.472
Calculated bioavailable
25(OH)D3 *
r −0.451 −0.363 −0.404
p-value 0.031 0.089 0.056
Adjusted p-value 0.248 0.712 0.448
1,25(OH)2D/25(OH)D3 *
r 0.122 0.272 0.218
p-value 0.578 0.209 0.318
Adjusted p-value 1.000 1.000 1.000
1,25(OH)2D
/24,25(OH)2D3 *
r 0.126 0.136 0.211
p-value 0.565 0.536 0.333
Adjusted p-value 1.000 1.000 1.000
* Log-transformed parameters.
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Abstract: Hypovitaminosis D (25-hydroxyvitamin D (25(OH)D) <75 nmol/L) is associated
with neuropathic pain and varicella-zoster virus (VZV) immunity. A two-part retrospective
hospital-based study was conducted. Part I (a case-control study): To investigate the prevalence
and risk of hypovitaminosis D in postherpetic neuralgia (PHN) patients compared to those in
gender/index-month/age-auto matched controls who underwent health examinations. Patients aged
≥50 years were automatically selected by ICD-9 codes for shingle/PHN. Charts were reviewed. Part
II (a cross-sectional study): To determine associations between 25(OH)D, VZV IgG/M, pain and
items in the DN4 questionnaire at the first pain clinic visit of patients. Independent predictors of
PHN were presented as adjusted odds ratios(AOR) and 95% confidence intervals (CI). Prevalence
(73.9%) of hypovitaminosis D in 88 patients was high. In conditional logistic regressions, independent
predictors for PHN were hypovitaminosis D (AOR3.12, 95% CI1.73–5.61), malignancy (AOR3.21, 95%
CI 1.38–7.48) and Helicobacter pylori-related peptic ulcer disease (AOR3.47, 95% CI 1.71–7.03). 25(OH)D
was inversely correlated to spontaneous/brush-evoked pain. Spontaneous pain was positively
correlated to VZV IgM. Based on the receiver operator characteristic curve, cutoffs for 25(OH)D to
predict spontaneous and brush-evoked pain were 67.0 and 169.0 nmol/L, respectively. A prospective,
longitudinal study is needed to elucidate the findings.
Keywords: hypovitaminosis D; 25-hydroxyvitamin D; postherpetic neuralgia; spontaneous pain;
brush-evoked pain; varicella-zoster virus immunoglobulin; DN4questionnaire
1. Introduction
Vitamin D is essential for musculoskeletal health in humans. The major circulating form of vitamin
D is serum 25-hydroxyvitamin D (25(OH)D)—the main storage form. Currently, serum total 25(OH)D
is considered to be the best marker of vitamin D status among the possible markers [1]. However, the
definition of hypovitaminosis D is a central controversy in vitamin D research [1]. In the present study,
sufficiency of vitamin D is defined as 25(OH)D ≥ 75 nmol/L (30 ng/mL) as defined by the Endocrine
Society Clinical Practice Guideline [2]. Low vitamin D (hypovitaminosis D) includes insufficiency
(50–75 nmol/L) and deficiency (< 50 nmol/L, 20 ng/mL) [2,3]. This cut-off is based on studies showing an
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increased intestinal calcium absorption and a decreased level of circulating parathyroid hormone when
25(OH)D levels were >75 nmol/L [2]. Notably, extra-skeletal functions of vitamin D are increasingly
recognized. Vitamin D possesses anti-viral effects through vitamin D-induced peptides [4,5]. Vitamin
D can inhibit neuroinflammation by downregulation of proinflammatory cytokines and upregulation
of anti-inflammatory cytokines [6,7]. Vitamin D has concentration-dependent anti-inflammatory effects
on glia and astrocytes through inhibiting the production of nitric oxide (NO) [8,9]. Importantly, NO
increases phosphorylated N-methyl-D-aspartate (NMDA) receptors in spinal dorsal horn neurons
which have been shown to be essential for the initiation of central sensitization and the development
of mechanical allodynia [10]. In animal neuropathic pain models, vitamin D deficiency increases
the production of reactive oxygen species (ROS) [11] which result in cold pain via the activation of
transient receptor potential ankyrin 1 (TRPA1) [12,13] and contribute to mechanical hyperalgesia via the
enhancement of NMDA receptor activation [14,15]. Vitamin D deficiency induces a marked dysbiosis
and alters nociception possibly via molecular mechanisms involving the endocannabinoid and related
mediator signaling system [16]. Vitamin D supplementation reduces mechanical hyperalgesia and cold
allodynia [17]. Hypovitaminosis D has been demonstrated to increase neuropathic pain in patients with
diabetic and rheumatoid arthritis [18–20]. Overall, vitamin D deficiency is associated with increased
neuropathic pain.
Herpes zoster (shingles) is a common infectious disease resulting from reactivation of latent
varicella-zoster virus (VZV). Patients with shingles suffer from herpetic pain which generally subsides
within four weeks. Approximately 8%–24% of all zoster patients develop chronic herpetic pain known
as postherpetic neuralgia (PHN) which lasts longer than 90 days after rash onset [21–23]. Although
shingles vaccines are effective for preventing shingles and PHN, one-third of vaccinated persons
aged ≥60 still develop PHN [24]. Besides, some PHN patients show inadequate responses to current
therapies [25]. Thus far, PHN treatment remains challenging. Chronic pain in older patients may
impair their ability to perform activities of daily living [26], leading to the development of vitamin D
deficiency. Serum 25(OH)D status is positively associated with zoster immunity in dialysis patients [27].
We, therefore, conducted a two-part retrospective hospital-based study. In Part (a case-control study),
we investigated the prevalence and the risk of hypovitaminosis D in PHN patients compared to those
in controls receiving health examinations.
PHN is a peripheral neuropathy PHN patients experience various spontaneous and/or
brush-evoked pain (allodynia) [28]. The Douleur Neuropathique 4 (DN4) questionnaire, which
consists of seven symptoms (burning, painful cold, electric shocks, tingling, pins and needles,
numbness, itching) and three items of physical examination (hypoesthesia to touch and pinprick as
well as brush-evoked pain), is a popular tool for assessing the probability of neuropathic pain [29].
Following the protocol of our previous studies and that of others [28,30–33], zoster patients in the
current study routinely received nutrient survey (e.g., serum 25(OH)D) and completed questionnaires
including the DN4 questionnaire and those on pain intensity during their first visits to our pain clinic
(Supplementary S1). Subsequently, the patients recruited for case-control study (i.e., Part I) were
enrolled in Part II study (i.e., a cross-sectional study) that assessed the associations among vitamin D
status, zoster immunity (VZV immunoglobulins), spontaneous/brush-evoked pain, and 10 items in the
DN4 questionnaire [27,30,34,35] in PHN patients.
2. Materials and Methods
The study was conducted in accordance with the Declaration of Helsinki. This retrospective study
was approved by the Institutional Review Board of the Chi Mei Medical Center in Tainan, Taiwan
(IRB-10606-002). Patients’ data in this study were drawn from the electronic medical database of Chi
Mei Medical Center which is a 1200-bed tertiary referral center in Tainan, Taiwan.
During their first pain clinic visit, zoster patients routinely completed the DN4 questionnaires
(seven questions and three clinical examinations) and received evaluation of their average daily
spontaneous pain severity and the worst spontaneous pain on an 11-point numeric rating pain scale
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(NRS, 0: no pain; 10: worst pain imaginable) [28] (Supplementary S1). Brush-evoked pain (mechanical
allodynia) was assessed by using a manual handheld cotton swab swept three times approximately
3–5 cm in length over the skin, with a speed of 1 cm/s. A positive test of brush-evoked pain was defined
as pain sensation elicited by at least two out of three strokes. The intensity of brush-evoked pain was
graded on the 11-point NRS (0–10). Fasting blood samples were collected in the morning after the
patients’ pain clinic visits for 25(OH)D and VZV IgG/IgM antibody tests. In our pain clinic, a serum
25(OH)D survey has been performed routinely in zoster patients since 2011 [28,30,31,36]. Additionally,
serological tests for VZV IgG/IgM have been a routine for the differential diagnosis of shingles from
other skin diseases in zoster patients since mid-2012 [27,30,31,34,35]. Patients’ information and data
were collected and recorded in the electronic medical database.
2.1. Autosearch and Chart Review Criteria for Postherpetic Neuralgia
In this retrospective study, zoster/PHN patients aged ≥ 50 [37] receiving serum 25(OH)D and
VZV IgG/IgM survey were selected by auto matched search from the computerized database (June
1, 2012–Dec. 31, 2016). Inclusion criteria for PHN were (1) International Classification of Diseases,
Ninth Revision, Clinical Modification codes (ICD-9) 053 herpes zoster/053.X combined with new
prescriptions of an analgesic, an anticonvulsant or an antidepressant for at least 90 days; (2) ICD-9
053.1X (herpes zoster with nervous system complications) [37,38]; and (3) patients with pain clinic visits
≥ 2 times during the study period [37,38]. Exclusion criteria were as follows: (1) patients diagnosed
with herpes zoster ICD-9 053 in the preceding years; (2) patients who had diagnostic codes of human
immunodeficiency virus infection (ICD-9 042, 043, 044) and organ transplants (ICD-9 3751, 1160, 1164,
1169, 5059, 5280, 5283, 5569, 3350–3352), which are potential confounders of shingles/PHN [21,38] and
hypovitaminosis D [39,40]; and (3) patients whose medical records showed no evidence of serum
25(OH)D and VZV IgG/IgM survey during the study period.
Physicians (JYC and YTL) signed a patient confidentiality agreement before chart reviews. Each
chart was reviewed for the inclusion and exclusion criteria. We included PHN patients who received
a prescribed analgesic, anticonvulsant, or antidepressant or treatments by physicians for persisting
pain ≥ 3 months and shorter than two years after zoster rash onset [28] as well as having a worst pain
score ≥ 4 on the 11-point NRS [25]. In addition, no other cause for pain was considered more likely
than PHN.
Age, gender and index-month are common confounders of vitamin D status [41]. Conditional
logistic regression models were used by matching gender, index month, and age (i.e., ≤ 2 years between
the two groups). The auto matched controls were individuals who received a health examination survey
during the same period when the study patients visited the pain clinic. The ratio of controls to patients
was 3 to 1 (Figure 1). The health survey package of our hospital included routine gastroduodenoscopy
and 25(OH)D quantification [42].
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Figure 1. Flowchart of participant recruitment and case–control selection in Part I study.
The present study was a two-part retrospective hospital-based study including Part I (a case-control
study) and Part II (a cross-sectional study). Using data from the electronic medical database of our
hospital, we included automatically selected PHN patients and the gender/index-month/age-auto
matched controls (non-PHN cases) in the case-control study. In the cross-sectional analysis, we included
participants who were PHN patients of the case-control study.
2.2. Comorbidities
Hypertension/diabetes mellitus diagnosis was defined as patients who had ICD-9 codes for
hypertension (ICD-9 401-405)/diabetes mellitus (ICD-9 250) and received a prescribed medication
for hypertension/diabetes mellitus. Malignancy, autoimmune diseases, and chronic liver disease
diagnosis were defined as patients who had ICD-9 code (malignancy 140-239; autoimmune diseases
710, 714, 725, 555, 556, 696, 340, 245.2; chronic liver disease 571) and received treatments by physicians
for the diseases. Patients with chronic kidney disease were those who had ICD-9 585 and received
dialysis regularly. Helicobacter pylori-related peptic ulcer disease was identified by ICD-9 530–534
and confirmed by positive findings on either hospital gastroduodenoscopy records or a self-reported
gastroduodenoscopy history with prescriptions for the disease within one year prior to shingles
outbreak [38].
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2.3. Specimen Collection, Handling, and Biochemical Determination
2.3.1. Determination of 25(OH)D
Automated immunoassays are currently popular methods for measuring the circulating level
of 25(OH)D. At our institute, a fasting blood sample was drawn in the morning from the testing
subjects. Once the serum was separated, it was kept frozen at a temperature of −70°C until analysis.
Serum 25(OH)D concentrations were measured by ARCHITECTi2000 (Abbott, Chicago, IL, USA)
(Chemiluminescent Microparticle Immuno Assay) [43] every weekday.
2.3.2. Zoster Immunity—VZV IgG/IgM Detected by ELISA
Serum samples of PHN patients were routinely obtained for the VZV IgG and IgM antibody
tests using enzyme-linked immunosorbent assay (ELISA) kits manufactured by Euroimmun (Lübeck,
Germany) [44] and TECAN washer. The absorbance [44] was measured using ELISA reader Multiskan
FC Thermo Scientific (Waltham, MA, USA). The result for VZV IgG was determined to be positive
with the cut-off ≥ 110 mIU/mL. A positive result of VZV IgG was considered good immunity against
VZV [44]. Positivity for VZV IgM was defined as an antibody index ≥ 1.0 [45]. A positive IgM result
indicates recent or current VZV infection [27,34]. All assays were performed at the Chi Mei Medical
Center Laboratory according to the instructions of the manufacturer.
2.4. Sample Size
In this study, the estimated rate of hypovitaminosis D in patients versus the controls was 70%
versus 50% [3]. Therefore, a minimum sample size of patients (84 in each group) was determined
to ensure a high power with a 5% significance level for an analysis of the difference between PHN
patients and the controls.
2.5. Statistical Analysis
Data processing and statistical analysis were performed using SAS statistical software (Version
9.4; SAS Institute, Cary, NC, USA). The significance of difference among continuous data between the
two groups was determined by student’s t-test. Chi-square test or Fisher exact test was used to test the
differences in categorical variables between the two groups. The risk of PHN was presented as an
odds ratio (OR) and 95% confidence intervals (CI). Patients were divided into two groups according
to age: patients aged 60years or older (n = 64) and patients aged 50–59 years (n = 24). Univariate
logistic regression analysis was used to examine the associations between all selected predictors and
PHN development in this study. A univariate association (p < 0.10) with PHN was included in the
conditional multiple logistic regression model. Independent predictors for PHN were identified in the
conditional multiple logistic regression model by gender, index month, and age (i.e., ≤ 2 years between
two groups) match. Furthermore, patients were divided into two groups according to 25(OH)D levels:
hypovitaminosis D (25(OH)D < 75 nmol/L) and sufficiency of vitamin D (25(OH)D ≥ 75 nmol/L). All of
the demographic and clinical variables were compared between patients with sufficient-vitamin D and
those with hypovitaminosis D.
The normality of variables was examined with the Kolmogorov–Smirnov test. Pearson’s or
Spearman’s correlation was performed to test the significance of the association between clinical
variables (e.g., 25(OH)D, VZV Ig) and severity of pain where appropriate. The correlation between
clinical variables and severity of pain was considered to be clinically significant if the rho>0.3 [28].
According to pain severity, PHN patients were dichotomized into two pain groups: patients with mild
pain (NRS ≤ 5) and those with moderate to severe pain (NRS 6–10). For identifying the optimal cutoff
point for these clinical variables (e.g., 25(OH)D, VZV Ig) in predicting moderate to severe pain (i.e.,
NRS 6–10), a receiver operating characteristic (ROC) curve was plotted. The optimal cutoff value was
determined with the Youden’s index via maximizing the point on the ROC curve furthest from the
line of equality. The area under the ROC curve (AUC) was used to measure the diagnostic ability of a
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variable (e.g., 25(OH)D, VZV Ig). Furthermore, the proportions of items in the DN4 questionnaire
between patients with 25(OH)D /VZV IgM ≤ the cutoff point and those with levels > the cutoff point
were compared to identify the associations between 25(OH)D /VZV IgM and symptoms/physical
findings. A p value of <0.05 was considered statistically significant.
3. Results
A total of 119 PHN medical records were selected for review. Three patients were considered
to experience other causes of chronic pain, while 19 patients were determined to suffer from
zoster-associated pain which was defined as herpetic pain beyond 30 days but less than 90 days. Three
patients were excluded due to incomplete records. In total, 25 patients were excluded after medical
record review. Additionally, six elderly patients were excluded because of no age-matched controls
(Figure 1).
3.1. Part I Study
Conditional Logistic Analysis for the Predictors of Postherpetic Neuralgia
The demographic characteristics of 88 patients and 264 controls are shown in Table 1. Comparisons
between patients and the controls showed that PHN patients had significantly lower serum 25(OH)D
(68.96 nmol/L, SD 18.72 nmol/L) and higher prevalence of hypovitaminosis D (73.9%) than those
(75.13 nmol/L, SD17.47nmol/L; 47.0%) in the controls (p = 0.005; <0.001). Furthermore, PHN patients
had higher prevalence of diabetes mellitus (29.5% vs. 15.9%, p = 0.005), malignancy (17.0% vs. 6.8%,
p = 0.007) and Helicobacter pylori-related peptic ulcer disease (26.1% vs. 9.5%, p < 0.001) compared to
that in the controls. There were no significant differences inbody mass index and the prevalence of
hypertension, autoimmune diseases, chronic liver and kidney disease between the two groups.











Age, years, mean (SD) 65.3 (9.4) 65.3 (9.0) 0.997
Age groups
≥60 years 64 (72.7%) 192 (72.7%)
50–59 years 24 (27.3%) 72 (27.3%)
Gender
Male, n (%) 47 (53.4%) 141 (53.4%)
Body mass index, mean (SD) 23.68 (3.26) 23.99 (3.07) 0.426
Body mass index (kg/m2) 1.29 (0.54-3.06) 0.563 1.01 (0.36-2.79) 0.990
<18.5 or ≥30 8 (9.1%) 19 (7.2%)
18.5~30 80 (90.0%) 245 (92.8%)
25(OH)D (nmol/L), mean (SD) 68.96(18.72) 75.13 (17.47) 0.005
Vitamin D status 3.31 (1.92-5.72) <0.001 3.12 (1.73-5.61) <0.001 *
Sufficiency, n (%) 23 (26.1%) 140 (51.9%)
Hypovitaminosis D, n (%) 65 (73.9%) 124 (47.0%)
Comorbidities
Hypertension 33 (37.5%) 84 (31.8%) 1.35 (0.78-2.37) 0.279 1.14 (0.59-2.17) 0.702
Diabetes mellitus 26 (29.5%) 42 (15.9%) 2.22 (1.26-3.90) 0.005 1.97 (0.96-4.06) 0.065
Malignancy 15 (17.0%) 18 (6.8%) 2.71 (1.31-5.59) 0.007 3.21 (1.38-7.48) 0.007 *
Chronic liver disease 10 (11.4%) 28 (10.6%) 1.08 (0.51-2.28) 0.846 1.24 (0.52-2.93) 0.630
Chronic kidney disease 2 (2.3%) 6 (2.3%) 1.00 (0.20-4.95) 1.000 0.75 (0.13-4.48) 0.757
Autoimmune diseases 8 (9.1%) 10 (3.8%) 2.40 (0.95-6.08) 0.065 2.85 (0.98-8.27) 0.055
H. pylori-related PUD 23 (26.1%) 25 (9.5%) 3.15 (1.70-5.84) <0.001 3.47 (1.71-7.03) 0.001 *
Antiviral therapy 38 (43.2%) -
Average spontaneous pain, mean (SD) (NRS 0–10) 5.84 (1.46) -
Brush-evoked pain, mean (SD) (NRS 0–10) 3.14 (3.10) -
n: number; SD: standard deviation; PHN: postherpetic neuralgia; 25(OH)D: serum 25-hydroxyvitamin D; PUD:
peptic ulcer disease; NRS: numeric rating pain scale. T-test was used for continuous data. Chi Square or Fisher exact
test was used for categorical data. Adjusted OR was determined using the conditional multiple logistic regression
model by gender, age and index season match. * A p-value <0.05 was considered significant. Chronic liver disease:
Patients had chronic hepatitis B and/or C or liver cirrhosis. Chronic kidney disease: Patients had hemodialysis.
Helicobacter pylori-related PUD was defined as either positive findings on hospital gastroduodenoscopy records or a
self-reported gastroduodenoscopy history with prescriptions for peptic ulcers/gastritis within one year prior to a
shingles outbreak. -: The controls did not receive any antiviral therapy for VZV or pain measurement.
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Although four risk factors for PHN were identified in univariate conditional logistic analysis, only
three risk factors remained after conditional multivariate logistic analysis, including hypovitaminosis
D (adjusted OR: 3.12, 95% confidence interval (CI) 1.73–5.61, p < 0.001), malignancy (adjusted OR: 3.21,
95% CI 1.38–7.48, p = 0.007) and Helicobacter pylori-related peptic ulcer disease (adjusted OR: 3.47, 95%
CI 1.71–7.03, p = 0.001).
3.2. Part II Study
3.2.1. Comparison of Demographic and Clinical Characteristics Between Vitamin D-Deficient Patients
and Vitamin D-Sufficient Patients
Patients with hypovitaminosis D had higher VZV IgM titers (0.63, SD 0.45), a lower vitamin D
supplementation rate (1.5%) and greater spontaneous/brush-evoked pain intensity (6.1, SD 2.1; 4.3,
SD 6.8), compared to those in patients with sufficient vitamin D (0.40, SD 0.25; 17.4%; 5.3, SD 1.8; 2.5,
SD 8.3) (p = 0.016; 0.005; 0.021; 0.007) (Table 2).




Sufficiency of vitamin D
(n = 23) p
Age group 0.075
≥60 years, n (%) 44 (67.7) 20 (87.0)
Gender 0.071
Male, n (%) 31 (47.7) 16 (69.6)
Body mass index (kg/m2) 0.357
<18.5 or ≥30, n (%) 7 (10.8) 1 (4.3)
VZV-IgG (mIU/mL), mean (SD) 4239 (1382) 4281 (1066) 0.955
VZV-IgG, positive, n (%) 65 (100) 23 (100) 1.0
VZV-IgM, mean (SD) 0.63 (0.45) 0.40 (0.25) 0.016 *
VZV-IgM, positive, n (%) 8 (12.3) 1 (4.3) 0.279
Comorbidities, n (%)
Hypertension 25 (38.5) 8 (34.8) 0.754
Diabetes mellitus 21 (32.3) 5 (21.7) 0.340
Malignancy 12 (18.5) 3 (13.0) 0.553
Chronic liver disease 8 (12.3) 2 (8.7) 0.639
Chronic kidney disease 2 (3.1) 0 (0.0) 0.416
Autoimmune diseases 6 (9.2) 2 (8.7) 0.939
Helicobacter pylori-related PUD 19 (29.2) 4 (17.4) 0.267
Vitamin D supplements, n (%) 1 (1.5) 4 (17.4) 0.005 *
Average spontaneous pain, mean (SD) (NRS 0–10) 6.1 (2.1) 5.3 (1.8) 0.021 *
Brush-evoked pain, mean (SD) (NRS 0–10) 4.3 (6.8) 2.5 (8.3) 0.007 *
n: number; VZV: varicella-zoster virus; PUD: peptic ulcer disease; NRS: numeric rating pain scale. VZV-IgG,
positive: >110 mIU/mL; VZV-IgM, positive: ≥1.0. T-test was used for continuous data. Chi Square or Fisher exact
test was used for categorical data.  All of the five patients irregularly received a self-prescribed supplement of
vitamin D (400 or 800 IU/day). * A p-value <0.05 was considered significant.
3.2.2. Correlations Between Pain and Serum 25(OH)D/VZV Igs in PHN
In Table 3, spontaneous pain was correlated to serum concentrations of 25(OH)D (Spearman
correlation coefficient: −0.329, p = 0.002) and VZV IgM (Spearman correlation coefficient: 0.363,
p = 0.001). Brush-evoked pain was correlated to the serum level of 25(OH)D (Spearman correlation
coefficient: −0.311, p = 0.003). The other Spearman correlation coefficients were ≤ 0.3 indicating no
clinical significance (Data not shown).
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Spontaneous pain (NRS 0-10) vs.
brush-evoked pain (NRS 0–10) 0.196 0.067
25(OH)D (nmol/L) −0.329 * 0.002
VZV IgG(mIU/ml) 0.249 0.019
VZV IgM 0.363 * 0.001
Brush-evoked pain (NRS 0-10) vs.
25(OH)D (nmol/L) −0.311 * 0.003
VZV IgG(mIU/ml) −0.181 0.092
VZV IgM −0.183 0.088
Ig: Immunoglobulin; NRS: 11-point numeric rating pain scale (0–10); 25(OH)D: 25-hydroxyvitamin D; VZV:
varicella-zoster virus; PHN: postherpetic neuralgia. * Spearman correlation coefficients indicate clinical significance
if the value is greater than 0.3.
The cutoffs for serum 25(OH)D concentration to predict spontaneous pain and brush-evoked pain
were 67.0 nmol/L (26.8 ng/mL) (sensitivity 71.4%; specificity 65.2%) and 169.0 nmol/L (67.6 ng/mL)
(sensitivity 79.2%; specificity 59.4%), respectively. The cutoff for IgM titer to predict spontaneous pain
was 0.60 with a sensitivity of 58.7% and a specificity of 76.2%. Based on the AUC values, we found
that serum 25(OH)D status (0.704; 0.721) and IgM titers (0.689) were good predictors for pain in PHN
(Figure 2a–c).
(a) (b) (c) 
Figure 2. (a)area under the receiver operating characteristic curve for 25(OH)D concentration in
spontaneous pain; (b)the area under the receiver operating characteristic curve for 25(OH)D status
in brush-evoked pain; (c)the area under the receiver operating characteristic curve for IgM titer in
spontaneous pain.
3.2.3. Proportions of 10 Items in the DN4 Questionnaire in Patients with Different Serum
25(OH)D/VZV Igs
In 88 PHN patients, 74 patients (84.1%) had a score greater or equal to 4 in the DN4 questionnaire.
In10items of the DN4 questionnaire, patients with vitamin D ≤ 67.0 nmol/L had greater proportions
of painful cold and brush-evoked pain compared to those in patients with vitamin D > 67.0 nmol/L
(p < 0.001; p = 0.002). Although vitamin D-deficient patients (< 50.0 nmol/L) had greater proportions of
painful cold and brush-evoked pain compared to those in vitamin D-insufficient patients (p = 0.005;
p = 0.225), no statistically significant difference in brush-evoked pain was found between the two
groups. Possibly, it was due to the small case number in the group with deficiency. (Table 4)
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Table 4. Proportions of items in the DN4 questionnaire between patients with serum 25(OH)D
















Burning pain, n (%) 28 (56.0) 22 (44.0) 0.422 14 (25.5) 2 (20.0) 0.713
Painful cold, n (%) 2 (11.8) 15 (88.2) <0.001 * 10 (18.2) 6 (60.0) 0.005 *
Electric sharp pain, n (%) 35 (53.8) 30 (46.2) 0.619 9 (16.4) 2 (20.0) 0.778
Tingling, n (%) 35 (47.9) 38 (52.1) 0.073 33 (60.0) 7 (70.0) 0.550
Pins and needles, n (%) 36 (49.3) 37 (50.7) 0.220 31 (56.4) 6 (60.0) 0.831
Numbness, n (%) 19 (54.3) 16 (45.7) 0.759 17 (30.9) 4 (40.0) 0.572
Itching, n (%) 15 (32.6) 13 (31.0) 0.868 17 (30.9) 2 (20.0) 0.485
Hypoesthesia to touch, n (%) 17 (50.0) 17 (50.0) 0.735 21 (38.2) 4 (40.0) 0.913
Hypoesthesia to pinprick, n (%) 13 (46.4) 15 (53.6) 0.453 19 (34.5) 3 (30.0) 0.780
Brush-evoked pain, n (%) 27 (42.2) 37 (57.8) 0.002 * 43 (78.2) 10 (100.0) 0.225
DN4 ≥4, n (%) 39 (84.8) 35 (83.3) 0.853 45(81.8) 9 (90.0) 0.526
n: number; VZV: varicella-zoster virus; DN4: the Douleur Neuropathique 4 questionnaire. * A p-value <0.05 was
considered significant.
For the10 items in the DN4 questionnaire, no significant finding was noted in patients with
IgM ≤ 0.6 compared to those with IgM > 0.6. (Table 5).
Table 5. Proportions of items in the DN4 questionnaire between patients with VZV IgM titer ≥the




≥0.6 (n = 37) <0.6 (n = 51)
Burning pain, n (%) 19 (38.0) 31 (62.0) 0.378
Painful cold, n (%) 7 (41.2) 10 (58.8) 0.936
Electric sharp pain, n (%) 27 (41.5) 38 (58.5) 0.871
Tingling, n (%) 30 (41.1) 43 (58.9) 0.691
Pins and needles, n (%) 32 (43.8) 41 (56.2) 0.453
Numbness, n (%) 14 (40.0) 21 (60.0) 0.752
Itching, n (%) 12 (32.4) 16 (31.4) 0.916
Hypoesthesia to touch, n (%) 13 (38.2) 21 (61.8) 0.566
Hypoesthesia to pinprick, n (%) 12 (42.9) 16 (57.1) 0.916
Brush-evoked pain, n (%) 28 (43.8) 36 (56.3) 0.597
DN4 ≥4, n (%) 30 (81.1) 44 (86.3) 0.511
n: number; VZV: varicella-zoster virus; DN 4: the Douleur Neuropathique 4 questionnaire.
4. Discussion
The current study demonstrated a significantly higher prevalence of hypovitaminosis D in PHN
patients than that in the controls. The rate in the controls was similar to that (44.1%) in subjects
living on similar latitudes in our country located in the subtropical region [3]. The present study
also showed that, compared to vitamin D-sufficient subjects, PHN patients with hypovitaminosis
D had a lower vitamin D supplementation rate, greater pain intensity, and higher VZV IgM titers.
There were several possible explanations for the high prevalence of hypovitaminosis D among PHN
patients. First, compared to the healthy controls, PHN patients had a higher prevalence of diabetes
mellitus [18], malignancy [46] and Helicobacter pylori-related peptic ulcer disease [42], all of which have
been linked to hypovitaminosis D. Second, because low vitamin D intake is a known independent
predictor of hypovitaminosis D [3], lack of vitamin D supplementation in the majority (94.3%) of
patients may contribute to this condition. Third, previous studies have reported elevated titers of VZV
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IgM titers in patients with hypovitaminosis D [27,45], indicating a current virus infection. Because
vitamin D could enhance antimicrobial peptide expression [4,5], hypovitaminosis D may suppress
antimicrobial peptide production and facilitate chronic infection. Moreover, higher VZV IgM titers
in patients with hypovitaminosis D imply persistent VZV infection that may contribute to chronic
pain and its severity. Chronic pain of high severity, in turn, could cause impaired activities of daily
living in patients [26], leading to vitamin D deficiency. Interestingly, a previous report showed a high
prevalence of hypovitaminosis D in hospitalized patients with shingles [47]. It raised a question of
whether hypovitaminosis D in PHN was pre-existing at the onset of shingles or it was the consequence
of depletion from PHN-related pain or chronic viral infection [27,30,35,47]. Instead of identifying
causality, a retrospective case-control study could only establish an association. Longitudinal and
experimental research is needed to further elucidate the findings.
In Part I study, hypovitaminosis D, malignancy and Helicobacter pylori-related peptic ulcer disease
independently predicted PHN in conditional multiple logistic analysis. Because the pathogenesis of
PHN includes neuronal excitability and persistent viral infection-induced neuroinflammation [48,49],
there are probable molecular associations between hypovitaminosis D and PHN. First, activated
microglia and astrocytes have been found to cause neuronal excitability, leading to neuropathic
pain [49]. On the other hand, vitamin D can inhibit the activation of microglia [50] and astrocytes [51].
Second, vitamin D inhibits neuroinflammation by suppressing the production of pro-inflammatory
cytokines and increasing that of anti-inflammatory cytokines [7,52]. Third, vitamin D possesses a direct
anti-viral effect by enhancing the expression of antimicrobial peptides to suppress VZV replication
in keratinocytes and B cells [4,5]. Taken together, hypovitaminosis D may induce PHN as a result of
hyper-excitability of neurons, neuroinflammation and persistent viral replication.
PHN patients experience various spontaneous pain and brush-evoked pain (allodynia) [28].
Significant inverse associations were found between serum 25(OH)D level and the presence
of spontaneous/brush-evoked pain in PHN patients. Spontaneous pain is related to the
neuroinflammation-induced spontaneous firing of intact C-fiber nociceptors [53]. In a PHN rat
model, inducible nitric oxide synthase (iNOS) in astrocytes, which produce large amounts of NO,
is induced in response to VZV infection [54]. NO activates NMDA receptors in spinal dorsal
horn neurons through phosphorylation, resulting in mechanical allodynia [10]. Therefore, the
experimental model demonstrated VZV-NO-astrocyte-induced allodynia. Besides, vitamin D is
anti-neuroinflammatory [6,7,52]. During inflammation, activated glia and astrocytes may synthesize
1,25(OH)D which inhibits iNOS expression and reduces the production of NO [8,9]. In mice, vitamin
D deficiency generates reduced mechanical threshold without altering the thermal nociceptive
threshold [16]. Vitamin D deficiency also induces a significant increase in the spontaneous activity and
activation frequency of spinal nociceptive specific neurons as well as the duration of the evoked activity
of spinal nociceptive specific neurons [16]. Accordingly, symptoms and signs in PHN patients may be
augmented by hypovitaminosis D, perpetuating a vicious cycle involving spontaneous pain/allodynia
and hypovitaminosis D at the molecular level. As for malignancy [55] and Helicobacter pylori-related
peptic ulcer disease [38], both have been identified as the risk factors of PHN based on previous reports.
In Part II study, hypovitaminosis D was found to be associated with increased neuropathic
pain in PHN patients. Vitamin D is a neuroactive steroid that may mediate pain processes by
modulating several signal transduction systems. Patients with statin-induced musculoskeletal pain
often have low vitamin D levels [56]. Statins decrease cholesterol synthesis through the reversible
block of the hydroxy-3-methylglutaryl-coenzyme A reductase. As a result, statins may reduce the
production of 7-dehydrocholesterol which can be photochemically converted to pre-vitamin D in the
skin. Subsequently, pre-vitamin D is metabolized into 25(OH)D in the liver and is then converted into
1,25(OH)2D in the kidney. Vitamin D is essential for the maintenance of musculoskeletal health; thus,
its deficiency may produce muscular weakness and pain. A recent study showed a significant negative
correlation between vitamin D levels and the severity of pain in patients with lower back pain [57].
Seemingly, patients suffering from chronic pain often have hypovitaminosis D. Recently, Guida et
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al. [16] demonstrated that spared nerve injury in normal or vitamin D deficient mice does not induce
changes in gut microbiota. Nonetheless, vitamin D deficiency induces a marked dysbiosis (i.e., a
lower microbial diversity characterized by an increase in Firmicutes and a decrease in Verrucomicrobia
and Bacteroidetes). In addition, vitamin D deficiency alters the endocannabinoid system through
reducing the expression of spinal cannabinoid receptor type 1, increasing levels of spinal cannabinoid
receptor type 2 as well as changing endocannabinoid and endocannabinoid-like mediator levels in
the gut. Concurrently, vitamin D deficiency causes tactile allodynia associated with spinal neuronal
sensitization. Vitamin D deficiency affects nociception possibly via molecular mechanisms involving
the endocannabinoid and related mediator signaling systems. Based on the findings of our studies and
those of others, screening for hypovitaminosis D is suggested in the management of PHN.
In the current study, the cutoffs for 25(OH)D level to predict spontaneous pain and
allodyniawere67.0 and 169.0 nmol/L, respectively. The difference in thresholds is consistent with the
finding of a previous experimental study showing different thresholds for eliciting pain, allodynia,
and hyperalgesia in rats [58]. In 88 PHN patients, 74 (84.1%) had a score greater or equal to 4 in
the DN4 questionnaire. Our results suggest that a physical examination by the physician is still
necessary [29]. Compared to patients with vitamin D >67.0 nmol/L, those with vitamin D ≤ 67.0
nmol/L had significantly greater proportions of painful cold among the seven symptoms in the
DN4 questionnaire. The results support those of previous reports showing that lower 25(OH)D
levels were correlated to lower cold detection thresholds in patients with painful diabetic peripheral
neuropathy [19]. However, our findings demonstrated no association between 25(OH)D level and
burning pain or other symptoms in PHN. In mice, vitamin D deficiency increases the production of
ROS [11] which activates TRPA1 [12] and TRPV1 [59]. Sensitization of TRPA1 via ROS signaling causes
noxious cold pain [13]. On the other hand, vitamin D inhibits TRPV1 channels which are involved in
thermal hyperalgesia only in the acute phase of neuropathic pain [59]. The results of animal models
support our clinical findings. Importantly, vitamin D supplementation has been demonstrated to
reduce neuropathic pain in vitamin D-insufficient diabetic patients [18,60]. Optimization of vitamin D
status may potentially prevent and treat PHN as an alternative therapy for spontaneous pain (painful
cold) and allodynia.
The positive rate of VZV IgM in shingles ranges from 10% to 70% [45]. The positive rate of VZV
IgM in our PHN patients was 11.4%. The current study is the first to report the positive rate of VZV IgM
in patients with PHN. Our results showed that VZV IgM titer was positively correlated to spontaneous
pain. Our findings support that some PHN is associated with VZV ganglionitis caused by persistent
viral infection [48] and that high VZV IgM titers in zoster patients imply a high risk for PHN [61,62].
The cutoff for IgM to predict spontaneous pain was 0.60, indicating that antiviral therapy may decrease
pain for patients with IgM ≥ 0.60. However, the analgesic efficacy of antiviral therapy for PHN remains
conflicting [48,63,64]. This may be attributed to the lack of information on the concentrations of VZV
immunoglobulins in those clinical trials. Further studies are needed to elucidate whether antiviral
therapy is more effective in patients with high IgM titers than those with low titers as well as to assess
the impact of hypovitaminosis D on the efficacy of antiviral therapy for PHN [35,65].
In terms of limitations, we did not assess sun exposure time, sunscreen use, daily activity, and
vitamin D-rich food consumption [3], although the effects of these factors on our findings are likely to
be limited. Second, patients aged >85 years were not included due to a lack of age-matched controls.
Third, although race is a risk factor of hypovitaminosiss D [66], only Taiwanese were enrolled in this
study. Further studies on other ethnic groups are warranted to generalize the results. Fourth, because
of a small patient number and the retrospective nature of the present study, it is impossible to draw
conclusions about causality. This demonstrates the need for large-scale prospective cohort studies to
identify the causes and underlying mechanisms of hypovitaminosis D in PHN.
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5. Conclusions
PHN patients aged 50–85 had a high prevalence of hypovitaminosis D which was associated with
increased spontaneous and brush-evoked pain. PHN patients with hypovitaminosis D had greater
pain, higher VZV IgM titers, and a lower vitamin D supplementation rate than those in subjects without
the condition. The cutoffs for 25(OH)D to predict spontaneous pain and brush-evoked pain were
67.0 and 169.0 nmol/L, respectively. Patients with vitamin D ≤ 67.0 nmol/L had significantly greater
proportions of painful cold. Spontaneous pain was also correlated to VZV Ig Mtiters. The cut-off for
IgM to predict spontaneous pain was 0.60. Further prospective, longitudinal studies are warranted to
confirm these findings.
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Abstract: Background: Milk products fortified with vitamin D may constitute an alternative
to pharmacological supplements for reaching the optimal levels of serum 25-hydroxyvitamin D
[25(OH)D]. Our aim was to analyze the response of serum 25(OH)D and its predictive factors in
postmenopausal healthy women after a dietary intervention with a milk fortified with vitamin D
and calcium. Methods: We designed a prospective study including 305 healthy postmenopausal
women who consumed a fortified milk with calcium (900 mg/500 mL) and vitamin D3 (600 IU/500 mL)
daily for 24 months. Results: The 25(OH)D concentrations at 24 months were correlated to weight,
to body mass index, to the percentage of fat, triglycerides and to baseline 25(OH)D levels. We found
significant differences in the levels of 25(OH)D at 24 months according to baseline 25(OH)D levels
(p < 0.001) and body mass index (p = 0.019) expressed at quartiles. Multivariate analysis showed an
association between levels of 25(OH)D after the intervention and at baseline 25(OH)D (Beta = 0.47,
p < 0.001) and percentage of body fat (Beta = −0.227, p = 0.049), regardless of the body mass index.
Conclusions: In healthy postmenopausal women, the improvement in 25(OH)D after an intervention
with a fortified milk for 24 months depends mainly on the baseline levels of serum 25(OH)D and on
the percentage of body fat.
Keywords: Vitamin D; postmenopausal women; obesity; fat mass
1. Introduction
The Institute of Medicine (IOM) states that the Recommended Dietary Allowance (RDA) of
vitamin D is 15 μg (600 IU, international units) for 97.5% of the population aged 1–70, and 20 μg
(800 IU) for 97.5% of the population >70 years. These are the recommendations for achieving the
circulating levels of 25-hydroxyvitamin D (25(OH)D) ≥ 20 ng/mL needed to maintain bone health [1].
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However, other guidelines recommend serum levels of at least 20–30 ng/mL [2,3], and according to these
recommendations, many people are vitamin D deficient and will need vitamin D supplementation [4].
However, there is an important controversy about the target serum levels of 25(OH)D that must be
reached to achieve the maximum health benefits and how to supplement 25(OH)D in cases where it is
indicated [5].
The consumption of foods fortified with vitamin D is an alternative to treatment with
pharmacological supplements to reach the optimal serum levels of 25(OH)D. Factors influencing
the response to this strategy constitute an interesting area of research to optimize the nutritional
recommendations about fortified foods. Although there is no consensus, several clinical factors have
been reported to influence the dose–response relationships between vitamin D supplementation and
serum 25(OH)D [6,7], such as body weight, percentage of fat, age, baseline 25(OH)D levels, and type
and the duration of the intervention. In addition, genetic factors like single nucleotide polymorphisms
in the vitamin D-binding protein gene can also be significant [8].
Obesity is one of the main factors related to a lower response after vitamin D supplementation [7].
Different causes have been proposed to explain this finding, one of them is a decreased bioavailability
of vitamin D3 from skin and from dietary source due to its deposition in body fat compartments. Also,
an increased distribution volume for vitamin D has been proposed. Vitamin D deficiency is related to
obesity regardless of age and the latitude, and it is also independent of the cut-offs to define vitamin
D deficiency [9]. In the context of the increasing prevalence of obesity in the worldwide population,
a better knowledge of the relationship between obesity and vitamin D after nutritional interventions is
of interest.
Therefore, the aim of our study was to evaluate the changes occurring in serum 25(OH)D levels
and their predictive factors in postmenopausal Spanish women after a nutritional intervention with a
dairy product fortified with vitamin D.
2. Materials and Methods
2.1. Study Design
The findings presented in this study are a post-hoc analysis of data from a previously published
clinical trial [10]. Here we analyze the predictive factors of response of vitamin D after 24 months
of a nutritional intervention with a fortified milk with calcium (900 mg/500 mL) and vitamin D3
(600 IU/500 mL) on serum 25(OH)D. For this analysis, we selected 305 postmenopausal healthy women
(mean age 59 ± 6 years) who completed 24 months of follow up. Inclusion and exclusion criteria of the
study have been previously published [10].
Women consumed the dairy drinks for 24 months (500 mL/day, two intakes per day of 250 mL
each), in the context of their usual diet. Counselling about Mediterranean diet and physical activity
were provided to all women. The adherence to the intervention was evaluated every three months by
telephone calls and empty dairy containers were collected. Compliance with the intervention was above
90%. The dairy drinks were produced in white 1 L Tetra Bricks by Lactalis Puleva (Granada, Spain).
The study was approved by the Ethics Committee of Hospital Universitario San Cecilio of Granada.
All the volunteers provided informed written consent. The study was conducted in accordance with the
ethical principles of the Declaration of Helsinki, following the EEC Good Clinical Practice guidelines
(July 1996).
2.2. Anthropometric Measurements
In the first visit anthropometric measurements were obtained, and also after 24 months of
intervention. We measured body weight (kg) using a standard balance beam scale (Seca), and body
height (cm) using a precision stadiometer (Seca), attached to the balance beam scale. Obesity was
defined as body mass index >30 kg/m2.
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2.3. Body Composition Measurements
Skeletal muscle mass was estimated from bioelectrical impedance analysis (Tanita BC418) at
baseline and at 24 months after the onset of the intervention. This device calculates the percentage
of body fat, fat mass, fat-free mass, and the predicted muscle mass, based on the data obtained by
Dual-Energy X-ray Absorptiometry (DXA), using Bioelectrical Impedance Analysis with an operating
frequency of 50 kHz at 500 lA. Obesity was defined as percentage of fat mass above 35% [11].
2.4. Biochemical Parameters
Blood samples were obtained at 0 and at 24 months after a 12 hour overnight fast. The blood
was collected in a SST-Vacutainer (BD) and serum was separated by centrifugation at 3000 rpm for
15 min at 22–24 °C, then it was divided into aliquots and frozen and stored at −80 °C until analysis.
Serum total cholesterol, high-density lipoprotein cholesterol (HDL-c), triglycerides (TGs), glucose
levels, HbA1c, and apo B were determined by standard automated procedures (Biosystems, Barcelona,
Spain). LDL-c was calculated using the Friedewald formula. Serum 25(OH)D levels were measured by
chemiluminescence immunoassay from Diasorin (LIAISON® 25 OH Vitamin D TOTAL Assay).
2.5. Statistical Analyses
Data were evaluated for normality and homogeneity of variance, and they are expressed as
mean standard ± deviation. The relationship between serum vitamin D and biochemical and clinical
factors were assessed by univariate analysis. A logistic regression and multiple regression analysis
were performed to analyze the association between vitamin D levels at baseline and the levels found
after 24 months of intervention. The variables related to vitamin D after 24 months of intervention
(percentage of fat mass, weight, BMI, triglycerides and baseline 25 OH vitamin D) were included as
covariates. SPSS software (version 17.0, IBM, Armonk, NY, USA) was used for doing statistical analysis.
We considered p values < 0.05 as significant.
3. Results
Baseline clinical characteristics are shown in Table 1. Mean age was 59.3 ± 5.9 years.
Table 1. Characteristics of study subjects at baseline and after 24 months of intervention.
Baseline 24 months p
Weight (kg) 70 ± 11 70 ± 11 0.5
Body mass index (kg/m2) 28 ± 4 28 ± 4 0.084
Obesity (%) 28 32
Overweight (%) 47 48
Percentage of fat mass 37 ± 5 37 ± 5 0.047
Serum calcium (mg/dL) 9.7 ± 0.6 9.8 ± 0.6 <0.001
Parathyroid hormone (pg/mL) 57 ± 21 58 ± 20 0.102
25(OH)D (ng/mL) 22 ± 8 25± 6 <0.001
Total cholesterol (mg/dL) 214 ± 33 208 ± 32 <0.001
HDL colesterol (mg/dL) 55 ± 15 55 ± 14 0.62
LDL colesterol (mg/dL) 141 ± 32 135 ± 32 <0.001
Triglycerides (mg/dL) 87 ± 44 88 ± 46 0.6
3.1. Changes in Biochemical Parameters
Serum 25(OH)D concentrations increased significantly at 24 months compared to the baseline
values (25.4 ± 6.3 ng/dL vs. 21.7 ± 8.3 ng/dL, respectively, p < 0.001). At baseline, 51.3% of the women
had 25(OH)D concentrations > 20 ng/mL, and 14.1% > 30 ng/mL. After 24 months of intervention,
we observed a significant increase in the percentage of women with 25(OH)D levels > 20 ng/mL (78.5%)
and > 30 ng/mL (18.8%) compared to baseline, p < 0.001 for both.
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3.2. Factors Related to 25(OH)D Levels after the Intervention
Serum 25(OH)D levels at 24 months were correlated to weight (r = −0.243, p < 0.001), BMI
(r = −0.177, p = 0.006), percentage of fat mass (r = −0.32, p < 0.001), triglycerides (r = −0.301, p < 0.001)
and baseline 25(OH)D levels (r = 0.5, p < 0.001). (Figure 1). We found statistically significant differences
in the levels of 25(OH)D at 24 months according to baseline 25(OH)D (p < 0.001) and BMI (p = 0.019)
distributed by quartiles (Figure 2).
 
Figure 1. Correlations between serum 25(OH)D levels at 24 months and weight (A), body mass index
(B), percentage of fat mass (C), triglycerides (D) and baseline 25(OH)D levels (E).
Figure 2. The 25(OH) D levels at 24 months according to quartiles of baseline 25(OH) vitamin D (A)
and quartiles of body mass index (B).
We did not find differences in baseline 25(OH)D according to BMI: (<30 kg/m2) 21.9 ± 8 vs.
(>30 kg/m2) 21.3 ± 8.5, p > 0.05. However, lower 25(OH)D levels were observed in women with
BMI > 30 kg/m2 (24.1 ± 6.5 ng/mL) vs. those women with a BMI < 30 kg/m2 (26.2 ± 6 ng/mL) at
24 months (p = 0.026).
In women with obesity, defined by percentage of fat mass, baseline levels of 25(OH)D were lower
(21.2 ± 8.1 ng/mL) compared to women with percentage of fat mass below 35%: (24.6 ± 9 ng/mL),
p < 0.01. Women with obesity, defined by percentage of fat mass, also reached lower 25(OH)D levels
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after 24 months of intervention: 23.7 ± 5.9 ng/mL vs. 27.4 ± 5.9 ng/mL, p < 0.001, compared to women
with percentage of fat mass below 35%.
3.3. Multivariate Analysis
When we analyzed the probability of reaching adequate vitamin D levels after 24 months of
intervention, women with obesity (defined as BMI > 30 kg/m2 or percentage of fat mass above 35%)
have a higher risk of 25(OH)D < 20 ng/mL at 24 months: odds ratio (OR) 2.3, confidence interval,
CI, 95%: 1.2–4.4, p = 0.013 for BMI > 30 and OR 5, CI 95% 2–12.6, p < 0.001, for percentage of fat mass.
The influence of adiposity, defined as percentage of fat mass, in 25(OH)D levels after 24 months persisted
after adjusting for BMI: 25(OH)D < 20 ng/mL OR 4.5 CI 95% 1.6–12.3, p = 0.003, 25(OH)D < 30 ng/mL
OR 3.2 CI 95% 1.2–8.9, p = 0.02.
In women with percentage of fat mass above 35%, there was a 3.2 times higher probability of
reaching 25(OH)D levels< 30 ng/dL at 24 months, regardless of the BMI. However, when we adjusted by
baseline 25(OH)D levels, only the relationship with 25(OH)D < 20 ng/dL persisted (OR 3.6, CI 1.3–10.1,
p = 0.007).
In the multivariate analysis, we observed an association between serum 25(OH)D after 24 months
of intervention, baseline 25(OH)D levels (Beta= 0.47, p<0.001) and percentage of fat mass (Beta=−0.227,
p = 0.049), regardless of weight, BMI and triglycerides.
4. Discussion
The daily consumption of a dairy product providing 600 IU of vitamin D3 for 24 months is effective
to improve serum concentrations of 25(OH)D in healthy postmenopausal women. The nutritional
intervention described in our study allows that 78.5% of women reach 25(OH)D levels > 20 ng/mL,
and 18.8% of women reach 25(OH)D > 30 ng/mL. Baseline 25(OH)D levels and the percentage of
body fat mass are the main factors explaining the responsiveness. The risk of having 25(OH)D below
20 ng/mL after 24 months of intervention was 3.6 times higher in the women with fat mass above 35%,
regardless of BMI and baseline 25(OH)D levels.
This study shows that a simple nutritional intervention with a vitamin D3-enriched milk that
supplies 600 IU/day is effective in increasing 25(OH)D levels and helps to reach adequate 25(OH)D levels
in a high percentage of women. These results are comparable to those described when pharmacological
supplements of vitamin D were used, which often are not well tolerated by patients, especially if
combined with calcium [12]. Although there is not a total consistency regarding the adequate 25(OH)D
levels in healthy subjects [1–3,13], the most accepted serum values are 20 ng/mL, which will be reached
for most of the women after this intervention.
Basel concentrations of 25(OH)D influence the achievement of adequate 25(OH)D levels after
24 months, regardless of other factors. This fact reinforces previous data found in older [14,15] and
younger adults [16], and confirms the importance of considering baseline vitamin D in postmenopausal
healthy women who receive a nutritional intervention with vitamin D.
Another independent predictor of the response of 25(OH)D levels after 24 months of intervention
was body fat. Although weight, triglycerides and BMI showed and association with 25(OH)D levels at
24 months, only the percentage of fat mass persisted in multivariate analysis. BMI is a simple and
worldwide measurement of obesity. However, its validity has been discussed in recent years [17],
and other measures of fat may provide a better estimation of obesity, as percentage of fat mass. In the
present study, only the percentage of fat mass remained as an independent factor influencing the
response of vitamin D after the nutritional intervention, and not BMI. In older healthy women, fat mass
was negatively related to 25(OH)D in a cross-sectional study [18]. Our data showing an independent
association between the fat mass percentage and the evolution of 25(OH) D after 24 months confirms
this relationship, and reinforces the utility of this measurement when addressing the response to an
intervention with vitamin D. Other authors [16] found that body fat mass and BMI were not related the
25(OH)D response, speculating that total body mass instead than fat mass may determine the 25(OH)D
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response. The disparity in the results may be explained by the duration of the intervention and also by
the mean BMI of the subjects included in the study.
There is no agreement regarding why obesity would affect serum 25(OH)D levels. This influence
could be explained by a reduced intake of vitamin D, a reduced sun exposure, an increased storage
and/or sequestration of vitamin D in the adipose tissue. A volumetric dilution due to the distribution
of 25(OH)D in larger fat volumes [6,7,19,20]. In addition, vitamin D stored in the adipose tissue may be
less available for hydroxylation [14,16]. Therefore, if the increased prevalence of obesity worldwide is
the explanation for the high rates of hypovitaminosis D reported is a matter that should be investigated.
However, our study could not demonstrate a favorable effect of the consumption of a dairy product
supplemented with vitamin D on the loss of body weight or fat mass. This finding is consistent with
previously described findings [21].
Although BMI is the most widely used method to evaluate the presence of overweight and
obesity, it has been criticized because BMI does not always reflect true body fatness, that may be better
evaluated by the assessment of body fat and fat-free mass [22]. Bioelectrical impedance analysis is
considered as the simplest, most reproducible and least expensive method for the evaluation of body
composition in clinical practice. It has shown a high accuracy and an excellent correlation with DXA
when assessing the percentage of body fat [23]. Therefore, bioelectrical impedance is cost-effective and
feasible, and may replace DXA in assessing the body composition. Our results highlight the usefulness
of bioelectrical impedance analysis in the evaluation of healthy postmenopausal women. This analysis
may be useful in the selection of women at higher risk of vitamin D deficiency or in the selection of
women who need a higher supplementation of a more frequent evaluation of vitamin D levels.
Our results show that, in healthy postmenopausal women, baseline 25(OH)D levels and obesity,
defined as the percentage of fat mass, are independent determinants of 25(OH)D levels after 24 months
of a nutritional intervention, and they are of clinical relevance. These findings may allow a
better personalization of the supplementation with vitamin D for reaching adequate levels after
the intervention. Moreover, it has been described that the response to vitamin D may differ according
to the dose of vitamin D and the duration of the intervention [24]. Furthermore, the factors influencing
this response may differ between pharmacological and nutritional supplementation, and this potential
difference must be addressed. Considering our findings, the recommended vitamin D dose may be
adapted to baseline vitamin D levels. In addition, the estimation of the percentage of fat mass may be
better for predicting the response to nutritional interventions with vitamin D.
Our study has several strengths, as the long follow-up for a nutritional intervention, and the
exhaustive evaluation of compliance with the intervention. Limitations of the study are the absence
of a comprehensive assessment of dietary intake of vitamin D, which may influence the results.
However, women were advised not to change their lifestyle habits, and exercise was evaluated
semi-quantitatively and showed no changes during the intervention, as an example of no changes.
In addition, we evaluated Caucasian healthy women, and the generalization of this finding to males or
to other ethnic groups must be confirmed. Moreover, we only measured total 25(OH)D, and we did
not evaluate other metabolites.
5. Conclusions
In summary, the response of serum 25(OH)D levels to the supplementation with a fortified milk
consumed for 24 months depend on baseline levels of serum 25(OH)D and on the percentage of body
fat, regardless of BMI, in healthy postmenopausal women. In these women, the determination of the
percentage of fat mass by bioelectrical impedance may allow a better prediction of the response to
vitamin D after a nutritional intervention.
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Abstract: The aim was to investigate the possible association of dietary calcium intake with adiposity,
insulin resistance, and adipocytokine values in adolescent boys. In this cross-sectional study,
participants were 123 adolescent boys aged 13–15 years, who were divided into tertiles according to
their dietary calcium intake. Dietary calcium intake was assessed using three 24 h dietary recalls. In
addition, energy intake, body composition, physical activity (PA), and blood biochemical values were
also measured. Mean body fat%, fat mass (FM), trunk FM, trunk fat%, and leptin differed between
high and low tertiles of calcium intake after adjustment for age, pubertal stage, and PA. For the
entire cohort, mean calcium intake was 786 ± 380 mg/day and was related to body mass index (BMI),
FM, and trunk fat% but not to insulin resistance or adipocytokine values after adjusting for possible
confounders. In addition, only 15.4% of the participants obtained or exceeded their mean dietary
calcium intake requirements. These subjects who met their dietary calcium intake had significantly
lower body fat% in comparison with subjects not meeting their dietary calcium intake. Odds ratio of
being in the highest tertile of FM, trunk FM, and trunk fat% was 3.2–4.4 (95% confidence interval
1.19–12.47; p < 0.05) times higher for boys in low calcium intake tertile, compared to those boys in
high calcium intake tertile. In conclusion, dietary calcium intake is inversely associated with total
body and abdominal adiposity values in a specific group of healthy male adolescents with different
body mass values.
Keywords: dietary calcium intake; adolescent boys; adiposity; percentage of body fat; insulin
resistance; adipocytokines
1. Introduction
Obesity during childhood has become a major health issue that can lead to several chronic diseases
and health problems later in life [1]. While some plateauing or decline in the prevalence of obesity
has been observed in younger children [2], it is not the case in adolescents [1]. Childhood obesity
appears to be the most common cause of insulin resistance in children and adolescents [3], and has been
associated with type 2 diabetes mellitus, dyslipidemia, atherosclerosis, and coronary artery diseases [4]
as well as with increased morbidity and mortality in later adulthood [5]. Adolescence is recognized as
a critical period for the development of obesity [6]. Accordingly, it is important to identify modifiable
risk factors during adolescence to prevent lifelong diseases related to obesity.
These modifiable risk factors include dietary habits, as dietary intervention is an important
aspect in the treatment of obesity [7]. While it is commonly accepted that various combinations of
macronutrients are able to regulate body mass, there is a need to further explore the effects of different
micronutrients on body adiposity values [3,7,8]. Among different micronutrients, calcium and vitamin
D intake may influence obesity and other health characteristics [9]. Studies with adults have reported
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inverse associations of calcium intake with body mass index (BMI) [10], body fat% [9], body fat mass
(FM) [11], waist circumference [12], insulin resistance [13], and systemic inflammation [14] values.
However, only few investigations have examined the association between dietary calcium intake and
body adiposity values in children and adolescents with conflicting results [7]. There are studies to
suggest that daily calcium intake may play a role in the modulation of body fat during growth and
maturation [15,16], while other investigations have not found a relationship between daily calcium
intake and body adiposity values in children and adolescents [17,18].
The association between dietary calcium intake with adiposity, insulin resistance, and
adipocytokine values during growth and maturation has not yet been clarified. Accordingly, the aim
of the present study was to investigate the possible association of daily calcium intake with adiposity,
insulin resistance, and adipocytokine values in a specific group of healthy adolescent boys with a wide
range of BMI values. It was hypothesized that adolescent boys with higher calcium intake would have
lower body fat, insulin resistance, and adipocytokine values compared with adolescent boys with
lower calcium intake values.
2. Material and Methods
2.1. Participants
The participants of the study were 123 pubertal boys aged between 13 and 15 years from different
schools in Tartu, Estonia. The inclusion criteria for current study were that a boy had to be healthy
and took part in obligatory physical education lessons at school. Participants were recruited as a
part of larger longitudinal study. Boys using calcium supplementation were not included, nor were
those taking any medications or having a clinical history of endocrine or metabolic problems, or
cardiovascular, respiratory, or musculoskeletal diseases. All participants had their ordinary everyday
diet. All procedures were approved by the Medical Ethics Committee of the University of Tartu, Estonia
(Consent No 179/T-4, issue date 16.02.2009), and were explained to the boys and their parents who
signed a consent form. Boys were divided in tertiles (low, medium, high) according to energy-adjusted
calcium intake [16]. According to the previous study [19], where participants in the low calcium intake
group (n = 26) compared with those in the high calcium intake group (n = 31) exhibited significantly
higher values for BMI after adjustments for confounders, we should have had 50 participants per
group to have a 0.80 chance (80% power) to detect the difference at 0.05 level of significance between
the groups. In our study with 41 boys per group, we had 72% power to detect the difference of similar
significance between the low calcium intake goup and high calcium intake group.
2.2. Maturity Assessment
Pubertal development was assessed by self-report using an illustrated questionnaire on pubertal
stages according to Tanner [20]. Each boy was given line drawings, pictures, and descriptions
representing genitalia and pubic hair development stages. The pubertal stage assessment according
to the Tanner method, which uses the self-assessment of genitalia and pubic hair stage, has been
previously validated [21] and used in our laboratory with previous studies with boys [22–25].
2.3. Anthropometry and Body Composition
Body mass and height were measured using calibrated medical digital scales (A&D Instruments,
Abington, UK) and portable stadiometer (GMP anthropological instruments, Zurich, Switzerland) to
the nearest 0.05 kg and 0.1 cm, respectively, with the participant wearing light clothing without shoes.
Body mass index (BMI; kg/m2) was calculated as body mass in kg divided by squared height in meters.
Whole body fat percentage, fat mass (FM), fat free mass (FFM), trunk FM, and trunk fat percentage
were measured by dual-energy X-ray absorptiometry (DXA) using the DPX-IQ densitometer (Lunar
Corporation, Madison, WI, USA) equipped with proprietary software, version 3.6. During DXA
measurements, subjects were scanned in a light clothing while lying flat on their backs with arms on
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their sides. The medium scan mode and the standard subject positioning was used for whole body
measurements, which were analyzed using the extended analysis option. The DXA measurements and
results were evaluated by the same examiner. The precision of measurement expressed as coefficient of
variation (CV) was less than 2% for all measurements [25].
2.4. Dietary Intake
Dietary intake was assessed using the average of three 24-h dietary recalls, including two
weekdays (i.e., Thursday and Friday) and one weekend day (Saturday). Participants were asked to
record everything they ate and drank for these days, and cup and bowl sizes were provided to help
estimate portion sizes. The same dietitian interviewed all participants face-to-face and asked probing
questions about their diet recalls. The nutrition data were entered into Nutridata System for Research
(National Institute for Health Development, Tallinn, Estonia) and were analyzed for total daily energy
(kcal/day), calcium (mg/day), and vitamin D (μg/day) intakes [22]. To estimate the prevalence of
nutrient intake below or above the recommendations, the intakes of calcium and vitamin D were
compared with their estimated average requirement (EAR), which are 1100 mg/day and 10 μg/day,
respectively, according to the Institute of Medicine [26]. Finally, to control for confounding and mitigate
for extraneous variation, calcium intake was adjusted for energy intake and expressed as mg per
1000 kcal consumed (i.e., energy-adjusted calcium intake) as suggested previously [27].
2.5. Physical Activity
The Actigraph uniaxial physical activity monitor (model GT1M; ActiGraph, Pensacola, CA), USA)
was used to measure physical activity (PA) level and pattern for seven consecutive days. Epoch length
was set at 15 s, and data were expressed as counts per min [23,28]. All participants were asked to
wear accelerometer on the right hip, allowing removal for sleeping, bathing, and swimming. Physical
activity was included for further analyses, if the participant had accumulated a minimum of 10 h of
activity data for at least two weekdays and one weekend day [23,28].
2.6. Blood Analysis
After an overnight fast, between 08:00 and 09:00, a 10 mL blood sample was collected from the
antecubital vein with the participant in an upright position. Blood serum was separated and then
frozen at −80 ◦C for further analysis. Leptin was determined by radioimmunoassay (RIA) (Mediagnost
Reutlingen, Germany) with intra- and inter-assay CVs<5%, and the least detection limit was 0.01 ng/mL.
Adiponectin was also determined with a commercially available RIA kit (Linco Research, St. Charles,
MO; USA). The intra- and inter-assay CVs were <7%, and the least detection limit was 1 μg/mL.
Insulin was analyzed using Immulite 2000 (DPC, Los Angeles, USA). The intra- and inter-assay CVs
for insulin were 4.5% and 12.2% at an insulin concentration of 6.6 μIU/mL, respectively. Glucose
was measured with a commercial kit (Boehringer, Mannheim, Germany). Insulin resistance index
was calculated using homeostasis model assessment (HOMA-IR): Fasting insulin (μIU/mL) × fasting
glucose (mmol/L)/22.5 [29].
2.7. Statistical Analysis
Data analysis was performed using SPSS 25.0 for Windows (Chicago, IL, USA). Descriptive
data are presented as means and standard deviations (SD). Boys were divided in tertiles according
to energy-adjusted calcium intake [16]. Differences between tertiles (Low, Medium, High) groups
were assessed by ANOVA using Bonferroni method. In addition, differences between tertiles were
assessed after adjustment for age, pubertal stage, and total PA using univariate analysis of covariance
(ANCOVA). Spearman correlation and partial correlation (controlling for age, pubertal stage, and
total PA) coefficients were conducted to describe relationships of energy-adjusted calcium intake
with body composition, insulin resistance, and adipocytokine values. Differences between EAR of
calcium and vitamin D intake were assessed by ANOVA. Regression analyses were used to examine
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the relationships between energy-adjusted calcium intake and body fatness components through
two separate models, where body fatness components were inserted as dependent variables and
energy-adjusted calcium intake as independent variable. Model 1 was unadjusted model, while Model
2 was adjusted for age, pubertal stage, and total PA to determine the independent association with
energy-adjusted calcium intake. Logistic regression analysis was also used to describe the odds ratio
(OR) (95% confidence interval (CI)) of being at the highest tertile of each body fatness components
according to the energy-adjusted calcium intake tertiles. Significance was set at p < 0.05.
3. Results
The study population included 123 adolescent boys, including 4 boys at pubertal stage 2, 30 boys
at pubertal stage 3, 55 boys at pubertal stage 4, and 34 boys at pubertal stage 5, with the mean age of
13.9 ± 0.6 years. The mean BMI was 21.6 ± 5.4 kg/m2, with a range from 13.8 to 45.5 kg/m2 including
71% normal weight and 29% overweight/obese boys. Participants presented mean energy intake of
1798 ± 535 kcal/day, and the range was 622 to 3300 kcal/day. The mean calcium intake for all adolescent
boys (n = 123) was 786 ± 380 mg/day, with a large range from 123 to 2460 mg/day. Data indicated that
only 15.4% (n = 19) of the participants obtained or exceeded their calcium intake EAR [26]. The mean
vitamin D intake was 3.2 ± 4.3 μg/day and only 8.1% (n = 10) of the participants met the recommended
vitamin D intake EAR [26]. Boys who met their calcium intake EAR (n = 19) had a mean vitamin D
intake of 5.1 μg/day, energy intake was 2330 kcal/day, and body fat% was 18.1 ± 9.1%, while boys
who did not meet their calcium intake EAR (n = 104) had a mean vitamin D intake of 2.8 μg/day, their
energy intake was 1700 kcal/day, and body fat% was 24.0 ± 12.%. These values were significantly
different (p < 0.05) from the corresponding values in those boys who met their calcium intake EAR.
Body composition, PA, dietary intake, and blood biochemical characteristics of the study population
are presented in Table 1. When the study participants were grouped by energy-adjusted calcium intake
tertiles, body mass, and body adiposity values were lower with increasing tertile of calcium intake. The
participants in the high calcium intake tertile had significantly lower body mass, BMI, body fat%, FM,
FFM, trunk FM, and trunk fat% than those in the low calcium intake group. In addition, body fat%,
FM, FFM, trunk FM, and trunk fat% remained significantly different between the high and low calcium
intake tertiles after adjustment for age, pubertal stage, and total PA. No significant differences between
different calcium tertiles were seen in blood biochemical characteristics. However, after controlling for
confounding factors, participants in the high calcium intake tertile had significantly lower leptin levels
when compared with the boys at the low calcium intake tertile. In addition, no significant differences
between the three studied groups were seen in energy intake and vitamin D intake values (Table 1).
Bivariate correlation analysis revealed that calcium intake was inversely related to BMI, FM,
trunk FM, and trunk fat% values (Table 2). The correlations between calcium intake and BMI, FM,
and trunk fat% remained significant after adjusting for age, pubertal stage, and total PA values. In
addition, calcium intake was correlated with body mass and FFM values after controlling for these
confounding factors. In contrast, calcium intake was not associated with leptin, adiponectin, or insulin
resistance (glucose, insulin, HOMA-IR) values (Table 2). Linear regression analysis showed that in
unadjusted model (Model 1), the energy-adjusted calcium intake was negatively associated with trunk
FM (β = −0.183; p = 0.043) (Table 3). After adjustment for age, pubertal stage and total PA (Model 2),
the association slightly increased (β = −0.185; p = 0.042). There were no associations between calcium
intake and other body fatness parameters in Model 1 as well as in Model 2 (p > 0.05) (Table 3). In
addition, the OR of being in the highest tertile of FM was 4.4 (95% CI 1.55–12.47; p = 0.005) times
higher for participants with low calcium intake tertile compared to those with high calcium intake
tertile (Table 4). Similarly, the OR of being highest tertile of trunk FM and trunk fat% was 3.2 (95% CI
1.19–8.35; p = 0.021) and 3.3 (95% CI 1.19–9.05; p = 0.021) times higher, respectively, in the participants
with low calcium intake tertile, compared to those with high calcium intake tertile (Table 4).
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Table 1. Mean ( ± SD) descriptive characteristics of the studied sample according to tertiles of
energy-adjusted calcium intake.
Variable
Total Low Ca Intake Medium Ca Intake High Ca Intake
(n = 123) Tertile (n = 41) Tertile (n = 41) Tertile (n = 41)
Age (yrs) 13.9 ± 0.6 13.9 ± 0.6 13.8 ± 0.6 14.1 ± 0.6 #
Height (cm) 169.0 ± 8.6 170.7 ± 8.7 167.5 ± 8.4 168.9 ± 8.7
Body mass (kg) 62.5 ± 19.4 70.5 ± 24.1 58.7 ± 15.2 * 58.2 ± 15.4 *
BMI (kg/m2) 21.6 ± 5.4 23.8 ± 6.5 20.7 ± 4.3 * 20.3 ± 4.4 *
Overweight/obese (n/%) 36/29.3 16/39.0 12/29.3 8/19.5
Body fat% 23.1 ± 11.7 26.6 ± 12.1 22.3 ± 11.4 † 20.3 ± 11.0 *†
FM (kg) 15.2 ± 12.3 19.8 ± 15.4 13.6 ± 9.4 *† 12.2 ± 10.0 *†
FFM (kg) 46.5 ± 10.0 49.8 ± 11.4 44.4 ± 8.6 * 45.3 ± 9.3 *†
Trunk FM (kg) 6.3 ± 5.6 8.5 ± 7.2 5.6 ± 4.3 *† 4.7 ± 4.4 *†
Trunk fat% 21.4 ± 12.1 25.3 ± 12.7 20.7 ± 11.7 † 18.1 ± 11.0 *†
Total PA (counts/min) 398 ± 161 397 ± 165 403 ± 145 393 ± 174
Energy intake (kcal/day) 1798 ± 535 1785 ± 543 1769 ± 561 1839 ± 512
Calcium intake (mg/day) 786 ± 380 515 ± 189 738 ± 240 * 1104 ± 408 *#
Calcium intake (mg/1000 kcal) 434 ± 146 287 ± 60 418 ± 40 * 597 ± 98 *#
Vitamin D intake (μg/day) 3.2 ± 4.3 2.7 ± 3.0 3.5 ± 5.4 3.5 ± 4.1
Leptin (ng/mL) 6.1 ± 8.6 8.1 ± 11.2 5.6 ± 7.5 4.6 ± 6.2 †
Adiponectin (μg/mL) 8.0 ± 4.4 7.5 ± 4.1 8.3 ± 4.3 8.3 ± 4.9
Glucose (mmol/L) 5.1 ± 0.4 5.1 ± 0.4 5.0 ± 0.4 5.1 ± 0.4
Insulin (μIU/mL) 14.2 ± 7.7 15.8 ± 8.5 12.7 ± 6.4 14.2 ± 7.9
HOMA-IR 3.2 ± 1.8 3.6 ± 1.9 2.9 ± 1.5 3.3 ± 1.9
* Significantly different from Low Ca intake tertile; p < 0.05; # Significantly different from Medium Ca intake tertile;
p < 0.05; † Significantly different from Low Ca intake tertile after adjustment for age, pubertal stage, and total PA;
p < 0.05.
Table 2. Correlation coefficients of energy-adjusted calcium intake with body composition and blood
biochemical variables.
Variables Bivariate Correlation
Partial Correlation Adjusted for Age,
Pubertal Stage, and Total Physical Activity
Body mass (kg) −0.157 −0.211 *
BMI (kg/m2) −0.192 * −0.205 *
Body fat% −0.167 −0.132
FM (kg) −0.195 * −0.190 *
FFM (kg) −0.104 −0.194 *
Trunk FM (kg) −0.188 * −0.150
Trunk fat% −0.189 * −0.199 *
Leptin (ng/mL) −0.111 −0.103
Adiponectin (μg/mL) 0.072 0.130
Glucose (mmol/L) 0.022 0.033
Insulin (μIU −0.061 −0.059
HOMA-IR −0.064 −0.053
* Statistically significant; p < 0.05.
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Table 3. Linear regression coefficients examining the associations of energy-adjusted calcium intake
with body fatness components.
Calcium Intake
B ± SE 95% CI R2 β p value
Model 1
Body fat% −0.01 ± 0.01 −0.03; 0.01 0.13 −0.128 0.157
FM −14.60 ± 7.58 −29.61; 0.41 0.03 −0.172 0.056
Trunk FM −7.10 ± 3.47 −13.97; −0.23 0.03 −0.183 0.043
Trunk fat% −0.01 ± 0.01 −0.03; 0.003 0.02 −0.147 0.104
Model 2
Body fat% −0.01 ± 0.01 −0.03; 0.001 0.06 −0.125 0.168
FM −14.70 ± 7.65 −29.84; 0.45 0.05 −0.174 0.057
Trunk FM −7.20 ± 3.50 −14.13; −0.26 0.05 −0.185 0.042
Trunk fat% −0.01 ± 0.01 −0.03; 0.003 0.05 −0.146 0.108
Model 1: Unadjusted model. Model 2: Adjusted for age, pubertal stage, and total PA. B—unstandardized coefficient.
SE—standard error. CI—confidence interval. β—standardized coefficient.
Table 4. Odds ratios of highest tertile of body fat components versus other tertiles (medium+lower) of
body fat components.
Body Fat% FM Trunk FM Trunk Fat%
Ca tertiles OR 95%CI p value OR 95%CI p value OR 95%CI p value OR 95%CI p value
High Ref Ref Ref Ref
Medium 0.92 0.36; 2.35 0.867 1.56 0.62; 3.93 0.342 1.97 0.78; 4.97 0.154 1.24 0.49; 3.12 1.24
Low 2.79 0.99; 7.83 0.051 4.39 1.55; 12.47 0.005 3.15 1.19; 8.35 0.021 3.29 1.19; 9.05 0.021
All models were adjusted for age, pubertal stage, and total PA.
4. Discussion
This study was aimed to investigate the possible associations between calcium intake with adiposity,
insulin resistance, and adipocytokine values in a heterogeneous group of 123 male adolescents with
different adiposity values. An independent inverse association of calcium intake with different
adiposity, but not with insulin resistance and adipocytokine values was observed in adolescent boys.
Individuals with higher calcium intake had lower body adiposity values. Furthermore, those boys
who met their calcium intake EAR had lower body fat% in comparison with those who did not met
their daily calcium intake EAR. Accordingly, it could be suggested that adequate calcium intake is
needed to maintain lower body fat values in adolescent boys during pubertal growth and maturation.
Our results demonstrated that lower calcium intake was associated with higher total body
adiposity values in adolescent boys in this important developmental age, which is a critical period
for the development of obesity [6]. These results are in accordance with a recent study in a large
European cohort of children and adolescents [16]. In that study, an inverse correlation of total calcium
intake with different adiposity indices was consistently observed in boys but not in girls, and the
prevalence of obesity decreased significantly across tertiles of calcium intake [16]. While relatively
few investigations have studied the role of calcium intake in modulating adiposity in children and
adolescents [16], most of them have supported a significant association between calcium intake and
adiposity measures [3,15,16,30], similarly to our results. In contrast, other studies have not found
this relationship in children and adolescents [17,18,31]. The relationship between calcium intake and
body adiposity has also been evaluated longitudinally demonstrating that lower calcium intake at
baseline was associated with an increase in adiposity indices over a six-year period in boys with a
wide range of BMI values but not in girls [16]. Similarly, calcium intake was not related to two-year
change in body fat in lean peripubertal girls [17]. In addition to possible gender differences, it has
been suggested that a certain threshold for calcium intake and/or BMI may be needed to observe the
relationship between calcium intake and total body adiposity values [13]. It has also been argued that
the effects of calcium intake on body adiposity depend on higher percentage of body fat in children [7].
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In accordance with this, the OR being in the highest tertile of FM in our study was more than four
times higher for participants with low calcium intake compared to those with high calcium intake and
more than three times higher being in the highest tertile of trunk FM or trunk fat%.
Inverse association of calcium intake with abdominal adiposity was also identified in the current
investigation, which is in accordance with the results of other studies carried out with 8–9-year-old [32],
9–12-year-old [17], and 12–19-year-old [3] children with various BMI values as well as 7–18-year-old
children and adolescents with obesity [33]. Interestingly, Barr [17] demonstrated that calcium intake
below the median was independently associated with higher trunk fat% in 9–12-year-old girls. Similarly,
calcium intake was negatively correlated with trunk fat% after controlling for potentially confounding
variables in our study. It has been suggested that trunk fat may be preferentially affected by calcium
intake [17,34], and abdominal adiposity is closely related to metabolic syndrome, type 2 diabetes
mellitus, and cardiovascular diseases [3,4].
Another important finding of the present study was the inadequate calcium intake in majority
of studied adolescents. It appeared that only 15.4% (n = 19) met their daily calcium intake EAR,
similarly to the results of other studies in children and adolescents [3,32,35]. In fact, most studies
have observed that more than 90% of studied children and adolescents do not meet the required daily
calcium intake [3,32,35]. Therefore, calcium appears to be one of the micronutrients with the highest
rate of inadequate consumption worldwide [36]. In our study, adolescent boys with adequate calcium
intake had significantly lower body fat% in comparison with adolescents with inadequate daily calcium
intake.The importance of adequate calcium intake in adolescent boys should be emphasized because
about 45% of bone mineral accrual occurs during early adolescence [37]. This age and maturation
period provides a limited window of opportunity for maximizing peak bone mass [38], which is a
major determinant of fractures, a major public health problem in adults [6].
Different mechanisms have been proposed to explain the association between calcium intake and
body adiposity. For example, it has been suggested that adequate calcium intake increases the oxidative
capacity of adipose tissue [32]. Higher calcium intake is associated with reduced 1,25-vitamin D levels,
which in turn induce intracellular calcium content to decrease in adipose tissue, stimulating lipolysis,
and inhibiting lipogenesis in the adipocyte [39]. In contrast, low calcium intake is associated with
high intracellular calcium concentrations, which may then increase the rate of lipogenesis and inhibit
lipolysis, resulting in increased adiposity [39]. Furthermore, dietary calcium intake may influence
fat metabolism by increased faecal fat excretion [40] and decreased hunger or increased satiety [41].
Anti-obesity mechanisms of vitamin D have also been suggested [16], with vitamin D interacting in a
complex system of absorptive and endocrine functions [10]. However, it has to be considered that all
these suggested mechanisms still lack confirmation in human longitudinal studies [16].
There was no association between daily calcium intake and measured adipocytokine values in
adolescent boys with various adiposity values. Therefore, leptin is synthesized by adipocytes and is
directly related to the amount of body fat [42]. While calcium intake was related to body FM in current
study, it would have expected to also observe an association between calcium intake and leptin values,
similarly to a study with premenopausal women [13]. The differences between the results of our study
and that of da Silva Ferreira et al. [13] could be explained by different leptin levels in these studies,
premenopausal women having considerably higher leptin and adiposity values compared to adolescent
boys in the present study. However, leptin concentration was significantly lower in high calcium intake
tertile compared with leptin value in low calcium intake tertile after controlling for energy intake, PA
and maturation values in adolescent boys, which was also observed in premenopausal women [13].
Further studies are needed before any conclusion about possible association of daily calcium intake
with leptin can be drawn.
The possible relationship of calcium intake and insulin resistance has not yet been fully clarified.
Unlike previously reported investigations in adults [13,43,44] and adolescents [28], no association
between calcium intake and HOMA-IR as an index of insulin resistance was seen in our specific group of
adolescent boys with different adiposity values. While dos Santos et al. [30] found a significant inverse
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association between calcium intake and HOMA-IR among obese but not normal weight adolescents.
In accordance with our results, a recent study reported no relationship between calcium intake
and HOMA-IR in adult males, while calcium intake was related to HOMA-IR in adult females [43].
Accordingly, the reported association between calcium intake and insulin resistance that has been
found in adults [13,43,44], should be further investigated in adolescents using a direct measure of
insulin resistance.
There are some limitations in our study that should be considered. Firstly, this is a cross-sectional
study, which limits our ability to make causal inferences. In addition, although the same dietitian
interviewed all participants and reviewed their diet recalls with each participant, self-reported dietary
intakes are subject to error as it depends on the memory of adolescents, and is susceptible to under-
and over-reporting. Another potential limitation is that some significant associations would have not
been detected due to slightly underpowered study, although the number of participants was similar to
previous cross-sectional studies in this area [3,9,13,19]. The specific information about socioeconomic
status and/or maternal/paternal overweight/obesity was also not collected. Finally, our findings are
limited to a specific group of Caucasian male adolescents with specific age and maturation range, and
wide range of total body adiposity values.
This study has also some strengths. Firstly, objective assessment of PA by accelerometry and
body composition by DXA were used in this study. In addition, the present study is one of the few
studies that has evaluated possible associations of calcium intake with adiposity, insulin resistance,
and adipocytokines taking into account several confounders including pubertal maturation, energy
intake, and PA. These findings help to understand the possible associations between calcium intake
levels and adiposity values during growth and maturation.
5. Conclusions
Dietary calcium intake is inversely associated with total body and abdominal adiposity values
in a specific group of healthy male adolescents with different body mass values. In contrast, no
relationships of calcium intake with adipocytokine and insulin resistance values were observed. In
addition, adolescents with adequate calcium intake had significantly lower body fat% in comparison
with those adolescents with inadequate daily calcium intake. Odds ratio of being in the highest tertile
of FM, trunk FM, or trunk fat% was more than three times higher for participants in low calcium intake
tertile compared to those with high calcium intake tertile.
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Jeznach-Steinhagen, A. Assessment of dietary calcium intake on metabolic syndrome frequency in obese
children and adolescents. Pediatr. Endocrinol. Diabetes Metab. 2008, 14, 231–235.
34. Zemel, M.B.; Richards, J.; Mathis, S.; Milstead, A.; Gebhardt, L.; Silva, E. Dairy augmentation of total and
central fat loss in obese subjects. Int. J. Obes. 2005, 29, 391–397. [CrossRef] [PubMed]
35. Magalhaes, E.I.; Pessoa, M.C.; Franceschini, S.D.; Novaes, J.F. Dietary calcium intake is inversely associated
with blood pressure in Brazilian children. Int. J. Food Sci. Nutr. 2017, 68, 331–338. [CrossRef] [PubMed]
36. Beal, T.; Massiot, E.; Arsenault, J.E.; Smith, M.R.; Hijmans, R.J. Global trends in dietary micronutrient supplies
and estimated prevalence of inadequate intakes. PLoS ONE 2017, 12, e0175554. [CrossRef] [PubMed]
37. Bailey, D.A.; Martin, A.; McKay, H.; Whiting, S.; Mirwald, R. Calcium accretion in girls and boys during
puberty: A longitudinal analysis. J. Bone Miner. Res. 2000, 15, 2245–2250. [CrossRef] [PubMed]
38. Jürimäe, J.; Gruodyte-Raciene, R.; Baxter-Jones, A.D.G. Effects of gymnastics activities on bone accrual during
growth: A systematic review. J. Sports Sci. Med. 2018, 17, 245–258.
39. Zemel, M.B.; Miller, S.L. Dietary calcium and dairy modulation of adiposity and obesity risk. Nutr. Rev.
2004, 62, 125–131. [CrossRef]
40. Bendsen, N.T.; Hother, A.L.; Jensen, S.K.; Lorenzen, J.K.; Astrup, A. Effect of dairy calcium on fecal fat
excretion: A randomized crossover trial. Int. J. Obes. 2008, 32, 1816–1824. [CrossRef]
144
Nutrients 2019, 11, 1454
41. Gilbert, J.A.; Joanisse, D.R.; Chaput, J.P.; Miegueu, P.; Cianflone, K.; Almeras, N.; Tremblay, A. Milk
supplementation facilitates appetite control in obese women during weight loss: A randomised, single-blind,
placebo-controlled trial. Br. J. Nutr. 2011, 105, 133–143. [CrossRef]
42. Jürimäe, J. Adipocytokine and ghrelin responses to acute exercise and sport training in children during
growth and maturation. Pediatr. Exerc. Sci. 2014, 26, 392–403. [CrossRef]
43. Kim, J.H.; Lee, S.H.; Park, S.J.; Yeum, K.J.; Choi, B.; Joo, N.S. Dietary calcium intake may contribute to
the HOMA-IR score in Korean females with vitamin D deficiency (2008–2012 Korea National Health and
Nutrition Examination Survey). J. Obes. Metab. Syndr. 2017, 26, 274–280. [CrossRef] [PubMed]
44. Tremblay, A.; Gilbert, J. Milk products, insulin resistance syndrome and type 2 diabetes. J. Am. Coll. Nutr.
2009, 28, 91S–102S. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Vitamin D Food Fortification and Nutritional Status in
Children: A Systematic Review of Randomized
Controlled Trials
Paula Nascimento Brandão-Lima 1, Beatriz da Cruz Santos 2, Concepción Maria Aguilera 3,4,5,*,
Analícia Rocha Santos Freire 2, Paulo Ricardo Saquete Martins-Filho 1,6 and Liliane Viana Pires 2
1 Health Sciences Post-Graduation Program, Department of Medicine, Federal University of Sergipe, Rua
Cláudio Batista, S/N, Cidade Nova, Aracaju, 49060-108 Sergipe, Brazil; paulanblima@gmail.com (P.N.B.-L.);
saqmartins@hotmail.com (P.R.S.M.-F.)
2 Nutrition Sciences Post-Graduation Program, Department of Nutrition, Federal University of Sergipe,
Avenida Marechal Rondon, S/N, Jardim Rosa Elze, São Cristovão, 49100-000 Sergipe, Brazil;
cruz14_bia@outlook.com (B.d.C.S.); alicia.nutri@gmail.com (A.R.S.F.); lvianapires@gmail.com (L.V.P.)
3 Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology, Center of
Biomedical Research, University of Granada, Avda. del Conocimiento s/n. Armilla, 18100 Granada, Spain
4 Instituto de Investigación Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de Granada,
18014 Granada, Spain
5 CIBEROBN (Physiopathology of Obesity and Nutrition Network CB12/03/30038), Institute of Health Carlos
III (ISCIII), 28029 Madrid, Spain
6 Investigative Pathology Laboratory, Federal University of Sergipe, Rua Cláudio Batista, S/N, Cidade Nova,
Aracaju, 49060-108 Sergipe, Brazil
* Correspondence: caguiler@ugr.es; Tel.: +34-958-241-000 (ext. 20314)
Received: 27 September 2019; Accepted: 12 November 2019; Published: 14 November 2019
Abstract: Children are in the risk group for developing hypovitaminosis D. Several strategies are used
to reduce this risk. Among these, fortification of foods with vitamin D (25(OH)D) has contributed to
the achievement of nutritional needs. This systematic review aims to discuss food fortification as a
strategy for maintenance or recovery of nutritional status related to vitamin D in children. The work
was developed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) and registered in the International prospective register of systematic reviews (PROSPERO)
database (CRD42018052974). Randomized clinical trials with children up to 11 years old, who were
offered vitamin D-fortified foods, and who presented 25(OH)D concentrations were used as eligibility
criteria. After the selection stages, five studies were included, totaling 792 children of both sexes
and aged between two and 11 years. Interventions offered 300–880 IU of vitamin D per day, for a
period of 1.6–9 months, using fortified dairy products. In four of the five studies, there was an
increase in the serum concentrations of 25(OH)D with the consumption of these foods; additionally,
most children reached or maintained sufficiency status. Moreover, the consumption of vitamin
D-fortified foods proved to be safe, with no concentrations of 25(OH)D > 250 nmol/L. Based on the
above, the fortification of foods with vitamin D can help maintain or recover the nutritional status of
this vitamin in children aged 2–11 years. However, it is necessary to perform additional randomized
clinical trials in order to establish optimal doses of fortification, according to the peculiarities of
each region.
Keywords: enriched food; child; cholecalciferol; ergocalciferols; dairy products
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1. Introduction
Vitamin D (25(OH)D) is an important nutrient during childhood because of its involvement in
bone formation, as well as in the immune system, which can result in higher body needs for this
vitamin [1–3]. Thus, children are among the groups at risk of developing hypovitaminosis D [4].
Dietary intake is one of the ways to obtain this vitamin, but the food contribution is limited
(10% to 20%) [4–6]. The main way of obtaining vitamin D is endogenously from sun exposure:
ultraviolet B (UVB) rays are absorbed by 7-dehydrocholesterol, producing a thermally unstable
compound that is converted in the liver to 25(OH)D, and subsequently converted to the active form
1,25-dihydroxycholecalciferol in the kidneys [3,6–9].
Even in sunny countries, vitamin D deficiency is observed in different population groups [10–13].
Considering the issue raised, the fortification of foods with vitamin D is an alternative for wide
population coverage for reducing the risk of vitamin D deficiency, and its adoption is increasing
worldwide [14,15]. In some countries with high prevalence of vitamin D deficiency and ineffective sun
exposure, fortification of foods with vitamin D is compulsory or voluntary, with dairy products being
the most frequently fortified foods [16–18].
There are few clinical trials evaluating food fortification as a strategy to improve or maintain vitamin
D nutritional status in child population [14,16–19], as well as systematic reviews and meta-analysis have
evaluated this outcome [20,21]. In this context, the fortification of ready-to-eat foods may contribute
to the achievement of the nutritional needs of vitamin D in children, who commonly present a high
inadequacy in vitamin D intake [15,22]. Although promising, vitamin D fortification is not yet widely
explored by public health policies because more studies are needed to assess the contribution of fortified
foods consumption to serum 25(OH)D levels in children and other risk groups of hypovitaminosis D,
given the need to obtain information regarding dose, safety, and fortification food vehicle. The objective
of this study is to evaluate the available evidence of dairy food fortification as a strategy for maintenance
or recovery of nutritional status related to vitamin D in children.
2. Materials and Methods
This study was conducted following the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement (PRISMA) [23] (Supplementary 1) and supplemented by guidance from the
Cochrane Collaboration Handbook for Systematic Reviews of Interventions [24]. Institutional review
board approval and informed consent were not required for this systematic review. A study protocol
was designed a priori and was registered in the International prospective register of systematic reviews
PROSPERO database (registration number CRD42018052974).
2.1. Eligibility Criteria
For the construction of this review randomized clinical trials (RCTs) with children up to 11
years old, who presented data regarding serum or plasma vitamin D (25(OH)D) concentrations at
baseline and after the intervention, were considered eligible. The comparators were foods fortified
with cholecalciferol or ergocalciferol with non-fortified foods.
Animal or in vitro studies, manuscript published only in summary form, and review studies were
excluded. In addition, studies including children diagnosed with diseases that compromised vitamin
D metabolism were excluded. To avoid interference from other nutrients, studies who offered fortified
foods with vitamin D in conjunction with other nutrients were not considered.
2.2. Search Strategy
Searches for RCTs were performed in PubMed, SCOPUS, Bireme, Lilacs, and the website
ClinicalTrials.gov from inception to January 2019. A gray-literature search included Google Scholar
and OpenThesis. The structured search strategy used the following terms: (child) AND (“vitamin
d” OR cholecalciferol OR ergocalciferol OR “fortified food” OR “fortified foods”) (Supplementary 2).
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The search was limited to studies published in full-text versions, without language restriction.
The reference lists of all eligible studies and reviews were scanned to identify additional studies
for inclusion.
2.3. Study Selection and Data Extraction
Two evaluators (B.C.S and P.N.B-L) conducted all the selection stages of studies independently,
first reading the Titles and Abstracts, and subsequently reading the full studies selected in the first
stage. Any disagreement was resolved in conjunction by three evaluators (B.C.S, P.N.B-L, and L.V.P).
To evaluate the agreement between the evaluators in the selection stages of the studies, the kappa
coefficient proposed by Landis and Koch [25] was used. The results were classified according to the
interval <0 to 1, where <0 = no agreement, 0–0.19 = poor agreement, 0.20–0.39 = fair agreement,
0.40–0.59 = moderate agreement, 0.60–0.79 = substantial agreement, and 0.80–1= almost perfect
agreement [25].
The following information was extracted from studies: characteristics of the participants; season
of the year; dosage and food matrix used as the fortification vehicle; sun exposure; duration of
intervention; and 25(OH)D status. The cut-off points proposed by the World Health Organization were
adopted for the classification of BMI (Body Mass Index) for age, with z-score values ≥ −2 and ≤+1
considered normal weight [26].
In the included study that presented the serum 25(OH)D concentration as a graph [16], mean and
standard deviation values were extracted using Web Plot Digitizer software version 4.1 (Ankit Rohatgi,
Austin, Texas, USA). If the means and standard deviations were not directly reported in the publication,
indirect methods of extracting estimates were used [27,28].
2.4. Assessment of Risk of Bias
The risk of bias in the studies was independently assessed by two reviewers using the Cochrane
Collaboration’s tool for assessing risk of bias in randomized trials [24]. The tool presents seven
domains in which random sequence generation, allocation concealment, blinding of participants and
professionals, blinding of outcome evaluators, incomplete outcomes, selective outcome reporting, and
other sources of bias are evaluated. Other sources of bias were non-descriptions of skin color and
frequency of sun exposure of children assessed in the studies. The items contained in this checklist
were classified as low risk, high risk, or unclear risk of bias.
2.5. Data Synthesis
In order to assess the main outcome, vitamin D intake values were converted into international
units per day (μg × 40 = IU) [4] when not provided by the studies. Furthermore, serum concentrations
of 25(OH)D were presented in nanomoles per liter (ng/mL × 2.5 = nmol/L) [4]. 25(OH)D levels were
analyzed based on change-from-baseline measures [24]. However, due to the heterogeneity observed
between the studies, the meta-analysis of the data was not performed. Thus, the results of the studies
were reported individually and were not summarized.
The graphical representation of the bias risk analysis was elaborated with Review Manager
software 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark, 2008).
3. Results
3.1. General Characteristics
The initial search identified 1778 studies, and, after all the selection stages, five studies met the
inclusion criteria and were included in this review [14,16–19]. The kappa coefficient for two selection
stages was, respectively, 0.664 and 0.683, which characterizes a substantial agreement between the
evaluators in both stages. The selection stages of the studies are presented in Figure 1.
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Figure 1. Flowchart of search and selection steps of the studies.
Of the included randomized clinical trials, four are double-blind type [14,16,17,19], and one is
blind [18]. The studies were conducted in four different countries, two being conducted in Canada
(latitude > 40◦ N) [16,17], and the others in Sweden (latitude 55◦ N e 63◦ N) [19], Germany (latitude >
50◦ N) [14], and Mongolia (latitude 48◦ N) [18].
3.2. Risk of Bias
Regarding the analysis of bias risk (Figure 2), among the five included studies, 100% were classified
as low risk of selection bias (random sequence generation). This result was due to the studies using a
table of random numbers [14,17] or a computer program [16,18,19] to generate the random sequence.
In relation to selection bias (allocation concealment), 100% of the studies presented low risk, while
80% of the studies presented a low risk for the performance bias domain, with only one of the studies
lacking sufficient information on the blinding process of participants and professionals [18].
The evaluation of detection, attrition, and reporting bias showed that 100% of the studies presented
low risk of bias [14,16,17,19], considering the description of the blinding, the loss of data, and their
respective reasons, together with the intention-to-treat analysis, as well as the proposed outcomes were
reported, and no bias was observed in the observed effect size.
According to the analysis of other sources of bias (assessment of sun exposure and skin color),
60% of the studies presented low risk [16,17,19]. Only one study did not evaluate such information,
being assigned a high risk of bias [18], and another did not clearly describe the method used to evaluate
these aspects, being classified as an unclear risk of bias [14].
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Figure 2. Authors’ judgment about the risk of bias for each included study. Caption: (+) indicates low
risk; (−) high risk; and (?) unclear risk.
3.3. Sample Characterization
The five studies selected present data on 792 children of both sexes and aged between two and
11 years, distributed in the intervention groups with vitamin D-fortified foods (n = 568) and control
(n = 224). Regarding nutritional status, three studies were conducted with normal weight children
according to BMI for age [16–18]. Two other studies included in the sample children with normal
weight, thinness [14], overweight, and obesity [14,19]. In the studies, no differences were observed
between the intervention and control groups in relation to age, sex, and BMI. The general characteristics
of the study and the children at baseline are presented in Table 1.
Skin pigmentation was evaluated in four studies, and three of these studies [16,17,19] classified
skin pigmentation according to Fitzpatrick’s scale, which considers the existence of six phototypes
according to the person’s skin color and response to sun exposure (degree of burning and tanning).
Two studies used a spectrophotometer to measure the individual typological angle and found
that more than 50% of the children evaluated had types I to III skin [16,17], whereas Ohlund et al. [19]
evaluated the pigmentation of the skin through visual means, characterizing 52% of the children with
skin types I to IV in the fair skin group. One of the studies observed that 98% of the children in the
sample had a fair skin color, but the methodology used for this classification was not described by the
authors [14]. Only the study by Rich-Edwards et al. [18] did not evaluate this information.
The incidence of UVB rays is also a variable that can influence the availability of vitamin D.
Two studies were conducted exclusively during a period with no efficient sun exposure (autumn and
winter) [18,19], and two other studies also included spring [16,17]; only the study by Hower et al. [14]
covered all seasons.
Another relevant aspect to be evaluated is sun exposure. In two studies, no significant differences
were observed regarding direct sun exposure among the evaluated children [16,17]. The other studies
did not present this information clearly [14,19] or did not evaluate it [18]. Regarding the use of
sunscreens, only three studies presented this information [16,17,19].
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The children’s vitamin D status at baseline was variable, with the presence of children at risk of
deficiency (<30 nmol/L) and of insufficiency (30–49 nmol/L), and with status classified as sufficiency
(≥50 nmol/L) of vitamin D (Table 1). However, the experimental design by Hower et al. [14] took
into consideration the previous nutritional status as inclusion criterion for the study (>25 nmol/L).
The study sample by Rich-Edwards et al. [18] was almost completely composed of children at risk for
vitamin D insufficiency and deficiency.
3.4. Food Fortification and Intervention Outcomes
Corroborating aspects of vitamin D status, four studies also considered the usual intake of this
vitamin. Different methods of assessing food intake were used; among them, semiquantitative food
frequency questionnaire (FFQ) [14], short FFQ [19], and the combination of 24-h dietary recall (24HR)
and 13-item semiquantitative FFQ [16,17]. The FFQs used were composed of food items with a known
contribution to the daily intake of vitamin D (e.g., milk and dairy products, fish, mushrooms) in the
study countries. The study by Rich-Edwards et al. [18] was the only one that did not assess the habitual
vitamin D intake, only used 24HR to quantify the number of portions of Mongolia’s dairy products
consumed daily.
The results showed that at baseline, dietary vitamin D intake was lower than the adequacy
recommendations adopted in each study. Dairy products used as vehicles for vitamin D fortification
were cheddar cheese, yogurt [16,17], and milk [14,18,19], with concentrations ranging from 42 to 880
IU of vitamin D per serving. Thus, the results were discussed considering the exclusive intervention of
the fortified foods offered [14,18,19] or in association with usual daily diet [16,17], for periods ranging
from 1.6 to 9 months (Table 2).
By observing the effects of intake of fortified foods on serum vitamin D levels, in three studies,
an increase of 25(OH)D levels after the intervention period was observed in all groups receiving
fortified foods, whereas the respective control groups did not present alteration of this vitamin in the
serum [16,17,19] (Table 3).
In the study by Hower et al. [14], the fortified milk intervention was evaluated during different
climatic seasons, showing an increase in the serum 25(OH)D levels after winter in the intervention
group that was statistically different from the control group, which presented a reduction in the
concentrations of vitamin. In contrast, during the summer, the intervention and control groups
remained similar.
Different behavior was observed in the study by Brett et al. [17], in which the fortified dairy
products (yogurt and cheddar cheese) promoted maintenance of serum 25(OH)D concentrations
during the first 3 months, but at the end of the study (6 months) those concentrations were reduced
(Δ = −6.9 nmol/L). On the other hand, in the control group, serum 25(OH)D concentrations reduced at
3 months of the study and remained unchanged until the end of the study (6 months).
Differently, Ohlund et al. [19] observed differences in the 25(OH)D concentrations at baseline
according to skin color (dark skin and fair skin) and, with this, the post-intervention data were
compared using the analysis of covariance with study groups as a fixed factor and the skin type as a
random factor.
The methods used to determine serum 25(OH)D concentrations were liquid chromatography
coupled with tandem mass spectrometry (LC-MS/MS) [18,19], high performance liquid chromatography
(HPLC) [17], and chemiluminescence immunoassays [14,16]. The quantified forms corresponded to
total vitamin D [14,16], and the D2 [18,19] and D3 forms [17–19] (Table 3).
In none of the studies, serum 25(OH)D concentrations were above safety limits (>250 nmol/L) in
the groups receiving fortified foods, even during the months with abundant sunshine.
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4. Discussion
This study evaluated the available evidence regarding food fortification as a strategy for
maintenance or recovery of vitamin D nutritional status in children. The results of the individual
studies suggest that consumption of vitamin D-fortified foods seems to be an important strategy to
reduce the prevalence of hypovitaminosis D in this age group, which present greater vulnerability to
developing this deficiency. However, due to the clinical and methodological heterogeneity of these
studies, a meta-analysis could not be performed.
Previous systematic reviews and meta-analysis sought to evaluate the effect of fortification of foods
with vitamin D, demonstrating a significant increase in 25(OH)D concentrations from the consumption
of these foods in different population groups [15,20,21,29]. However, when considering only the child
group, only one systematic review and meta-analysis has been observed in the literature, with children
aged 2–18 years [20].
The effects of fortification with vitamin D are reported to be dependent on increased intake of
fortified foods, previous vitamin D status, age, body composition, skin pigmentation, sun exposure,
geographic aspects, and food intake [14,18,30–32]. In addition, for food fortification there is also a need
to evaluate the population’s eating habits, especially in the children’s group, so that the used vehicle is
routinely present in the food in order to guarantee greater acceptance [14,16].
As noted in the included studies, the use of fortified foods to improve or maintain vitamin D
status considered the consumption of milk and dairy products as part of the population’s eating habits.
Milk and its products are among the foods often fortified with vitamin D, as they are widely consumed
by children, especially in developed countries, and have good bioavailability of the vitamin [33,34].
Dairy products naturally feature in their composition nutrients that act together with vitamin D,
thus contributing to the metabolism of this vitamin, as well as in the physiological processes in which
it is active [35].
Furthermore, vitamin D is directly related to the calcium present in these foods, in which the
1,25(OH)2D stimulates the intestinal absorption and renal reabsorption of this mineral, as well as acting
in the processes of bone mineralization, due its participation in the synthesis of osteocalcin [34]. At the
same time, calcium participates in the processes of biosynthesis and regulation of vitamin D, and the
reduced content of dietary calcium stimulates the catabolism of 25(OH)D as a result of the elevation
of parathormone and 1,25(OH)2D concentrations [34,36]. Despite its sensitivity to light, vitamin D is
considered as good micronutrient for fortification [30].
In the countries of origin of the included clinical trials, in areas with restricted sun exposure,
it is noted that, although increasing, food fortification is still not widely adopted. In Canada, where
two of the five included studies were conducted [16,17], only liquid cow’s milk (35–45 UI/100 mL),
and margarine (530 UI/100 g) must be fortified in accordance with current legislation [4,31]. In Sweden,
the Swedish National Food Agency has established recent changes in fortification policy by expanding
the list of foods and the levels to be fortified [37]. However, in Germany and Mongolia there is no food
fortification policy, although they are located in a region with a latitude greater than 45◦ N and have a
high prevalence of vitamin D deficiency [14,18,38].
Different responses to food fortification at serum vitamin D concentrations can be observed
depending on previous nutritional status [16,18]. Children with poor or insufficient vitamin D status
had a significant increase in serum 25(OH)D concentrations after the intervention [14,16,18,19], which
was not identified in children with sufficient status [17]. This is because the evidence of the relationship
between vitamin D intake and serum concentrations is non-linear in nature; that is, the intake of
vitamin D has less impact on their serum concentrations when they are at high or sufficient levels [4,39].
Considering this, Aloia et al. [39] showed that in order to alter serum vitamin D concentrations above
50 nmol/L, there would be a need for a higher intake of vitamin D when compared to the amount
necessary to increase serum vitamin D levels under 50 nmol/L.
When circulating 25(OH)D concentrations are present in sufficiency, a portion of this vitamin can
be transferred to body stores once saturation of the vitamin D 25-hydroxylase (CYP2R1)—the enzyme
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responsible for vitamin D hydroxylation in the liver—occurs [16,17]. The aspects related to the tissue
distribution of vitamin D in children are not widely known; however, studies indicate that vitamin D
intake is associated with an increase in lean mass and bone mineral density in healthy children [17,36].
The discussion of dose-response of fortification at 25(OH)D concentrations is little explored. Brett
et al. [16] observed, by linear regression analysis, that each 100 IU per day increase in vitamin D intake
by through fortified foods resulted in an increase in serum 25(OH)D concentrations of 0.6–10 nmol/L in
the children. A similar result could be observed in the study by Rich-Edwards et al. [18] in which the
increase in serum concentrations of 25(OH)D was 15 nmol/L per 100 IU of vitamin D intake. In the only
systematic review and meta-analysis performed in children (2–18 years) to date, the authors sought
to investigate the effect of vitamin D interventions (fortified foods, supplements, bolus injections) on
vitamin D status. In this study, the authors observed greater results in the mean change in serum
25(OH)D per 100 IU vitamin D/d in trials only using fortified food (n = 7; 6.9 nmol/L; 95% CI: 3.7,
10.0 nmol/L; I2 = 99.9%) than trials that offered daily supplements (n = 15; 2.9 nmol/L; 95% CI: 2.4,
3.5 nmol/L; I2 = 56%) (p = 0.001), and bolus injections (n = 2; 2.3 nmol/L; 95% CI: 0.9, 3.9 nmol/L;
I2 = 0%) (p = 0.04). The authors demonstrated that the serum 25(OH)D response to vitamin D intake
differed on the basis of baseline status, intakes, and delivery mode, but not age, sex, or latitude [20].
However, the overall results should be used cautiously due to the high level of heterogeneity observed.
A meta-analysis published by Black et al. [15], performed with adults, showed similar results.
The increase of 1.2 nmol/L (95% CI: 0.72, 1.68; I2 = 89%) was observed in the 25(OH)D concentrations
for each 40 IU day of vitamin D ingested from fortified foods. In the paper by O’Donnell et al. [29],
the combining results of four trials that offered vitamin D fortified-milk (n = 466 individuals; 138–800
IU vitamin D/day) also demonstrated an increase in the 25(OH)D concentrations in adults (15.63 (12.79,
18.48) nmol/L; I2 = 0.0%; p = 0.77).
From the evaluated results, it is not possible to determine the optimal fortification dose, since
changes in 25(OH)D concentrations were observed in almost all trials in different populations. However,
the dose range of vitamin D used in fortification of foods from included studies (300–800 IU/day) were
effective in maintaining or recovering vitamin D status in children. Besides, the optimal dose could be
dependent on the characteristics of the population targeted, including those with vitamin D deficiency.
The intervention period, another relevant aspect for the study outcome, varied among the
studies. In some of the included studies, this variable was chosen because it corresponds to the
length of the season of interest. Even so, all studies exceeded the considered half-life of 25(OH)D
which is between 2 and 3 weeks [40]. Vitamin D3 obtained orally has a circulatory peak of 12 h,
returning to basal concentrations within 7 days, even when given high doses [41]. Chronic vitamin D
supplementation is shown to be the best alternative for promoting gradual increase and sustaining
constant 25(OH)D concentrations [20,42], reaching a steady state in healthy adult subjects at 3 months,
approximately [43,44]. More importantly, there is not enough evidence on vitamin D metabolism in
children [45,46].
In children, deficient vitamin D status is the main cause of rickets, a disorder characterized by
disturbances in bone growth and skeletal abnormalities, besides negatively influencing cognitive
development, hormone formation, and immune function [32,47,48]. It is important to consider that the
early years of childhood are characterized by high rates of growth velocity, requiring specific values of
energy and micronutrients such as vitamin D [32,49].
In addition, other variables that may affect the vitamin D bioavailability should be considered.
Body composition is an important aspect for understanding the metabolism of this vitamin because
adiposity has been inversely associated with 25(OH)D concentrations by acting on vitamin D storage,
increasing its clearance [4,17,50,51]. Thus, children with excess body fat may present an increased
risk for the development of 25(OH)D deficiency, requiring two to three times higher concentrations of
vitamin D to meet bodily needs [50].
Overall, studies have shown that fair-skinned individuals have higher levels of 25(OH)D compared
to darker skinned individuals [6,52], a fact that could be observed in one of the included studies [19].
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The variation in skin pigmentation depends on the type and amount of melanin generated, as well
as on the activity of keratinocytes, which are responsible for the sequestration and degradation of
melanin [53]. Thus, the greater the pigmentation of the skin, the lower the vitamin D production, since
the melanin absorbs the UVB radiation that would act in the synthesis of this vitamin [36].
Geographical location and climatic characteristics also directly influence the synthesis of vitamin
D in the skin, with low or absent synthesis observed during most of the winter in places with latitudes
above 33◦ [50]. In this study, all studies included were performed in countries with a latitude greater
than 35◦, and the individuals studied presented mostly fair skin (Fitzpatrick classification I to III). Since
during a part of the year the UVB radiation in these places is not sufficient to activate the endogenous
synthesis and consequently maintain the status of this vitamin [50], food fortification takes on greater
importance in the context of public policy.
It is known that diet has a lower participation in 25(OH)D concentrations [47]. This is because the
reduced variety of vitamin D food sources means they cannot be part of the eating habits of individuals,
especially children [14,18,33]. Among the available food sources, we can mention fatty fish, cod liver oil,
mushrooms, egg yolk, and liver steak [4,29,33]. In addition, regular consumption of vitamin D-fortified
foods can provide better results in maintaining sufficient vitamin D status compared to other strategies
such as seasonal capsule supplementation or the supply of high-dose vitamin D acutely [14,16].
In addition, methods of serum 25(OH)D assessment have a strong influence on the diagnosis
of vitamin D status. There is no consensus regarding the reference standard due to susceptibility to
problems in the pre-analytical, analytical, and post-analytical phases. Immunoassays are dependent on
the specificity of the antibodies used, not being able to identify the 3-epi-25(OH)D molecule. The HPLC
method has been replaced by the LC-MS/MS method, currently considered the gold standard because of
its higher sensitivity [4,54]. It should be noted the included studies showed clinical and methodological
heterogeneity that could not be sufficiently explored in the subgroup analysis and could produce
clinically inconsistent results. Thus, the food fortification strategy is promising, but there is a need to
evaluate the dose-response of vitamin D-fortified foods in vitamin D status, considering all aspects
involved in bioavailability, especially population-wide implementation.
This is the first systematic review that addresses the effects of vitamin D-fortified food intake by
children aged 2–11 years, taking into account the other factors that influence vitamin D metabolism,
such as latitude, sun exposure, skin color, use of sunscreen, and usual dietary intake. Furthermore,
this review included studies that offered fortified foods exclusively with vitamin D in order to minimize
additional factors that could interfere in the bioavailability of this vitamin.
Regarding limitations of the present study, it is possible to mention the low number of studies
available in the literature that offered vitamin D-fortified foods for children. Thus, this study
recommends further randomized clinical trials of this age group to increase evidence and identify the
optimal dose for vitamin D food fortification. Moreover, it should be emphasized that the habitual
consumption of the evaluated groups should be considered, even in the face of the limitations inherent
in the methods used to evaluate habitual nutrient intake.
5. Conclusions
The results of the individual studies suggest that the fortification of foods with vitamin D can
be used for maintaining or recovering the vitamin’s nutritional status in children aged 2–11 years.
In addition, the intake of 300–880 IU of vitamin D per day through the consumption of fortified foods
appears to be safe under the conditions studied, with no increase in serum 25(OH)D concentrations
above the tolerable limits. However, due to the insufficient number and heterogeneity between the
studies, a meta-analysis evaluating the outcomes of interest was not performed, and a pragmatic
recommendation on the fortification of foods with vitamin D is not possible. It is necessary to carry
out additional randomized clinical trials in order to increase the strength of evidence, and to establish
ideal doses of fortification at the population level.
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Abstract: The vitamin D receptor is expressed in multiple cells of the body (other than osteoblasts),
including beta cells and cells involved in immune modulation (such as mononuclear cells, and activated
T and B lymphocytes), and most organs in the body including the brain, heart, skin, gonads, prostate,
breast, and gut. Consequently, the extra-skeletal impact of vitamin D deficiency has been an active
area of research. While epidemiological and case-control studies have often suggested a link between
vitamin D deficiency and conditions such as type 1 and type 2 diabetes, connective tissue disorders,
inflammatory bowel disorders, chronic hepatitis, food allergies, asthma and respiratory infections,
and cancer, interventional studies for the most part have failed to confirm a causative link. This review
examines available evidence to date for the extra-skeletal effects of vitamin D deficiency, with a focus
on randomized controlled trials and meta-analyses.
Keywords: vitamin D; type 1 diabetes; type 2 diabetes; metabolic syndrome; autoimmune; children; cancer
1. Introduction
While the skeletal effects of vitamin D are well recognized and described extensively in the
literature [1–3], its extra-skeletal effects have been subject to some controversy with conflicting data
reported, particularly for case-control or epidemiologic vs. prospective and interventional studies.
This review aims to summarize and synthesize data regarding many extra-skeletal effects of vitamin D.
Given the extensive literature reported in this area over the last two decades, we have discussed key
papers that illustrate variations in data reported from the various kinds of studies, with a focus on
randomized controlled trials (RCTs) and meta-analyses of existing studies.
Vitamin D3 (cholecalciferol) is synthesized primarily in the skin on exposure to ultraviolet radiation,
while vitamin D2 (ergocalciferol) is derived from plant sources. 7-dehydrocholesterol (provitamin D;
present in the stratum basale and stratum spinosum of the epidermis), is converted to previtamin D on
exposure to ultraviolet radiation-B (UV-B), which is then isomerized to vitamin D. Vitamin D passes
into dermal capillaries and is carried by vitamin D binding protein (DBP) to the liver, where microsomal
vitamin D 25-hydroxylase catalyzes its conversion to 25-hydroxy vitamin D [25(OH)D], the storage
form of vitamin D. 25(OH)D is what is reported when we ask for levels of vitamin D, and most assays
report both 25(OH)D2 and 25(OH)D3. While controversy persists around the normative range for
25(OH)D levels, the Institute of Medicine has indicated that a 25(OH)D level at or above 20 ng/mL
(50 nmol/L) is likely sufficient to optimize its skeletal effects [4]. Normative ranges for its possible
extra-skeletal effects remain to be determined. Vitamin D supplements may contain either vitamin D2
or D3, or alfacalcidiol (1-hydroxycholecalciferol). Overall, data suggest that vitamin D3 may be more
effective in raising 25(OH)D levels than vitamin D2 (reviewed in [5]).
25(OH)D is transported to the kidney by DBP, where cytochromal 25-hydroxyvitamin D 1-α
hydroxylase catalyzes its conversion to 1,25 dihydroxy vitamin D [1,25(OH)2D], the active form of
vitamin D. The vitamin D receptor (VDR) is expressed in multiple cells including the osteoblasts,
mononuclear cells, activated T and B lymphocytes and beta cells, and most organs in the body including
the brain, heart, skin, gonads, prostate, breast, and gut. How vitamin D deficiency affects disease states
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in these multiple organ systems has been an active area of research. Repletion of vitamin D stores to
mitigate and improve disease processes has been attempted in certain conditions, although there is
a paucity of data to direct clear treatment protocols, especially in the pediatric population.
2. Immune and Anti-Inflammatory Effects
There is evidence that vitamin D modulates B and T lymphocyte function [6–9], and vitamin
D deficiency has been associated with conditions such as multiple sclerosis, type 1 diabetes (T1D),
rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, inflammatory bowel disease,
hepatitis, asthma and respiratory infections.
2.1. Type 1 Diabetes
Data regarding associations of 25(OH)D levels or vitamin D sufficiency/insufficiency/deficiency status
are conflicting with some [10,11], but not all [12–14], studies reporting an association between low vitamin
D status and occurrence of T1D. Pancreatic beta cells have VDRs and express 1-α hydroxylase (encoded by
CYP27B1) [15], and the human insulin gene promoter has a vitamin D response element [16]. Further, vitamin
D plays a role in T-cell regulatory responses and may protect beta cells from immune attack [17]. In addition,
T1D patients are reported to have lower 25(OH)D levels compared to age matched controls [11,18,19].
Cooper et al. [20] linked the genetic determinants of circulating 25(OH)D (DHCR7 and CYP2R1, which
encode 7-dehydrocholesterol reductase and 25-hydroxylase) and vitamin D signaling in T cells (CYP27B1)
with risk of T1D, while others (including a meta-analysis of nine studies with 1053 patients and 1017 controls)
have linked specific polymorphisms of the VDR gene with risk for T1D [21]. Another study linked T-cell
proliferation with DBP, and reported higher levels and frequencies of serum anti-DBP antibodies in patients
with T1D vs. controls. This study postulated that DBP (expressed in α-cells of pancreatic islets) may be
an autoantigen in T1D [22]. Further, lower maternal third trimester DBP levels and cord blood DBP levels
have been associated with risk of T1D in offspring [23,24]. Further investigation into the role of CYP27B1
in immune cells such as monocytes, macrophages and T-cells is needed to better understand the role of
vitamin D in the pathogenesis and perhaps prevention of T1D. Under this umbrella of research, prospective
studies of vitamin D supplementation have attempted to elucidate causality of T1D and use of vitamin D as
a potential therapy.
Interventional studies: Table 1 describes details of some representative studies of vitamin D
supplementation in T1D. a beneficial effect of cholecalciferol supplementation on regulatory T-cells
(T-regs) has been reported, with an increase in T-reg percentage [25] and suppressive capacity [26],
and reduced progression to undetectable C-peptide. Consistent with these findings, a meta-analysis
of five observational studies reported a protective effect of vitamin D supplementation in early
childhood against development of T1D with a dose response effect [27], while another reported that
such supplementation may have prevented 27% of the predicted T1D cases in England and Wales
in 2012 [28]. Similarly, a beneficial impact has been reported with respect to fasting C-peptide with lower
daily insulin doses [29], peripheral vascular resistance and inflammatory renal markers [30]. However,
many other studies have not demonstrated a beneficial effect of vitamin D supplementation in preventing
or improving the course of T1D. Importantly, the prospective Environmental Determinants of Diabetes
in the Young (TEDDY) Study demonstrated no benefit of maternal vitamin D supplementation
during pregnancy on the risk of islet autoimmunity in the offspring [31]. Other studies have failed
to demonstrate a beneficial impact on beta cell function [32], HbA1C levels [25,33,34] or insulin
requirement [25,34]. While the reason for these conflicting results is unclear, one may speculate that
differences in study design, sample size and vitamin D dosing may contribute. Overall, randomized
controlled studies investigating vitamin D replacement in preventing T1D or treating at diagnosis to
prolong endogenous insulin secretion are few. Vitamin D replacement is necessary in those deficient for
optimal bone health. However, current data do not provide definitive evidence that supplementation
will improve the inflammatory state in a clinically significant manner.
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2.2. Multiple Sclerosis
The risk for multiple sclerosis (MS) is higher in people living above 35◦ latitudes than those who
live below this latitude [53] (although effects were attenuated over time in this study), and studies
have reported an association between risk for MS and lower sunlight exposure [54–59], vitamin D
intake [60] and serum 25(OH)D levels [61–64]. Increased sun exposure in children has been linked to
a lower risk of MS in studies out of Tasmania [57], twin studies where only one monozygotic twin
developed MS [55], a study from Cuba, Martinique and Sicily [54], as well as studies in adults from
Iran [58] and Sweden [59]. Other studies have linked the reduced risk of MS following sun exposure to
the melanocortin 1 receptor genotype [56]. Further, polymorphisms in genes that impact 25(OH)D
levels have been linked to risk of relapse in children with MS [65].
Munger et al. reported an inverse relationship between serum 25(OH)D and the risk of MS [61],
and that before onset, MS risk decreases by 40% for every 20 ng/mL increase in 25(OH)D levels.
In another study, women (but not men) with MS had lower 25(OH)D levels than controls 11 years
after disease onset [62], with a 19% reduction in the odds for MS for every 4 ng/mL increase in winter
25(OH)D concentrations. Similar lower 25(OH)D in patients with MS versus controls has been reported
in other studies for winter [63] or summer levels [64].
Data suggest that vitamin D sufficient states in the mother and infant may protect against MS [66].
Increased first trimester exposure to UVR reduced MS risk in the child in a dose dependent fashion [67].
Higher MS rates in children born in the summer or spring, and lower rates in those born in the fall
may be related to maternal vitamin D insufficiency [68,69]. In the Nurses Health Study, women born
to mothers with high vitamin D intake during pregnancy had a reduced risk of MS [70].
Interventional Studies: protective effects of vitamin D supplementation have been demonstrated
against MS in a few studies [60]. The Nurses Health Study reported that women taking at least 400 IU
of vitamin D supplements daily were at lower risk compared to those not on supplements [60,71].
a meta-analysis of 12 RCTs that included 950 adult patients with MS reported non-significant trends
in improvement in annualized relapse rate Expanded Disability Status Scale scores and MRI findings
in those who received vitamin D supplementation, although higher vitamin D doses (2850–10,400 IUs)
performed significantly worse compared to lower doses (800–1000 IUs) [72]. One RCT did report
an improvement in MRI lesions when vitamin D3 was employed as add-on treatment to interferon
beta-1b in patients with MS [73]. Data are lacking for effects of vitamin D supplementation in children
with MS.
Overall, although case-control and epidemiological studies suggest that people with lower
25(OH)D levels may be at higher risk for MS, confounding factors, such as the association of higher
latitudes (also a risk factor for MS) with lower 25(OH)D levels need to be considered. Interventional
studies examining the preventive effect of vitamin D supplementation on the risk for developing MS
are lacking. Existing RCTs in adult patients with established MS are not convincing for a significant
role for vitamin D supplementation in reducing MS outcomes, although trends for a positive effect have
been reported, particularly with low dose supplementation. Data to date indicate deleterious effects
of high dose vitamin D supplementation on MS outcomes. RCTs assessing the impact of vitamin D
supplementation on MS outcomes in children are lacking.
2.3. Rheumatoid Arthritis
One meta-analysis of 15 studies (including 1143 rheumatoid arthritis (RA) patients and 963 controls)
confirmed lower 25(OH)D levels and a higher prevalence of vitamin D deficiency in patients compared
with controls (55% vs. 33%) [74]. Similarly, a meta-analysis of three cohort studies that included
215,757 participants and 874 incident cases of RA reported that individuals in the highest quartile for
vitamin D intake had a 24% lower risk of developing RA compared to those in the lowest quartile [75].
In addition, inverse associations of 25(OH)D levels with disease activity scores in RA patients have
been reported [74,76–79]. Further, specific VDR polymorphisms have been demonstrated to contribute
significantly to RA risk [80,81].
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Interventional Studies: consistent with the findings from epidemiologic studies, protective
effects of vitamin D supplementation have been demonstrated against RA in some studies [82].
Chandrashekara and Patted reported a reduction in disease severity scores following vitamin D
replacement (60,000 IU of vitamin D weekly for six weeks followed by 60,000 IU monthly) over
three months in RA patients who were vitamin D deficient (25(OH)D levels <20 ng/mL) and had
persistent disease activity [83]. However, a meta-analysis that included five RCTs in patients with RA
reported borderline significance for reduction in disease recurrence, but not for disease activity [84].
Calcitriol enhances inhibition of T cell activation by abatacept (CTLA-4-Ig), a CD28-ligand blocker to
which patients with RA respond with variable efficacy [85], suggesting that vitamin D or calcitriol
may be used as an adjunct therapy to improve efficacy of abatacept in RA patients. Overall, these data
suggest that lower 25(OH)D levels may predict susceptibility to RA and its severity, but it is not clear
that vitamin D supplementation reduces the risk of developing RA or its disease activity/severity.
Further, data in children with RA are currently lacking.
2.4. Systemic Lupus Erythematosus (SLE) and Juvenile Dermatomyositis
Many studies have reported inverse associations of 25(OH)D levels with the occurrence and
severity of SLE and dermatomyosits in adults and children [86–92]. In children, greater disease severity
of SLE is reported in those with 25(OH)D levels <20 ng/mL [88].
Interventional Studies: in contrast to other autoimmune conditions, several interventional
studies have reported an improvement in markers of severity of disease following vitamin D
supplementation in patients with SLE. One study in adolescents and adults with juvenile onset
SLE reported an improvement in disease severity scores and fatigue in those randomized to 50,000 IU
per week of vitamin D supplementation compared to placebo over 6 months [93]. Similar findings
are reported in studies of adults with SLE. a reduction in inflammatory and hemostatic markers,
and disease activity was reported in those randomized to 2000 IU of vitamin D daily compared to
placebo for 12 months [94]. Further, a meta-analysis of three RCTs of vitamin D supplementation
in patients with SLE reported a significant reduction in anti-dsDNA positivity with supplementation [84].
Another study reported an increase of T-regs and a decrease of effector Th1 and Th17 cells, memory B
cells and anti-DNA antibodies in adults with SLE given 100,000 IU of vitamin D weekly for 4 weeks
followed by 100,000 IU monthly for 6 months [95]. No flares were observed over the study duration [95].
Overall, these data suggest that low 25(OH)D levels are concerning for greater risk of developing
SLE and increased severity of the condition, and a possible beneficial effect of vitamin D supplementation
on disease severity, particularly when levels are low. However, more RCTs, including in children,
are necessary to confirm these data. Of note, symptoms of SLE can worsen after UV radiation exposure
which will otherwise increase the vitamin D status of the individual [96]. Thus, excessive sun exposure
to improve 25(OH)D levels in patients with SLE may worsen symptoms of the disease.
2.5. Psoriasis
Keratinocytes express the vitamin D receptor (VDR), and vitamin D inhibits the growth of
keratinocytes, stimulates them to differentiate, and helps maintain the cutaneous barrier integrity [97].
This has led to the use of topical vitamin D analogs to treat psoriasis [98]. However, no VDR
genotype (other than the Taql polymorphsm in Caucasians) has been linked to an increased risk for
psoriasis [99,100]. In addition, there is no correlation between the change in 25(OH)D post phototherapy
and change in severity of symptoms of psoriasis [101,102].
Interventional Studies: a 6-month RCT of 60,000 IUs of vitamin D vs. placebo given every 2 weeks
to 45 patients with psoriasis showed an increase in 25(OH)D levels in the active group associated
with a reduction in the Psoriasis Area and Severity Index (PASI) [103]. Topical vitamin D analogs
(calcipotriene/calcipotriol/maxacalcitol) given with topical betamethasone have also been shown to
be effective in improving plaque psoriasis [104–106] by disrupting the IL-36 and IL-23/IL-17 positive
feedback loop, key factors in the pathogenesis of psoriasis.
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Overall, while studies suggest an association between 25(OH)D levels and psoriasis, causation is
yet to be established. Additionally, RCTs to date are promising for an impact of vitamin D on psoriasis
severity, but studies are small, and more and larger RCTs are necessary to confirm these preliminary
findings. Data in children are lacking.
2.6. Inflammatory Bowel Disease (IBD)
Protective effects of vitamin D supplementation have been demonstrated against IBD [107].
Vitamin D deficient and vitamin D receptor (Vdr) null mice are at high risk of IBD [108], with more
severe disease and more spontaneous recurrences. Further, polymorphisms in the Vdr gene (TaqI) may
confer susceptibility to IBD [109]. a meta-analysis of VDR genotyping in relation to IBD reported that
ApaI polymorphism may increase the risk of Crohn’s disease, whereas the TaqI polymorphism may
decrease the risk of ulcerative colitis, especially in Caucasians [110]. a connection has been proposed
between seasonal vitamin D status and risk for both Crohn’s disease and ulcerative colitis [111,112],
with an association between vitamin D deficiency and more complicated disease course. a recent
meta-analysis reported lower 25(OH)D levels in patients with both Crohn’s disease and ulcerative
colitis than controls, a two-fold risk of vitamin D deficiency in those with IBD, and greater severity of
Crohn’s disease in those with vitamin D deficiency [113,114]. However, these studies are associative
and confounded by the fact that malabsorption (particularly in Crohn’s disease) may contribute to
lower 25(OH)D levels, with more severe disease being associated with more malabsorption.
Interventional studies: there are few randomized controlled trials that have examined the impact
of vitamin D supplementation on disease occurrence or severity. One randomized controlled trial of
400 vs. 2000 IU of vitamin D supplementation in children and adolescents with IBD did report that the
higher dose of vitamin D led to lower levels of pro-inflammatory markers [115]. Vitamin D has also
been shown to exert marked anti-inflammatory effects on peripheral and intestinal CD4+ and CD8+ T
cells of patients with inflammatory bowel disorders in vitro, and inhibit production of TH1 and TH17
cytokines in patients with Crohn’s disease in vivo [116].
Overall, while data to date suggest that vitamin D deficiency may impact disease course in patients
with inflammatory bowel disorders, we are in need of robust RCTs that will help determine whether
vitamin D supplementation is indeed efficacious in reducing disease severity in these patients, including
in children.
2.7. Food Allergies
Although associations of low 25(OH)D levels with a risk of atopy, asthma and food allergies have
been reported [117], recent birth cohort studies demonstrate no association of 25(OH)D levels (including
antenatal vitamin D exposure) with the incidence of food allergy [118,119]. One meta-analysis of more
than 5000 children did not find a significant association between vitamin D status and food allergy [120].
Interventional Studies: data for the role of vitamin D supplementation in preventing food allergies
is inconsistent, and large trials are necessary to determine the role if any of vitamin D in reducing the
risk for food allergies [121]. One RCT of 400 vs. 1200 IUs of vitamin D supplementation in 975 infants
from the age of 2 weeks found no impact of higher-dose vitamin D supplementation on allergic
sensitization or allergic diseases (food or aeroallergen) at 12-months of age [122]. Overall, current
data do not support a role of vitamin D status in impacting the risk for food allergies in children,
and non-interventional studies may be confounded by variables such as associated malabsorption.
2.8. Chronic Hepatitis B and C
Certain vitamin D receptor gene (VDR a/a) polymorphisms have been linked to greater severity of
hepatitis B infection and a higher viral load [123]. In addition, polymorphisms in the T/T allele of exon 9
of the VDR gene (but not intron 8 polymorphisms) are associated with occult hepatitis B infection [124].
Further, a meta-analysis of seven studies involving 814 patients with chronic hepatitis B and 696
controls showed lower 25(OH)D levels in patients with chronic hepatitis B associated with higher viral
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loads [125]. Petta et al. [126] reported that lower 25(OH)D levels in chronic hepatitis C infection were
related to decreased CYP27A1 expression, female gender, necrosis and inflammation, severe fibrosis
and poor viral response to interferon based therapy. Of note, polymorphisms in the VDR gene have
been associated with development of hepatocellular carcinoma in patients with hepatitis C [127].
Interventional Studies: in in vitro studies, 25(OH)D has been shown to inhibit hepatitis C virus
production by suppressing apolipoprotein expression [128]. In 42 patients with recurrent hepatitis C
infections treated with INF-α and ribavirin for 48 weeks, vitamin D deficiency was associated with
an unfavorable response to antiviral medication, and 15 patients given oral vitamin D supplements
had a better and more sustained response to antiviral treatment [129]. One short 6-week RCT of
vitamin D supplementation vs. placebo in 54 patients with chronic hepatitis C with vitamin D deficiency
demonstrated improved serum markers of hepatic fibrogenesis upon correction of 25(OH)D levels [130].
Overall, data suggest deleterious effects of vitamin D deficiency on the course of chronic hepatitis
B and C infections, with some studies suggesting a possible role (and mechanism) for vitamin D
supplementation in improving outcomes in these patients. However, we are in need of larger RCTs
and of longer duration to effectively confirm these findings, and data in children are lacking.
2.9. Asthma and Respiratory Infections
Several studies have reported an association between vitamin D deficiency (25(OH)D < 20 ng/mL)
and increased airway inflammation, decreased lung function, increased exacerbations, and poor
prognosis in patients with asthma (reviewed in [131]).
Interventional Studies: a literature review of RCTs of vitamin D supplementation in children older
than 2 years found a possible effect of vitamin D supplementation in improving bronchial asthma
exacerbation [132,133], but no effect on the severity of asthma [132]. a subsequent meta-analysis
that included 435 children (seven trials) and 658 adults (two trials) similarly reported a reduction
in asthma exacerbations requiring systemic corticosteroids and the risk for an exacerbation requiring
an emergency department visit or hospitalization in those who received vitamin D supplementation,
but not on measures of severity (% predicted forced expiratory volume in one second or Asthma
Control test Scores [134]. The improvement in asthma exacerbation has been attributed to a decrease
in respiratory infections [12].
RCTs of vitamin D supplementation (300–1200 IUs per day) vs. placebo report a potential effect
of vitamin D in reducing the risk for influenza infections during the winter months [135], although
a subsequent analysis reported that benefits observed in the first month of supplementation were lost
in the second month, and overall there was no difference among groups for influenza prevalence over
the entire season [136]. a meta-analysis of 25 RCTs using vitamin D supplementation of any duration
in individuals 0–95 years old demonstrated that vitamin D reduced the risk for acute respiratory
infections overall, with the greatest benefit in those with low 25(OH)D levels (<10 ng/mL), and those
receiving daily or weekly vitamin D supplementation vs. bolus doses [137,138]. Effects may be less
robust in those 1–5 years old [139], and a dose effect has not been demonstrated [140].
Overall, these data suggest that vitamin D may have an effect in reducing the risk for respiratory
infections in children, with more pronounced effects after 5 years of age, and in those that are vitamin
D deficient. This effect may explain the reduced risk of asthma exacerbations in children with
vitamin D supplementation (although asthma severity does not appear to improve with vitamin D).
The mechanism underlying the effect on respiratory infections needs to be determined, but may involve
the impact of vitamin D on inflammatory pathways.
3. Metabolic Syndrome and Type 2 Diabetes Mellitus
Although, VDR polymorphisms are unlikely to play a major role in obesity-related phenotypes,
as reported in a population of Caucasian adults [141], vitamin D deficiency has been associated with
obesity in both pediatric and adult populations. The prevalence of vitamin D deficiency is about
50% in children with obesity [142,143], and attributable to decreased sun exposure secondary to low
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activity level, poor nutrition with decreased consumption of vitamin D containing foods such as milk,
as well as storage in adipose tissue [142]. With the increased prevalence of obesity in children there
has also been concern of increased prevalence of type 2 DM (T2D), dyslipidemia and hypertension,
the metabolic syndrome [1]. The role vitamin D plays in contributing to these disorders has been of
interest given the above association and implications for potential treatment. Exactly which aspects of
the metabolic syndrome are associated with vitamin D deficiency have not been definitively delineated
as studies show varied results. Olson et al. found a negative correlation between 25(OH)D levels and
HOMA-IR (homeostasis model assessment of insulin resistance) and weaker but significant inverse
correlations with 2-h glucose levels in an oral glucose tolerance test (OGTT). There was no correlation
with HbA1C, systolic blood pressure (SBP) or diastolic blood pressure (DBP) [142]. In another study
vitamin D deficiency in children with obesity was associated with higher BMI and SBP, and decreased
HDL-C [143]. After adjusting for BMI in Native American children, 25(OH)D levels were inversely
associated with log transformed fasting 2-h glucose, fasting insulin, HOMA-IR, triglyceride and CRP
levels, and SBP and DBP. There was a positive correlation with HDL but no correlation with total or
LDL cholesterol [144]. Studies have postulated that adipokines such as adiponectin and resistin may
be involved in the pathogenesis of insulin resistance and vitamin D deficiency. a study of 125 children
and adolescents with obesity showed a trend toward lower 25(OH)D levels being associated with low
adiponectin levels and higher insulin resistance even after adjusting for body mass, though there was
no correlation between 25(OH)D levels and resistin [145].
Conversely, Poomthavorn et al. [146] found no correlation between vitamin D deficiency and
abnormal glucose homeostasis in 150 children and adolescents with obesity living in Thailand. In fact,
the five children identified with T2D in this study were all vitamin D sufficient. They also found the same
degree of vitamin D deficiency in 29 healthy children without obesity [146]. Similarly, Bril et al. found
no relationship between lower 25(OH)D levels and insulin resistance (using an euglycemic insulin
clamp), liver fat accumulation or steatohepatitis when adult patients with the latter were matched
for BMI and total adiposity with controls [147]. More recently, in a study of 215 children with T1D
and 326 children with T2D vs. youth of similar age without diabetes from the 2005–2006 NHANES
Survey, the prevalence of vitamin D deficiency or insufficiency did not differ in children with vs. those
without diabetes [14]. Additionally, although latitude and the winter months have been associated
with a higher risk of hypertension, recent studies suggest that the effect of ultraviolet light on blood
pressure is likely mediated via nitric oxide synthesis and not through vitamin D production [148].
Limitations of pediatric studies include the fact that these associative studies often do not include
controls matched for measures of adiposity, or use euglycemic clamps to assess insulin resistance.
In addition, sample sizes are small and length of studies short. Associations of vitamin D deficiency
with worsening insulin resistance or other aspects of the metabolic syndrome are yet to be proven.
Interventional studies in adults and adolescents are described in detail in Table 1 and are
summarized here.
Interventional Studies in Adults with Obesity, Prediabetes and T2D: the contribution of vitamin D
to the metabolic phenotype of obesity is of interest given implications for treatment. If these associations
have a biological basis, repleting vitamin D should improve the phenotype. How this should be
done, to what level of replacement, and the actual efficacy have been the basis of several studies.
Vitamin D administration in adults has had mixed results for progression to T2D and cardio-metabolic
outcomes. Among short-term studies with small numbers of participants, most have reported no
changes in insulin sensitivity [35], insulin secretion [36,37], CRP [36,38], BMI [36], lipids [36,37,39], blood
pressure, endothelial function, and arterial stiffness [38] following vitamin D administration, while a few
have reported an improvement in insulin sensitivity [36] and blood pressure [39]. Among larger
and longer-term studies, a five-year interventional study in 556 adults 25–80 years old at risk for
developing T2D, reported no impact of vitamin D administration on progression to T2D, measures of
glucose metabolism, serum lipids or blood pressure [40]. a subsequent pooled meta-analysis of 23 RCTs
similarly found no effect of vitamin D supplementation in controlling fasting plasma glucose levels,
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improving insulin resistance, or preventing T2D; however, stratified analysis suggested a possible
beneficial effect in those without obesity, those with prediabetes, when 25(OH)D levels were at least
20 ng/mL, and when the supplemental dose was >2000 IUs per day and given without calcium
supplementation [41]. Yet, an RCT in adult participants meeting criteria for prediabetes (but not
diabetes) reported no difference between groups for onset of diabetes over the study duration [42].
Interventional Studies in Children with Obesity, Prediabetes and T2D: similar to the adult literature,
the pediatric literature includes conflicting data regarding effects of vitamin D supplementation [43–52]
(Table 1). a retrospective study of vitamin D supplementation in 43 children 3–18 years old with
T2D reported a decrease in BMI-SDS and HbA1C in those supplemented with vitamin D [46]. A few
prospective studies in adolescents with obesity have similarly reported improved HOMA-IR and
QUICKI (but not in fasting glucose, HbA1C, CRP, inflammatory markers, blood pressure) [43,45]
following vitamin D administration, and an association of reductions in Apo-B and LDL-C, and increases
in HDL with increases in 25(OH)D levels after supplementation [44,49]. However, most prospective
interventional studies in children with obesity have failed to demonstrate a beneficial effect of vitamin D
administration on fasting lipids, glucose, insulin and CRP values [47,48,50,51], and insulin secretion or
sensitivity [52], and dose response studies have similarly not been able to demonstrate an effect of
increasing vitamin D doses on fasting glucose, insulin and insulin resistance [48,51] or lipid levels [48].
Overall data indicate that there is an association between obesity and vitamin D deficiency (likely
related to sequestration of vitamin D in adipose depots). However, the biological effect of vitamin D
deficiency on insulin resistance, hypertension, hyperlipidemia and progression to T2D is likely small.
Data are conflicting regarding associations of vitamin D deficiency with components of the metabolic
syndrome, as well as a treatment effect. Some differences may be attributable to the type of study,
sample size, and dose of vitamin D used (Table 1). Larger and longer-term prospective studies are
needed to definitively determine causality.
4. Cancer
In cell culture studies, 25(OH)D concentrations of>30 ng/mL prevent unregulated cell growth [149–151].
There are very little data for the role of vitamin D in preventing or ameliorating the course of cancer in children,
although low 25(OH)vitamin D levels may contribute to poor bone health in children with hematological
and other malignancies [152–154]. Much of the data for the impact of vitamin D in preventing or reducing
the morbidity of cancer comes from studies in adults, particularly in the context of breast, colorectal and
prostate cancer. This section briefly reviews existing literature for these three kinds of cancer.
In breast cancer cell lines, vitamin D signaling inhibits expression of a tumor progression gene (Id1),
and ablation of VDR expression causes increased tumor growth and development of metastases [155].
This pathway is inhibited in murine models of breast cancer associated with vitamin D deficiency,
and epidemiological studies in humans suggest associations of vitamin D deficiency and the risk
of breast, prostate and colon cancer [156–158]. However, data are conflicting regarding the impact
of vitamin D receptor genotype and cancer risk at this time [159]. One study reported that VDR
single nucleotide polymorphisms and haplotypes may determine how inflammatory markers change
in breast cancer survivors with vitamin D deficiency, following vitamin D supplementation [160].
In general, vitamin D deficiency is associated with increased risk of progression and mortality
in breast cancers [161–163]. Of note, these data have been questioned in that meta-analyses indicate that
while case control studies suggest a reduction in breast cancer risk in those with higher 25(OH)D levels,
this is not evident in prospective studies [163,164]. Data suggest that weight and alcohol intake may
modify associations between vitamin D intake and breast cancer risk [165]. Of note, the Women’s Health
Initiative demonstrated no reduction in risk for breast cancer in women receiving 400 IU vitamin D3 and
1000 mg of calcium vs. placebo [166]. However, a decreased risk was noted in postmenopausal women
on hormone replacement therapy from daily vitamin D and calcium supplements [167], and another
study reported improved breast cancer survival in patients after surgery of invasive breast cancer
in de novo vitamin D users [168]. One recent 12-month RCT of 20,000 IUs of vitamin D vs. placebo in 208
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premenopausal women at high risk for breast cancer found no effect of vitamin D supplementation
in reducing breast cancer risk (assessed using mammographic density) [169]. Similarly, an RCT of
2000 IUs of vitamin D and omega-3 fatty acids (1 g daily) (2 × 2 factorial design) in women 55 and
older and men 50 and older found no effect of vitamin D supplementation in lowering the incidence of
invasive cancer compared to placebo [170].
Meta-analyses have reported inverse associations of 25(OH)D levels and vitamin D intake with the
incidence and recurrence of colorectal adenoma [171–174]. One meta-analysis suggested a 10%–20%
reduction in risk of incidence or recurrence of colorectal adenomas with every 20 ng/mL increase
in 25(OH)D levels [171]. Another meta-analysis suggested a 26% reduction in risk with every 10 ng/mL
increase in 25(OH)D levels [175,176]. However, a large Mendelian randomization study that included
10,725 colorectal cancer cases and 30,794 controls found no evidence for a causal relationship between
circulating 25(OH)D and colorectal cancer risk. These authors suggested that circulating vitamin D
may be a biomarker of colorectal cancer, rather than a causative factor [177]. Thus far, data for a role of
VDR polymorphisms in mediating the risk of colorectal adenomas are conflicting, with no associations
reported in more recent studies [176,178].
Some studies have suggested that vitamin D with or without calcium supplementation promotes
colorectal epithelial cell differentiation, reduces proliferation, and promotes apoptosis, and is thus
chemopreventive against colorectal neoplasms [179]. Further, a higher expression of CYP24A1, which reduces
local 1,25-D (3) availability and thus its antiproliferative effect, has been demonstrated in colorectal
adenocarcinomas, associated with increased expression of the proliferation marker Ki-67 [180]. Despite these
data and consistent with the Mendelian randomization study, randomized controlled trials and meta-analyses
do not support a role of vitamin D supplementation in preventing these cancers [161,181,182] or
relapses [183–185]. Baron et al. disappointingly reported that daily supplementation with vitamin D3
(1000 IU), calcium (1200 mg), or both after removal of colorectal adenomas did not reduce the risk
of recurrence over a 3–5 year period [184]. Similarly, Urashima et al. reported no improvement in relapse
free survival in patients with digestive tract cancers (48% were colorectal cancers) randomized to 2000 IUs of
vitamin D vs. placebo (AMATERASU RCT) [185]. However, in the SUNSHINE trial (a phase 2 RCT in which
139 patients with advanced or metastatic colorectal cancer were randomized to chemotherapy plus high-dose
vitamin D3 supplementation (8000 IUs daily for one month followed by 4000 IUs daily vs. chemotherapy
plus standard-dose vitamin D3 (400 IUs daily)) the higher vitamin D dose was associated with a multivariable
hazard ratio of 0.64 for progression-free survival or death that was statistically significant [186].
Sun exposure may delay the onset of prostate cancer [157] while serum 25(OH)D levels of at least
20 ng/mL appear to reduce the risk for prostate cancer by 50% [187]. However, data for associations of
vitamin D deficiency with incidence of prostate cancer are weaker than those for colon cancer, and data
for associations with progression are inconsistent [161,188].
Overall, at this time, data do not support a significant role of vitamin D supplementation
in preventing or changing the course of breast, colorectal or prostate cancer.
5. Conclusions
In conclusion, vitamin D may have biological effects well beyond the skeleton. While it is
important to maintain adequate 25(OH)D levels for optimal bone health, this may have benefits
in a variety of different organ systems. However, interventional studies to prevent or ameliorate
disease processes attributable to vitamin D deficiency in large populations have been disappointing
thus far for the most part. More investigation is needed to determine optimal dosing and serum levels
to effect positive biological outcomes.
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